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Abstract
Central 5-HT containing pathways have been shown to play an important role in the 
control o f micturition with a focus on 5-HT receptor influence on the parasympathetic 
outflow to the bladder, and somatic outflow to the external urethral sphincter (EUS) in 
the rat. 5-HTja and 5 -HT7 receptors have been revealed to be physiologically involved in 
the control o f micturition. Moreover, from the literature, activation o f the 5 -HT2 
receptor, specifically 5 -HT2C receptor has been observed to be inhibitory on the 
micturition reflex, although no physiological role for this receptor subtype has yet been 
established. Using reportedly selective 5 -HT2 receptor agonists and antagonists, the 
present work reveals the excitatory actions o f the 5 -HT2A receptor on the external urethral 
sphincter and the micturition reflex, the inhibitory actions o f the 5 -HT2C receptor in 
micturition and the involvement o f 5-HT2B receptors in mediating urethral smooth muscle 
contraction. Further, data from the present study demonstrates that 5 -HT2A receptors 
excite the external urethral sphincter at the level o f the sacral spinal cord and further 
supports the view that the inhibitory action o f the 5 -HT2C receptors on micturition is 
centrally mediated. Molecular evidence regarding expression o f 5 -HT2 receptor subtypes 
in the lower urinary tract o f the rat is also provided in the present study, with 5 -HT2A, 5- 
HT2B and 5-HT2C receptor mRNA expression observed in the rat bladder, urethra and 
brain respectively.
Overall, this thesis provides evidence for the involvement o f 5 -HT2 receptors in the 
control o f micturition, although it is still unclear as to the physiological role of this 
receptor family in the control of micturition.
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Chapter 1
Introduction
1
1 Introduction
Urine is produced in the kidneys continuously and for a practical reason is first collected 
in the bladder where it is stored until disposal is possible. The lower urinary tract mainly 
functions in continence to store and void urine when convenient, and plays a role in 
sexual function in males. In many animals, micturition does not take place at random, 
but is part o f a rather complicated behaviour, directly related to the survival o f the 
individual or species, where urine is used for territorial marking or sexual function (Blok 
&Holstege, 1999).
Urine storage and its eventual expulsion from the body involves a complex pattern of 
efferent and afferent signalling in both the autonomic and somatic nervous systems which 
are dependant on central nervous system control. A great interest in the lower urinary 
tract is attributed to the fact that several pathological conditions exist particularly in the 
western world where development o f pharmacological therapies for the treatment of these 
conditions is o f great focus both in the pharmaceutical industry and academia. Part o f the 
focus on these pharmacological therapies is from gaining a better understanding o f the 
mechanisms by which neurotransmitters such as monoamines, amino acids and peptides 
are involved in the control o f the lower urinary tract. This thesis will therefore focus on 
the monoamine neurotransmitter 5-Hydroxytryptamine (5-HT), primarily concentrating 
on the 5 -HT2 receptor subtype and its role in both bladder and urethral function.
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1.1 The lower urinary tract
The lower urinary tract (LUT) which comprises o f the bladder and urethra serves to store 
and periodically eliminate urine. For this process to occur, close coordination between 
these two components is required in order for continence to be maintained and timely 
micturition to occur. The bladder forms a reservoir for urine storage, receiving urine 
from the ureters, but never under normal conditions, allowing it to flow back into the 
upper urinary tract (Lincoln & Bumstock, 1993). The urethra connects the bladder to the 
exterior and acts as an outlet, thus eliminating urine from the body (see de Groat & 
Yoshimura, 2001).
1.1.1 Bladder structure and function
The bladder consists o f two main components -  the bladder body, located above the 
ureteral orifices and the bladder base, consisting of the trigone, urethrovesical junction, 
detrusor and bladder wall. The bladder can be divided into two distinct regions -  the 
detrusor and the trigone. The detrusor forms the smooth muscle o f the bladder, is highly 
distensible and receives a parasympathetic input. Contraction o f the detrusor muscle 
encourages expulsion o f urine from the bladder. The trigone on the other hand is located 
dorsally at the bladder neck and undergoes little change in size during filling. The 
trigone is thought to prevent backflow of urine into the ureters following an increase in 
bladder pressure during voiding. It has been proposed that a sympathetic supply to the 
trigone aids in preventing this backflow into the ureters.
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1.1.2 Urothelium
The urothelium is a layer o f epithelial cells lining the surface o f the urinary bladder and is 
composed of at least three layers which include; a basal cell layer attached to a basement 
membrane, an intermediate layer, and a superficial (or apical) layer composed of large 
hexagonal cells which are also known as “umbrella cells”. In addition to functioning as a 
barrier o f fluid and ion transport (see Lewis, 2000), experimental and clinical evidence 
has shown the urothelium to be a highly specialized structure involved in the micturition 
reflex, as it increases the size of the umbrella cells during the filling phase, as well as 
releasing mediators that activate sensory fibers (Birder et al., 2001). Additionally, the 
urothelium has been implicated in metabolic secretion, regulation of inflammation and 
afferent functions. Molecules expressed by the urothelium include receptors for 
bradykinin (Chopra et al., 2005), neurotrophins (Wolf-Johnston et al., 2004), purines 
(Lee et al., 2000; Tempest et al., 2004), noradrenaline (Birder et al., 1998, 2002b) as well 
as chemical mediators and ion channels such as adenosine triphosphate (ATP), 
acetylcholine (ACh), nitric oxide (NO), transient receptor potential vallinoid 1 (TRPV1) 
and potassium (K) channels respectively. These multiple actions o f the urothelium have 
yielded a lot o f attention in present urological research especially as modifications of the 
urothelium in a number o f pathological conditions can result in passage of unwanted 
urinary constituents, or the release o f neuroactive substances that may lead to sensory 
nerves and sensory symptoms such as urinary frequency and urgency (see Birder & de 
Groat, 2007). Additionally, a correlation has been observed between interstitial cystitis 
(IC) and urothelial TRPV1 expression thus making the urothelium a possible target in the 
treatment o f this condition (Burcher, 2005). Therefore, in present day urology research
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the urothelium is a great target for pharmacological interventions aimed at either the 
urothelial receptor and ion channel expression or neurotransmitter release mechanisms. 
One current mode o f treatment targeting the urothelium is through injection of botulinium 
toxin A (BTX-A) into the bladder wall to prevent detrusor overactivity (Smith & 
Chancellor, 2004; Schurch et al., 2005). It has been hypothesised that the BTX-A acts by 
blocking the release o f ATP (Barrick et al., 2004) which would normally trigger 
sensations of fullness and pain, or induce reflex changes in bladder activity (Bumstock, 
2001). Additionally, BTX-A acts to reduce activation o f afferent nerves by bladder 
irritation (Chuang et al., 2004; Vemulakonda et al., 2005). The urothelium therefore 
provides important avenues that could lead to new strategies for the clinical management 
o f bladder disorders.
1.1.3 Urethral structure and function
The mammalian urethra is a highly complex tubular organ that connects the bladder to 
the exterior. In the human male, the urethra is divided into the bladder neck, prostatic, 
membranous, bulbar and penile sections with only the first three contributing to urinary 
continence (see Brading, 1999). In the human female, the urethra is more uniform in 
structure and is much shorter in length. A cross section o f the human female urethra 
shows a thick, internal band of longitudinal smooth muscle lying just under the 
submucosa, a thin, middle band o f circular smooth muscle and an omega-shaped, external 
band o f striated muscle also referred to as the rhabdosphincter (see Thor, 2004). A 
similar arrangement has been described in the female rat urethra (Hutch & Rambo, 1967). 
It has been suggested that longitudinal and circular smooth muscles play different but
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important roles in voiding where the former shortens the proximal urethra as well as 
opening the bladder neck and the latter functions to close the urethra as well as increasing 
urethral resistance to urine flow (see Andersson, 1993; Hassouna et al., 1983; Mattiasson 
et al., 1989). Smooth muscles traverse the entire length o f the urethra in the female and 
up to and including the membranous urethra in the male. The external urethral sphincter 
contains an intramural layer o f striated muscle that is separate from the periurethral 
skeletal muscle o f the pelvic floor (see Brading, 1999). In the human male, the striated 
muscle extends from the base of the bladder and the anterior aspect o f the prostrate along 
the full length o f the membranous urethra whereas in the human female, the striated 
muscle extends from the proximal urethra distally. The smooth and striated muscle fibers 
are intermingled in the middle circular smooth muscle layer (Watanabe & Yamamoto, 
1979) and it has been suggested that these two types o f muscles are closely linked 
functionally as they have been shown to contribute to urethral closure pressure.
During bladder filling, the main function o f the urethra is to prevent leakage o f urine 
from the bladder by having a urethral closure pressure that exceeds the intravesical 
pressure. If the pressure along the length o f the urethra is measured in both animals and 
man at rest during the filling stage o f the micturition cycle, a low urethral pressure is 
found to exist at the bladder neck, and this rises to a peak pressure in the mid urethra 
which declines towards the urethral opening (see Brading, 1999). During micturition, the 
pressure in the urethra drops thus relaxing the muscles generating intraurethral pressure. 
However, this is not enough to open the urethral lumen and therefore together with a drop 
in urethral pressure, the urethra shortens and funnelling o f the bladder neck occurs. This 
therefore actively prepares the urethra to allow urine flow.
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1.1.4 Comparisons between mammalian species used for urological 
research
Several mammalian species have been used as models in urological research when 
investigating potential therapeutic targets for dysfunctions o f the lower urinary tract. 
Species such as pigs, dogs, rats and guinea pigs have been greatly used both in the 
academic and industrial setting. The female pig has been identified as an excellent model 
o f bladder outflow obstruction as the pig produces a progressive obstruction that is 
similar to detrusor instability in humans (Sibley, 1985). However, anatomically, the 
female pig urethra is quite different to that o f the female human urethra, as the striated 
muscle in the pig is only present in the distal region (Dass et al., 2001) o f the urethra, 
whereas 80% of the urethral length in humans is covered by striated muscles (DeLancy, 
1994). On the other hand, the length of the smooth and striated muscle in the guinea pig 
urethra bears a closer structural resemblance to humans. Functionally, external urethral 
sphincteric activity in guinea pigs and humans is very similar. In both species, external 
urethral sphincteric activity is low during the early filling phase o f the bladder, with 
gradual rises in activity observed as the bladder volume increases. This activity is 
however completely inhibited immediately prior to and during bladder emptying, 
reappearing when voiding is completed (Walters et al., 2006). This phenomenon o f 
sphincteric activity ‘switch o ff  (also known as the guarding reflex) prior to and during 
bladder emptying is not observed in the rat, thus demonstrating the existence o f species 
differences in the actions of the striated urethral muscle. It therefore appears that for 
efficient voiding to occur in the different species, either a ‘switch o ff  in sphincteric 
activity immediately prior to contraction o f the bladder (humans and guinea pigs), or
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appearance o f sphincteric activity on the initiation of micturition (rodents) is essential. 
With regards to the voiding characteristics similarities and differences have been 
observed in the different species. For example, both the rat and human display similar 
patterns of flow and peak bladder pressure (Schmidt et al., 2003), whereas only the rat 
displays oscillatory activity on bladder pressure during voiding (Van Asselt et al., 1995) 
It is therefore important to note that the choice o f which species to use as a comparative 
animal model for humans is primarily dependant on the research interest.
8
Ureter
Mucosa
Urethral orifices
1
4
Ureter
Rugae 
Peritoneum
Detrusor muscle
Submucosa
Trigone 
Bladder neck
Urethral sphincter
/
External urethral sphincter 
Urethra
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1.2 Autonomic innervation of the lower urinary tract
Coordinated activity o f smooth muscle (urinary bladder and urethra) and striated muscle 
(external urethral sphincter) is mediated by parasympathetic, sympathetic and somatic 
pathways in the brain and spinal cord.
1.2.1 Parasympathetic nervous system
Excitatory bladder parasympathetic afferents and efferents associated with the lower 
urinary tract are located in the sacral spinal segments. Species variation exists with 
regards to the specific spinal cord segments from which parasympathetic preganglionic 
nerves arise; S2-S4 in humans, S I-S3 in cats and monkeys and L6-S1 in rats. These 
bladder afferents and efferents travel in the pelvic nerves and are the basis for the 
micturition reflex (see de Groat, 1975, 1986; Elbadawi, 1996; de Groat et al., 1999). 
Preganglionic axons leave the spinal cord and travel in the pelvic nerves to ganglia 
located in the pelvic plexus, on the surface o f the bladder (vesical ganglia) or within the 
walls o f the bladder and urethra (intramural ganglia). Postganglionic axons then leave 
the pelvic, vesical or intramural ganglia to innervate the smooth muscle o f the lower 
urinary tract. The parasympathetic nerves are excitatory (cholinergic and purinergic) to 
the bladder and have an inhibitory (nitrergic) effect on the urethra (de Groat et al., 1993; 
Ralevic & Bumstock, 1998). Damage to the sacral spinal or pelvic nerves results in 
major disruptions to the lower urinary tract.
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1.2.2 Sympathetic nervous system
The sympathetic outflow to the bladder and urethra originates in the lower thoracic and 
upper lumbar spinal segments (T10-L2) and travels via the sympathetic chain to the 
inferior mesenteric ganglia and then via the hypogastric nerves to the pelvic plexus o f the 
lower urinary tract. These sympathetic pathways which release noradrenaline are 
excitatory to the bladder neck and the proximal urethra and they provide both facilitatory 
and inhibitory inputs to the parasympathetic ganglia (Andersson, 1993; de Groat et al., 
1993). The sympathetic system is active between voids with the primary role of 
facilitating bladder filling via p adrenergic receptor-mediated relaxation of the bladder 
smooth muscle and a-adrenergic receptor mediated contraction o f the smooth muscle of 
the bladder neck and the urethra (see Andersson, 2000). It is also thought that the 
sympathetic nervous system plays a role in inhibiting parasympathetic activity during the 
accommodation phase o f urine storage. Disruption to the sympathetic outflow to the 
bladder (although not life threatening) may result in a decrease in the competency o f the 
bladder neck and proximal urethra as well as a decrease in bladder storage volumes, thus 
affecting continence.
1.2.3 Somatic nervous system
Motomeurones located in the O nuf s nucleus are responsible for innervation of the 
urethral striated muscle and, to a large extent the control o f urethral function via 
postsynaptic nerves. These motomeurones primarily receive a somatic input. Studies 
have revealed the existence o f a species variation with regards to the location o f the 
O nuf s nucleus. In mammalian species such as hamster (Gerrits et al., 1997), dog
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(Kuzuhara et al., 1980; Petras & Cummings, 1978), cat (Kuzuhara et al., 1980) and 
monkey (Nakagawa, 1980; Roppolo et al., 1985), the O nuf s nucleus is located in the 
ventrolateral aspect o f the ventral horn. In the rat, however, the O nuf s nucleus consists 
o f two separate cell groups, a dorsomedial group and a ventrolateral group. Structurally, 
motomeurones innervating the external urethral sphincter are different from other 
motomeurones as they are smaller in size and they possess bundled dendrites responsible 
for strong synchronous activation or inhibition (see Nitti, 2004). Innervation o f the 
striated muscle is largely via the motor branch o f the pudendal nerve (McKenna & 
Nadelhaft, 1986; Thor et al., 1989; Dubrovsky & Filipini, 1990; Vanderhorst & Holstege, 
1997) which provides an excitatory cholinergic input to the striated muscle o f the urethral 
sphincter. However, a GABAergic/glycinergic inhibitory intemeuronal mechanism also 
exists (see Fraser & Chancellor, 2003). The somatic nervous system is tonically active 
during bladder filling following activation o f pudendal motomeurones, and has been 
found to play a major role in continence by maintaining closure o f the urethral sphincter. 
Challenges to continence such as sneezing, coughing or postural changes are thought to 
be mediated by the somatic nervous system. Damage caused to the pudendal nerve could 
thus result in a hypoactive urethral sphincter and this may eventually lead to conditions 
such as stress urinary incontinence.
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1.2.4 Pelvic ganglia
Pelvic ganglia are clusters o f autonomic ganglion neurones that are the final motor 
pathways mediating storage and voiding functions o f the lower urinary tract, bowel and 
reproductive behaviours (see Keast, 2006). The pelvic ganglia provide a mixture of 
sympathetic and parasympathetic neurones where some neurones receive synaptic inputs 
from the lumbar spinal cord and some neurones receive inputs from the sacral spinal 
cord. In some species, there are pelvic ganglia that receive inputs from both lumbar and 
sacral spinal cord. Sympathetic neurones in the pelvic plexus tend to occur more 
centrally whereas parasympathetic neurones are located more dorsally. An interesting 
feature o f pelvic neurones is that pelvic parasympathetic neurones unlike other 
parasympathetic neurones lie quite some distance from their target tissues. Although a 
disadvantage during common surgical procedures such as prostatectomy and 
hysterectomy, this unique neuroanatomical feature makes these neurones easily 
accessible for experimental studies. Interspecies differences exist with regards to the 
structure o f the pelvic ganglia. Rodents tend to have large, paired pelvic ganglia whereas 
in humans, cats, rabbits, pigs and dogs, the pelvic ganglia consist o f a complicated 
meshwork of fibres. Overall, the pelvic ganglia play an important role in the 
coordination and integration of lower urinary tract function.
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Figure 1.2 Schematic representation of the innervation of the lower urinary tract (Ford et al., 2006).
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1.3 Central control of micturition and urine storage
The central nervous system regions that have been implicated in the control of bladder 
and urethral function include; specific areas of gray and white matter of the frontal 
lobes anterior to the frontal cortex, specific thalamic nuclei, several portions of the 
basal ganglia, certain portions of the cerebellum, pontine-mesenphalic reticular 
formation, the intermediolateral cell column and ventral horns of the sacral spinal 
cord (Bradley et al., 1974). These areas enable the maintenance of adequate bladder 
capacity by providing for a normal bladder and bladder outlet function, sufficient 
temporal duration, minimal residual urine and volitional control of micturition and 
urinary sphincter function. Two commonly known and important centers for 
micturition and continence, the pontine micturition center (PMC) which is responsible 
for urine emptying and the pontine urine storage center (PUSC) which is a urine 
storage facilitator have been described below.
1.3.1 Pontine micturition center (PMC) or M region
The PMC can be defined as the reflex centre where the bladder-to bladder micturition 
reflex is located (Barrington, 1925; de Groat et al., 1993; Kura, 1965). In the cat 
(Sugaya et al., 1987) and dog (Nishizawa et al., 1988), the PMC corresponds to the 
nucleus locus coeraleus alpha and in the rat it corresponds to Barrington’s nucleus, 
which is located near the nucleus locus coeraleus (Sugaya et al., 1998). The PMC 
comprising the bulbospinal arm of the spinobulbospinal micturition reflex loop 
projects to the bladder motomeurones (Loewy et al., 1979), whilst ascending bladder 
sensory information appears to be relayed back to the PMC via the periaqueductal 
gray (Liu, 1983; Blok & Holstege, 1994; Blok et al., 1995; Ding et al., 1997,1998; 
Marson, 1997; Matsuura et al., 1998, 2000). The PMC is also subject to excitation
15
and inhibition from other brainstem, subcortical and cortical regions such as 
cerebellum, periaqueductal gray, substantia nigra, red nucleus, thalamus, 
hypothalamus, amygdaloid body and the cerebral cortex (Sugaya et al., 1988c). 
Electrical or chemical stimulation of the PMC produces a sharp decrease in urethral 
pressure, pelvic floor relaxation and an increase in intravesical pressure (Holstege et 
al., 1986; Mallory et al., 1991). The PMC is therefore thought to act as a switch 
between continence and micturition, where it seems to regulate bladder capacity and 
bladder contraction as well as coordinating the activity between the bladder and the 
urethral sphincter.
1.3.2 Pontine urine storage center (PUSC) or L region
Anterograde axonal tracing studies in the cat established that the supraspinal circuitry 
controlling the urethral striated muscle was located ventrolaterally to the PMC. This 
region was referred to as the PUSC or L-region. The PUSC was found to correspond 
to the nucleus locus subcoeruleus in rats, cats and dogs. Neurones from this region 
project directly to the Onuf s nucleus (Holstege et al., 1986). Stimulation of the 
PUSC exerts a continuous excitatory effect on the Onuf s nucleus, thus resulting in 
urethral contraction and maintenance of urinary continence (Griffiths et al., 1990).
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1.4 Tracer studies using pseudorabies virus (PRV) -  What do they 
reveal?
Transneuronal tracing with the Bartha Strain of the PRV has been used to identify the 
putative spinal and brain neurones that innervate the lower urinary tract. Injection of 
the PRV results in its transportation to a neuronal cell body via its axon, where it is 
replicated and dispersed throughout the cytoplasm and dendritic area. The PRV 
crosses synaptic gaps into axons that are only synaptically connected and thus its wide 
application in retrograde labelling.
Bladder injections of PRV displayed labelling in the medulla and pons, raphe magnus, 
raphe pallidus and A5. Heavy labelling was also observed in Barrington’s nucleus 
following injection of PRV after bladder injections (Marson, 1997). Labelling in the 
spinal cord following bladder injections was observed in numerous cells located in the 
L6-S1, specifically the intermediolateral cell column (Marson, 1997) where majority 
of the parasympathetic preganglionic neurones and the dorsal gray commisure are 
located. Injections into the external urethral sphincter of rats resulted in the labelling 
of many regions in the brain (Nadelhaft & Vera, 1996). These labelled regions 
included serotonergic nuclei (raphe obscurus and raphe pallidus), noradrenergic nuclei 
(locus coeruleus and subcoeruleus), and to a lesser degree the pontine micturition 
center. Similarly, in cats, injections into the external urethral sphincter identified 
neurones in the raphe nuclei and the pontine micturition center. Areas of the spinal 
cord that were labelled following injections into the external urethral sphincter 
included the pudendal motomeurones in the dorsolateral nucleus of the L6 which is 
known to control external urethral sphincter activity. Also labelled were the 
contralateral and dorsomedial motomeurones (Marson, 1997).
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1.5 Mechanisms involved in voiding
When the bladder is empty, parasympathetic preganglionic neurones are quiescent. 
Following urine accumulation, information is relayed to the sacral spinal cord via 
pelvic nerve A8-fibers where this information has both segmental and supraspinal 
actions (see Barrington, 1925, 1931). This ascending bladder sensory information is 
relayed to the PMC which switches off continence and initiates micturition. 
Information from the PMC is relayed through direct connections to the sacral 
parasympathetic preganglionic neurons (Blok & Holstege, 1997) as well as actions 
mediated by sacral spinal intemeurones (Blok & Holstege, 1999; Shefyck, 2001) back 
to the bladder. For micturition to occur, the sympathetic efferent output to the bladder 
is depressed whilst sacral bladder parasympathetic preganglionic neurones are 
recruited (see de Groat et al., 1999; McMahon & Morrison, 1982). Bladder 
contraction and urine expulsion through the urethra occurs following parasympathetic 
efferent output to the bladder smooth muscle and relaxation of the urethral sphincter 
and pelvic floor. During bladder filling and micturition, in rats and dogs (Bennett et 
al., 1995; Kakizaki & de Groat, 1996; Kruse et al., 1993; Maggi et al., 1986), 
excitatory inputs mediated by somatic nerves exhibit external urethral sphincter 
activity which is thought to be necessary for efficient voiding as well as controlling 
alternate contractions and relaxations of the urethral outlet. In humans, external 
urethral sphincter activity is low during the early filling phase, rises with increases in 
bladder volume but is completely inhibited immediately prior to and during bladder 
emptying (guarding reflex; Brading, 1999). When the bladder volume reaches a 
critical threshold, the EUS relaxes, detrusor muscles contract and the bladder neck 
opens, thus resulting in voiding.
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1.6 Clinical evidence for the relevance of the 5-HT2 receptor to 
humans
A vast amount of research has been carried out to investigate the involvement of 5- 
HT2 receptors in obesity and depression. Briefly, the 5-HT2C receptor agonist mCPP 
has been vastly used in obesity studies where it was observed to reliably reduce food 
intake in lean and obese humans (see Halford et al., 2007). Additionally, other 5- 
HT2C receptor agonists such as Org 12962 (Organon), Ro 60-0175 (Roche and 
Vemalis), VER-3323 (Vemalis), BVT-933 (Biovitrum and GlaxoSmithKline) and 
YM348 (Yamanouchi Pharmaceuticals) have been investigated with some compounds 
passing into phase I of clinical trials (see Halford et al., 2007). With respect to 
depression, selective serotonin reuptake inhibitors (SSRIs) are the most widely used 
drugs to treat depression due to their minimal side effects. A few antidepressants 
(nefazodone, trazodone and mirtazapine) act as antagonists at the 5-HT2A receptor 
which is thought to be an important property that underlies the therapeutic properties 
of the drug. Indeed blockade of 5-HT2A receptors is thought to affect the onset of the 
therapeutic actions of the (SSRIs), thus improving the drug effects (Caleda et al., 
2004). There is currently no evidence for the clinical use of drugs acting at the 5- 
HT2B receptor to produce therapeutic effects in humans. Preclinical studies have also 
revealed a role for the 5 -HT2 receptor in other conditions such as sexual dysfunction, 
anxiety and schizophrenia amongst others.
1.7 5-HT/5-HT receptor involvement in the lower urinary tract
Currently, 14 different 5-HT receptor subtypes exist and these have been classified 
into seven different receptor families based on receptor homology, signalling pathway 
and operational characteristics (5 -HT1.7; see Hoyer et al., 1994; Saxena, 1995).
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Transneuronal tracer studies in rats using PRV, revealed labelling of the serotonergic 
nuclei following injections into the bladder and the external urethral sphincter. The 
labelled regions included the raphe magnus, raphe pallidus and raphe obscurus 
(Nadelhaft & Vera, 1996; Marson, 1997). Injections of PRV into the urethral smooth 
muscle also infected serotonergic regions, specifically the raphe magnus and 
periaqueductal gray (Vizzard et al., 1995). hnmunocytochemical studies in rats, cats 
and non-human primates also revealed that the lumbosacral sympathetic and 
parasympathetic autonomic nuclei, and the Onuf s nucleus in the lumbosacral spinal 
cord, received strong serotonergic inputs from the raphe nuclei (Skagerberg & 
Bjorklund, 1985; Kojima et al., 1983; Rajaofetra et al., 1992; Mizukawa, 1980; 
Bowker et al., 1981). Additionally, it was also revealed that the urothelium of the 
urethra contained endocrine-like cells storing 5-HT (Hakanson et al., 1974), and that 
5-HT induced increases in urethral pressure (Creed & Tulloch, 1978).
5-HT has been shown to play an important role in the control of the lower urinary 
tract. Studies investigating supraspinal influences on bladder function found that 
activation of the raphe nuclei inhibited reflex bladder contractions, as well as the 
sacral efferent pathways to the bladder (see de Groat et al., 1993; McMahon & 
Spillane, 1982). The mechanism proposed for these influences was that raphe 
neurones inhibited bladder activity through a spinobulbospinal negative-feedback 
circuit, where ascending sensory input from the bladder activated a descending 
inhibitory projection back to the sacral spinal cord (see Fraser & Chancellor, 2003). 
To elaborate further, the raphe neurones were proposed to influence bladder function 
by mediating an inhibitory control of sacral parasympathetic outflow and facilitatory 
control of the lumbar sympathetic outflow (possibly aiding in urine storage). What is
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interesting however is that neuronal recording of single units in the raphe nucleus of 
the cat revealed that these neurones were activated by bladder distension (Lumb, 
1986). This therefore raises the possibility that the raphe neurones may also be 
involved in a mechanism for voiding via excitatory influences.
Several pharmacological studies have tried to provide insight into the influences of 5- 
HT on bladder function. In cats, iontophoretic application of 5-HT to spinal 
autonomic neurones demonstrated prolonged activation of thoracic preganglionic 
neurones (de Groat & Ryall, 1967) and inhibition of firing of parasympathetic 
preganglionic neurones in the sacral spinal cord. Subsequent studies showed that 
reflex bladder activity and reflex bladder discharges on bladder parasympathetic 
nerves were depressed following intravenous administration of 5-hydroxytryptophan 
(5-HTP; a precursor for 5-HT), and tryptophan (Morgan et al., 1979). Additionally, it 
has been revealed that 5-HT inhibits firing of spinal dorsal hom neurones evoked by 
stimulation of pelvic nerve afferents. It was also revealed that 5-HT receptors within 
the Onuf s nucleus caused contractions of the external urethral sphincter following 
electrical stimulation (see Fraser & Chancellor; 2003; Holstege et al., 1986) and that 
5-HT agonists enhanced external urethral sphincter reflexes which were depressed by 
5-HT antagonists (Thor et al., 1990; Downie & Bialik, 1988). From the above 
studies, it would appear that 5-HT is mainly inhibitory on bladder and urethral 
function, although an excitatory effect cannot be ruled out. An important question to 
ask therefore is whether supraspinal and spinal influences of 5-HT render a 
mechanism for urine storage/continence. This notion may however be reinforced by 
the fact that activation of 5-HT receptors facilitates a bladder-to-sympathetic reflex 
following bladder distension (Thor et al., 1990; Morgan et al., 1979), and this reflex is
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clearly known to aid in maintaining urinary continence (de Groat & Lalley, 1972; de 
Groat & Theobald, 1976).
Outlined below is a detailed summary of distribution in die central nervous system 
(and peripheral tissues), receptor pharmacology, actions at the molecular level and 
functional characteristics of the 5-HTia, 5-HT2,5-HT3, 5 -HT4, 5-htsA, 5-HT6 and 5- 
HT 7 receptor families. The role of these receptors in micturition has also been 
described.
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1.7.1 5-HTia receptor
To date, the 5-HTia receptor is the best characterised of the 5-HT receptors. This 
mainly emerged from early studies identifying the selective 5-HTia agonist, 8-OH- 
DPAT (Gozlan et al., 1983) as well as from receptor cloning (Kobilka et al., 1987; 
A lb erts  al., 1990).
1.7.1.1 Receptor distribution
Receptor autoradiography studies using various ligands such as [3H]-5-HT, [3H]-8- 
OH-DPAT and more recently [3H]-WAY 100635 (Pazos & Palacios, 1985; Hoyer et 
al., 1986) identified 5-HT]a receptors in the limbic brain areas which included the 
hippocampus, lateral septum, cortical areas (cingulate and entorhinal cortex) and the 
mesenphalic raphe nuclei (dorsal and median raphe nuclei; see Barnes & Sharp,
1999). At the sub-cellular level, 5-HTia receptors were found to be located 
postsynaptic to 5-HT neurones in forebrain regions, as well as on the soma and 
dendrites in the mesenphalic and medullary raphe nuclei (see Miquel et al., 1991,
1992). Localization of the 5-HTia receptor to the somatodendritic region 
(presynaptic) of neurones isolated from the raphe nuclei have been shown to act as 
autoreceptors which inhibit cell firing. Furthermore, in situ hybridisation and 
immunocytochemical studies found 5-HTja receptors in pyramidal neurones of the 
cortex and hippocampus and also hippocampal granular neurones (Pompeiano et al., 
1992; Burnet et al., 1995). The receptors in the hippocampus were found to be 
heteroreceptors with a postsynaptic location (Palacios et al., 1991; Ghavami et al., 
1999; Riad et al., 2000). Additionally, the 5-HTia receptor is also expressed in 5-HT- 
containing neurones in the raphe nuclei, cholinergic neurones in the septum and 
possibly glutamatergic neurones in the cortex and hippocampus (Kia et al., 1996).
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Peripherally, mRNA coding for the 5-HTja receptor has been detected in the 
lymphatic tissue, gut, muscle and kidney (Kobilka et al., 1987; Albert et al., 1990; 
Chalmers & Watson, 1991).
1.7.1.2 Receptor pharmacology
Several agonists have been developed to act at the 5-HTia receptor and these include 
buspirone, ipsaspirone, gepirone, tandospirone, BMY 7378, and NAN-190 (Zifa & 
Fillon, 1992). These ligands were however found to act as partial agonists in animal 
models even though they acted as full agonists in recombinant systems. Breakthrough 
in 5-HTia studies came from the development of the highly selective prototypical 5- 
HTia receptor agonist 8-OH-DPAT (Kd = 0.23-1.8 nM) which displays high potency 
in vivo, and continues to be the agonist of choice in 5-HTia receptor studies. 
Non-selective antagonists propanolol, spiperone and pindolol were the only 
commercially available antagonist tools used to investigate the 5-HTia receptor for a 
long time. A number of 5-HTia ‘silent’ receptor antagonists have now been 
developed and these include WAY 100635, WAY 100135 and NAD-299. The term 
'silent' antagonist has been used for such compounds in order to distinguish them from 
several 5-HTi a receptor partial agonists that were initially designated 'antagonists'. Of 
the three compounds, WAY 100635 has been found to be the most potent antagonist 
of the group (Fletcher et al., 1996; Johansson et al., 1997). An in depth study carried 
out by Fletcher and colleagues (1996) investigating the electrophysiological, 
biochemical, neurohormonal and behavioural properties of WAY 100635 further 
demonstrated the potent selectivity properties of the antagonist at the 5-HTia receptor. 
Briefly, WAY 100635 was found to have an I C 5 0  of 1.35 nM, with greater than 100- 
fold selectivity for the 5-HTia site relative to a range of other receptors (Fletcher et
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al., 1996). In mice, intravenous administration of [ H]WAY-100635 was shown to 
bind selectively to brain 5-HTia receptors in vivo. Electrophysiological studies 
demonstrated blockade of the effects of agonists by WAY 100635, at both the 
postsynaptic 5-HTia receptor in the hippocampus, and the somatodendritic 5-HTia 
receptor located on raphe 5-HT neurones. Furthermore, WAY 100635 was found to 
dose-dependently block the inhibitory effects of 8-OH-DPAT on raphe 5-HT neuronal 
firing.
1.7.1.3 Signal transduction
The 5-HTja receptor couples negatively via G proteins (a;) to adenylate cyclase in 
both rat and guinea pig hippocampal cell lines expressing the cloned version of the 
receptor (see Boess & Martin, 1994; Sadou & Hen, 1994). Other effects involving the 
5-HTia receptor in transfected cell-lines include decreased or increased intracellular
^  I
Ca and activation of phospholipase C (see Boess & Martin, 1994). However, there 
is no solid evidence for such coupling in brain tissue.
1.7.1.4 Physiological functions
5-HTja receptors have been implicated in mediating various behavioural and 
physiological effects such as hyperphagia, hypothermia, altered sexual activity, a tail 
flick response (see Green & Grahame-Smith, 1976; Millan et al., 1991; Lucki, 1992) 
and bladder function. Additionally, there is a vast amount of basic and clinical data in 
the literature surmising the anxiolytic and antidepressant activity of 5-HTia receptor 
agonists (Traber & Glaser, 1987; Chamey et al., 1990; Handley, 1995).
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1.7.1.5 5-HTia receptors -  excitatory or inhibitory?
5-HTia receptor activation causes inhibition characterised by neuronal 
hyperpolarisation, and this is mediated via G-protein-coupled opening of K+ channels 
(see Nichol et al., 1990; Aghajanian, 1995). Ionotophoretic administration of 5-HTia 
receptor agonists and 5-HT have been shown to inhibit neuronal activity in rat 
hippocampus, frontal cortex and other brain areas (Sprouse & Aghajanian, 1988; 
Ashby et al., 1994 a,b), and these effects have been blocked by both non-selective 
(spiperone and methiothepin) and selective (WAY 100635) 5-HTia receptor 
antagonists. Similar effects have also been observed in 5-HT containing neurones in 
the raphe nuclei following administration of 5-HTiA receptor agonists and antagonists 
(Sprouse & Aghajanian, 1988).
1.7.1.6 5-HTia receptors and micturition
NAN 190 and BMY 7378 have been shown to demonstrate antagonist-like activity in 
measures of postsynaptic 5 -H T ia  receptor activation and agonist-like activity when 
examined at the somatodendritic 5 - H T ia  autoreceptors (Hjorth & Sharp, 1990; Sharp 
et al., 1990). By acting as partial 5-HTi a receptor agonists at the somatodendritic 5- 
HTia autoreceptors, NAN 190 and BMY 7378 were shown to inhibit the firing of 
raphe neurons in rats (Gobert et al., 1995) and cats (Fomal et al., 1994), thus leading 
to inhibition of 5-HT turnover in different brain areas and the spinal cord. It was 
proposed that decreases in spinal 5-HT inhibited the endogenous spinobulbospinal 
negative feedback mechanism, thus leading to excitatory effects on the micturition 
reflex. Similarly, full 5 - H T ja receptor agonist 8-OH-DPAT and strong partial agonist 
Rec 0/0249 also inhibited raphe neuronal firing, leading to increased frequency of 
voiding contractions (Lecci et al., 1992) and decreased bladder capacity (Testa et al.,
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1999). Conversely, WAY 100635 was observed to increase the firing rate of raphe 
nuclei cells of rats in vitro (Corradetti et al., 1996) as well as in cats and guinea pigs 
in vivo (Fomal et al., 1996), thus leading to an increase in spinal 5-HT which in turn 
inhibited the micturition reflex.
Several pharmacological studies have provided evidence for the involvement of 5- 
HTia receptor agonists and antagonists in the control of the lower urinary tract 
function. Lecci et al (1992) demonstrated that intravenous (i.v.), 
intracerebroventricular (i.c.v.) and intrathecal (i.t.) administration of the selective 5- 
HTja receptor agonist 8-OH-DPAT increased the frequency of bladder contractions in 
both normal and spinal-cord injured (SCI) rats, thus suggesting the 5-HTia receptor 
was excitatory in micturition. Additionally, bladder capacity was found to be reduced 
following i.v. administration of 8-OH-DPAT in conscious rats (Testa et al., 1999). 
Another study that corroborated with the above findings was from Conley et al (2001) 
where following administration of 8-OH-DPAT and BMY 7378 (also an aio- 
adrenoceptor antagonist), a significant decrease in bladder pressure and volume 
threshold in anaesthetized male rats was observed. The effects caused by BMY 7378 
were confirmed as 5-HTia receptor mediated rather than am receptor mediated, as a 
dose of WAY 100635 found to be ineffective on the micturition reflex blocked the 
effects of BMY 7378. Interestingly, Conley and colleagues found that BMY 7378 
and WAY 100635 reduced baseline urethral pressure and inhibited reflex urethral 
contractions. As BMY 7378 possesses selectivity for ai-adrenoceptor subtypes, it 
was concluded these effects were mediated via aiA- and dio-adrenoceptors which is 
the next receptor family that WAY 100635 has affinity for (Forster et al., 1995). Gu 
and colleagues (2004) investigated the effects of i.v. administration of 8-OH-DPAT
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on bladder capacity and EUS-EMG activity in chronic spinal cord injured (SCI) and 
intact cats. Their results from this study demonstrated that following administration 
of 8-OH-DPAT in intact cats, the effects on bladder capacity were variable, even 
though they tended towards an increase, with no significant effects observed on EUS- 
EMG activity. The group postulated that the inconsistencies observed on bladder 
capacity may have been due to the dual role of the 5-HTi a receptors as both 
presynaptic autoreceptors and postsynaptic receptors. Interestingly, i.v. 
administration of 8-OH-DPAT in SCI cats significantly increased volume threshold, 
bladder capacity and residual volume and these effects were reversed by the selective 
5 - H T ia  receptor antagonist WAY 100635 thus confirming that 5 - H T ja receptors were 
involved in mediating the effects observed. From these results, the group provided 
evidence for a possible beneficial role of the 5 - H T ja receptor in suppressing bladder 
hyperreflexia.
I.v. administration of spiroxitane, NAN 190 and high doses of buspirone, which all 
possess antagonistic-like properties at the 5 - H T ja receptor, were found to inhibit 
isovolumetric bladder contractions in a dose dependent manner (Lecci et al., 1992). 
However, dual/multiple actions of these compounds makes it difficult to draw solid 
conclusions regarding the physiological role of 5 - H T ja receptors in micturition. This 
issue has been overcome through the use of the selective 5 - H T jA receptor antagonist 
WAY 100635 which acts as an antagonist at both the pre- and postsynaptic level, 
unlike other 5 - H T ja receptor antagonists. Support for a physiological role of 5-HT ja 
receptor antagonists arises from isovolumetric experiments carried out by Kakizaki 
and colleagues (2001) where the group showed dose dependent inhibition of rhythmic 
bladder contractions following i.t. (L6-S1) administration of WAY 100635. The
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group also found that i.t. administration of WAY 100635 at the thoracic and cervical 
levels of the spinal cord did not have any effect on rhythmic bladder contractions, thus 
suggesting that spinal 5-HTia receptors at the L6-S1 level are involved in bladder 
function. Systemic (i.v.) administration of WAY 100635 also produced significant 
inhibition of rhythmic bladder contractions. In conscious rats, i.v. administration of 
WAY 100635 has also been shown to increase bladder capacity (Testa et al., 1999). 
More evidence for an inhibitory action of 5-HTia receptor antagonists on the 
micturition reflex was provided by i.v. injections of another structurally related 
antagonist to WAY 100635, p-MPPI, which was shown to inhibit the regular 
isovolumetric bladder contractions (Testa et al., 2001). Interestingly, the inhibitory 
effect of i.v WAY 100635 was antagonized by pretreatment with mesulergine, a 5- 
HT2 receptor antagonist in anaesthetized rats whereas the ‘partial agonist’ NAN-190 
was unaffected (Testa et al., 1999). Similar results have been obtained following pre- 
treatment of WAY 100635 with the 5-HT2A receptor antagonist ketanserin where the 
rats were devoid of inhibitory effects, therefore suggesting the involvement of 5-HT2 
receptors. De Groat (2002) proposed a supraspinal 5-HTia autoreceptor pathway 
involving 5 -HT2 receptors as a possible explanation for the blockade of the effects of 
WAY 100635 on the micturition reflex (see section 1.7).
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1.7.2 5-HT2 receptor
The 5 -HT2 receptor family comprises three receptor subtypes, 5-HT2A, 5-HT2B and 5- 
HT2C, which have been reported to play a major role in a range of central nervous 
system functions including anxiety, depression, migraine, sleep, satiety and 
schizophrenia (Baxter et al., 1994). All three receptor subtypes are classified into the 
same family as they couple to identical signalling pathways, possess similar 
pharmacological profiles as well as a similarity in (gene) structure (Humphrey et al.,
1993). The 5 -HT2 receptors are associated with the Gq family of G-proteins and upon 
activation, stimulate phospholipase C to increase phosphoinositide metabolism, thus 
causing a transient rise in intracellular free calcium (Martin & Humphrey, 1994; Roth 
et al., 1998; Porter et al., 1999).
1.7.2.1 5-HT2a receptor
1.7.2.1.1 Receptor distribution
The 5-HT2a receptor has been cloned from rat (Pritchett et al., 1988), human (Stam et 
al., 1992), mouse (Foguet et al., 1992; Yang et al., 1992), hamster (Chambard et al., 
1990; Van Obberghen-Schilling et al., 1991), pig (Johnson et al., 1995) and rhesus 
monkey (Johnson et al., 1995).
Receptor autoradiography, in situ hybridisation and immunocytochemistry have 
enabled the mapping of 5 -H T 2a receptors in the CNS. 5 -H T 2a  receptor distribution 
has been found in many cortical areas (neocortex, entorhinal and pyriform cortex, and 
claustrum), caudate nucleus, nucleus accumbens, olfactory tubercle and hippocampus 
of various species (Pazos et al., 1985, 1987; Lopez-Gimenez et al., 1997). Regarding 
location in the brain, it has been reported that the 5 -H T 2a  receptor-like
30
immunoreactivity or 5-HT2A receptor mRNA has been found in neurones such as 
local GABAergic intemeurons, cortical pyramidal neurones (Burnet et al., 1995) and 
cholinergic neurones in the basal forebrain and the brainstem (Morilak et al., 1993). 
5-HT2A receptor mRNA has also been detected in the spinal cord of the rat, cat, 
monkey and human tissue using polymerase chain reaction with southern 
hybridization analysis (Helton et al., 1994). Additionally, molecular studies have 
also revealed the presence of 5-HT2A receptors in the cardiovascular system of several 
species. In humans for example, 5 -HT2A receptors have been observed to be 
widespread on arterial smooth muscles (Ullmer et al., 1995).
A postsynaptic location has been implicated for the 5 -HT2A receptor. This is due to 
the fact that the 5-HT2A binding sites, 5-HT2A mRNA and 5-HT2A receptor-like 
immunoreactivity, which are all distributed within the same region (Mengod et al., 
1990; Morilak et al., 1993, 1994; Pompeiano et al., 1994; Burnet et al., 1995), are 
located in the region where the receptors are present. However, 
immunocytochemical studies also deduced a presynaptic location of 5-HT2A receptors 
on nerve terminals (Jakab & Goldman-Rakic, 1998).
1.7.2.1.2 Receptor pharmacology
Initially, discrimination of the 5-HT2A receptor subtype from either 5 -HT2B or 5-HT2C 
receptors proved to be a challenge due to the lack of selective agonists and antagonists 
for the receptor. Antagonists such as ketanserin and spiperone with 40-fold and over 
100-fold selectivity for 5-HT2A receptors (over 5 -HT2B or 5 -HT2C respectively;
Jerman et al., 2001) were initially used to make pharmacological distinctions between 
the 5 -HT2 receptor family. The development of MDL 100907 (Ki = 0.78 nM at the
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human 5-HT2A receptor; Gleason et al., 2001) a potent antagonist of the 5 -HT2A 
receptor with a low affinity for 5-HT2C and other receptors, enabled further 
discrimination between the 5 -HT2 family. In addition to the above, the development 
of selective 5-HT2B/2C receptor antagonists SB 200646A and SB 206553, 5-HT2B 
receptor antagonist SB 204741 and 5 -HT2C receptor antagonists RS 102221 and SB 
242084 have also made it possible to make further discriminations between the 5 -HT2 
receptor family. However, even though progress has been made regarding 
development of selective 5-HT2a receptor antagonists, at present there are still no 
suitable commercially available 5-HT2A receptor agonists. Therefore compounds 
such as DOI and its structural analogues (DOB and DOM; Newton et al., 1996; Porter 
et al., 1999) and quipazine have been labelled as 5-HT2A ‘preferring’ receptor 
agonists due to their appreciable affinity for the 5 -HT2A receptor.
Interestingly, a species variation was found to exist when studies comparing the 
pharmacological profile o f the rat and human 5-HT2A receptor were carried out. It 
was found that the rat receptor had a much higher affinity for mesulergine (5-HT2C 
receptor antagonist) than the human receptor (Ki = 5nM in rat vs Ki =150 nM in 
human), even though the human 5-HT2A receptor is highly homologous to that of the 
rat receptor (Kao et al., 1992; Johnson et al., 1994).
1.7.2.13 Signal transduction
When stimulated, the 5-HT2A receptor was found to activate phospholipase C in both 
heterologous expression systems (Pritchett et al., 1988; Stam et al., 1992) and brain 
tissue (Conn & Sanders-Bush, 1984; Godfrey et al., 1988) through a G-protein 
coupling mechanism. An example of this was shown in Xenopus oocytes or HEK293
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where expression of the 5-HT2A receptor led to activation of phospholipase C, Ca2+ 
mobilisation, or activation of Ca2+-induced Cl" current. However, additional 
signalling pathways have been reported for endogenously expressed 5-HT2A 
receptors. These include inhibition or activation of adenylyl cyclase (Gamovskaya et 
al., 1995; Berg et al., 1994 respectively) or activation of phospholipase A2 (Felder et 
al., 1990).
An interesting phenomenon reported for the 5 -HT2A receptor in some in vivo and in 
vitro models is a down-regulation of the receptor following chronic exposure to 
antagonists such as mianserin, spiperone and mesulergine (Sanders-Bush, 1990; Roth 
& Ciaranello, 1991; Grotewiel & Sanders-Bush, 1994). It has been proposed that this 
down-regulation may possibly be a contributory factor towards the action o f some 
ligands as inverse agonists (see Bames & Sharp, 1999).
1.7.2.1.4 Physiological functions
The involvement of the 5-HT2a receptor subtype in both peripheral and central 
functions has been widely investigated to date. The 5-HT2A receptor has therefore 
been implicated in various functions such as smooth muscle contraction, platelet 
aggregation, control o f hormone or transmitter release, control of sexual activity, 
sleep regulation, motor behaviour, and psychiatric disorders such as epilepsy, 
migraine, anxiety, depression, schizophrenia and hallucinations (see Gerhardt & 
Heerikhuizen, 1997). However, it should be noted that the functions listed above are 
not mediated exclusively by the 5-HT2A receptors as the agonists used to elucidate the 
above functions are only partially selective for the 5-HT2A receptor, possessing 
selectivity for other receptors.
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1.7.2.2 5-HT2b receptor
1.7.2.2.1 Receptor distribution
The 5-HT2B receptor (originally known as 5-HT2F receptor) was originally found to be 
located in the stomach fundus smooth muscle of the adult rat (Foguet et al., 1992; 
Kursar et al., 1992) and was thus implicated in contraction of this smooth muscle. 
Although previously reported as present in the human brain but not in the rat brain 
(Kursar et al., 1994; Schmuck et al., 1994), Duxon et al (1997) showed the presence 
of 5 -HT2B receptors in the rat brain, more specifically in the cerebellum, cortex, 
hippocampus and amygdala. Similar locations were found to express 5 -HT2B 
receptors in the mouse brain (Choi & Maroteaux, 1996). 5 -HT2B receptor mRNA was 
also identified in the spinal cord o f the rat, cat, monkey and humans (Helton et al.,
1994). 5 -HT2B receptors have also been found in a variety of peripheral tissues such 
as the adult gut and cardiovascular system (Loric et al., 1992), which include the 
stomach, intestine and pulmonary smooth muscle, pulmonary and vascular endothelial 
cells and cardiomyocytes in mouse (Choi & Maroteaux, 1996), human (Choi et al., 
1994; Schmuk et al., 1994; Bonhaus et al., 1995) and rat (Foguet et al., 1992; Kursar 
etal., 1992; Baxter ef al., 1994; Ullmer et al., 1995).
1.7.2.2.2 Receptor pharmacology
The pharmacological profile o f the 5 -HT2B receptor has been elucidated using 
displacement of [3H] 5-HT (Foguet et al., 1992; Bonhaus et al., 1995) or [125I]DOI 
(Loric et al., 1992; Choi et al., 1994) binding. O f all the three 5 -HT2 receptor 
subtypes, the 5 -HT2B receptor has been the easiest receptor to discriminate from the 
other two due to its lower affinity for mianserin and ritanserin (non selective 5 -HT2 
receptor antagonists) and higher affinity for 5-HT and yohimbine (a2-adrenergic
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antagonist). Furthermore, the use of SB 204741 has shown 20-60 fold selectivity for 
the 5-HT2B receptor relative to 5 -HT2A, 5-HT2C or other receptors at which it has been 
tested (Bonhaus et al., 1995; see Baxter, 1996). RS 127445 has been described as the 
most selective commercially available 5-HT2B receptor antagonist as it has reduced 
selectivity for the 5 -HT2A receptor and greater than 400-fold selectivity over the 5- 
HT2C receptors. To date, the only agonist that has been described as possessing 
selectivity for the 5 -HT2B receptor is BW 723C86 as it has about 10-fold selectivity 
for the 5-HT2B receptor when compared to either the 5 -HT2A or 5 -HT2C receptor.
Interestingly, although both the rat and human 5 -HT2B receptors display a similar 
pharmacological profile, there are some differences where for example affinity for the 
5-HT2A receptor antagonists ketanserin and spiperone is observed to be much higher 
for the human than the rat receptor. Similarly, a species difference exists between the 
mouse 5 -HT2B receptor compared to the rat or human 5 -HT2B receptors where the 
mouse 5 -HT2B receptor has a lower affinity for 5-HT and a higher affinity for 
spiperone (Bonhaus et al., 1995; Wainscott et al., 1996).
1.7.2.23 Signal transduction
When expressed in Xenopus oocytes, the rat 5 -HT2B receptor activation opens up 
Ca2+-activated chloride channels due to the activation of phospholipase C (Foguet et 
al., 1992). This response is less pronounced and thus distinct from the other 5 -HT2 
receptor subtypes. An additional signalling pathway, cAMP production, has been 
observed following expression of 5 -HT2B receptors in A V I2 cells (Lucaites et al., 
1996).
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1.7.2.2.4 Physiological functions
5-HT2B receptors have primarily been shown to contract stomach and intestinal 
smooth muscle (Vane, 1959; Baxter et al., 1994; Borman & Burleigh, 1995). 
However, several studies have shown that 5 -HT2B receptors, relax the vascular 
endothelium through stimulation of nitric oxide release (Glusa & Richter, 1993; 
Bodelsson et al., 1993; Ellis et al., 1995). In obesity, systemic administration of 5- 
HT2B receptor agonist BW 723C86 was found to dose-dependently increase food 
intake in free feeding rats (Kennett et al., 1997). This increase was suggested to be as 
a result o f an increase in gastric emptying due to the primary role played by 5-HT2B 
receptors in contracting smooth and intestinal smooth muscle. Activation of 5 -HT2B 
receptors has also shown an association of the receptors with pulmonary hypertension 
(Launay et al., 2002) and irritable bowel syndrome (Borman et al., 2002).
1.7.23 5-HT2c receptor
1.7.2.3.1 Receptor distribution
Pazos et al (1984) found the 5- HT2C receptor to be highly expressed in the choroid 
plexus of several mammalian species (Pazos et al., 1984). Subsequently, regional 
distribution studies identified 5- HT2C receptors in other parts of the rat, human and 
monkey brain. In the rat, 5-HT2c mRNA was found in the hippocampus, cerebral 
cortex, striatum and substantia nigra, whereas in humans 5 -HT2C mRNA was found in 
the cerebral cortex, substantia nigra, cerebellum and amygdala (Abramowski et al.,
1995). In the monkey brain, using in situ hybridization, Lopez-Gimenez et al (2001), 
detected 5 -HT2C mRNA in layer V of the cortex, nucleus accumbens, anterior caudate 
and putamen, septal nuclei, amygdala, as well as several thalamic, midbrain and 
brainstem nuclei. In the spinal cord of the rat, monkey and humans, 5-HT2c receptor
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mRNA was detected using polymerase chain reaction with southern hybridization 
analysis (Helton et al., 1994). Interestingly, even though 5-HT2c mRNA is widely 
expressed in the central nervous system, there is low to absent expression in the 
peripheral tissues.
5-HT2c receptors are mainly found postsynaptically (Palacios et al., 1991; Comea- 
Hebert et al., 1999; Verge & Calas, 2000), but there is the possibility o f a presynaptic 
location.
1.7.2.3.2 Receptor pharmacology
It is difficult to make a sufficient discrimination of 5-HT2c receptors from 5-HT2A and 
5 -H T 2b receptors due to a lack of selective ligands. This means that the selectivity for 
most o f the 5-HT2c receptor agonists is deduced from their reduced intrinsic efficacy 
at 5 -H T 2a and 5 - H T 2b receptors rather than their binding selectivity. For many years, 
mCPP has been used as the typical 5-HT2c receptor agonist as it has a greater affinity 
for cloned human 5-HT2c receptors (K,= 16 nM) over the 5-HT2A (Kj = 85 nM) and 5- 
H T 2b (K, = 40 nM; Kimura et al., 2004). Over the years, other commercially available 
5-HT2c receptor agonists have emerged and these include Ro 60-0175 (Kj = 1 nM) 
which is more selective over the 5-HT2A receptor (Kj = 32 nM; Hemrick-Luecke & 
Evans, 2002) in cloned rat binding studies. Other reportedly selective 5-HT2c 
receptor agonists include WAY 161503 (K, = 3 nM), WAY 163909 (Kj = 10 nM) 
which is more selective than 5-HT2A (Kj = 212 nM) and 5 - H T 2b (Kj = 485 nM;
Dunlop et al., 2005) receptors and YM-348 (Ki = 0.89 nM) which is more selective at 
the 5 -H T 2c  receptor than the 5-HT2A (Kj = 13 nM) and 5 -H T 2b (Kj = 2.5 nM; Kimura 
et al., 2004) receptors. Antagonist studies have also been used to further distinguish 
5 -H T 2c  receptors from either 5 - H T 2A/2b receptors. The development of selective 5-
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HT2c receptor antagonists SB 242084 and RS 102221, which are at least two orders of 
magnitude more selective for the 5-HT2c receptor versus the 5-HT2B, 5-HT2A 
receptors and other binding sites (Bonhaus et al., 1997; Kennett et al., 1997) have led 
to a better understanding of the pharmacology of 5-HT2c receptors.
1.7.2.3.3 Signal transduction
Phospholipase C activity is increased following activation o f the 5-HT2c receptors in 
the choroid plexus of various species (Sanders-Bush et al., 1988). This activity is 
mediated via a G-protein coupled mechanism (see Boess & Martin, 1994). It has also 
been suggested that in addition to activating phospholipase C, 5-HT2c receptors may 
also trigger cGMP in the choroid plexus (Kaufman et al., 1995).
Similar to 5-HT2A receptors, continuous exposure of 5-HT2c receptors to both 
agonists and antagonists down-regulates the receptor (Barker et al., 1994; Labrecque 
et al., 1995) and this is thought to contribute to the inverse agonist properties 
observed for certain 5-HT2c agonists (e.g. mCPP which has inverse agonistic 
properties at the 5-HT2A receptor).
1.7.2.3.4 Physiological functions
Activation of 5-HT2c receptors has been reported to mediate various effects, including 
hypophagia, hypolocomotion, anxiety, hyperthermia, induction o f penile erections 
(Kahn & Wetzler, 1991) and bladder function (Steers & de Groat, 1989). Most of 
these correlations have been based on behavioural results obtained using non-selective 
5-HT2c agonists such as mCPP, TFMPP, MK212 and antagonists such as ritanserin 
and mianserin. In addition to pharmacological studies, knockout mice have been used
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to model obesity, where the mice lacking the 5-HT2C receptor develop late-onset 
obesity (Tecott et al., 1995) with no reversal properties observed following 
administration o f mCPP, thus further elucidating the role of the 5-HT2C receptor 
subtype.
1.7.2.4 5 -HT2 receptors -  excitatory or inhibitory?
The role o f 5 -HT2 receptors in the control of neuronal firing activity in the central 
nervous system is fairly controversial as conflicting results have been obtained 
following electrophysiological studies carried out in vitro and in vivo, as described 
below.
1.7.2.4.1 Excitatory effects
Several studies have implicated a direct excitatory effect o f 5 -HT2 receptors on the 
central nervous system. In the brain, 5 -HT2 receptor activation was found to mediate 
neuronal excitation characterised by depolarisation, increased excitability o f the 
neurones and neurotransmitter release. Evidence for this comes from several 
electrophysiological recordings carried out in vivo and in vitro, on various brain 
regions, where the effects o f agonists and antagonists on these recordings were 
observed. 5-HT2A receptor-mediated excitation in the cortex has also been observed 
(Sheldon & Aghajanian, 1991; Marek & Aghajanian, 1995) following intracellular 
recordings of intemeurones in slices. This excitatory effect was concluded to occur as 
a result o f reducing outward potassium currents, and was blocked by selective 5-HT2A 
receptor antagonist MDL 100907. Depolarisations, thought to be 5-HT2A receptor 
mediated have also been detected in slice preparations of the nucleus accumbens 
(North & Uchimura, 1989), neocortex (Aghajanian & Marek, 1997) and the dentate
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gyrus (Piguet & Galvan, 1994). It has also been observed that glutamatergic 
pyramidal neurones in the rat cortex are depolarised following activation o f 5 -HT2C 
receptors (Sheldon & Aghajanian, 1991) in in vitro electrophysiological studies.
Raphe spinal neurones are known to be the main source of 5-HT in the spinal cord 
(Schmidt & Jordan 2000) and they project extensively to most cell types in the spinal 
cord including motomeurones (Jacobs & Azmitia 1992; Kiehn et al. 1992). An 
excitatory effect has been observed on spinal cord neurones following activation of 5- 
HT2 receptors. These receptors were found to cause depolarisations of dorsal horn 
neurones and motomeurones in the frog (Tan & Miletic, 1992; Holohean et al., 1990) 
and these depolarisations were blocked by the 5 -HT2 receptor antagonists ketanserin, 
methylsergide and mianserin. Hori and colleagues (1996) observed long-lasting 
potentiations of excitatory postsynaptic currents (EPSC) amplitude and miniature 
EPSC frequency following administration of DO I in whole-cell recordings from 
superficial dorsal horn neurones in neonatal rat spinal cord slices. The group 
concluded that the above effects on the dorsal hom neurones were possibly mediated 
by 5-HT2 receptors.
1.7.2.4.2 Inhibitory effects
Inhibitory effects o f 5 -HT2 receptors on neuronal firing have been recorded in the rat 
brain, following application of 5 -HT2 receptor agonists (DOI and mCPP) by 
microiontophoresis onto the medial prefrontal cortex and the orbito-frontal cortex 
(Bergqvist et al., 1999). However, this study ruled out the possibility that this 
inhibitory effect on firing was indirectly mediated by excitatory 5 -HT2 neurones on
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GABA intemeurons as bicuculline (GABA antagonist) and no effect on the inhibitory 
action of DOI and mCPP.
An electrophysiological study carried out on motomeurone slices from neonatal rats 
reported that 5 -HT2 receptors were inhibitory, as they caused potassium-mediated 
hyperpolarization (Wang & Dun, 1990). Additionally, the same study found that 5- 
HT via 5-HT2 neurones indirectly affected the activity of motomeurones by activating 
inhibitory intemeurones.
1.7.2.5 5 -HT2 receptors and micturition
Both in vitro and in vivo pharmacological studies have implicated the involvement of 
the 5 -HT2A and 5 -HT2C receptor subtypes in the control of the lower urinary tract in 
humans and animals. These receptors have been found to function as either excitatory 
or inhibitory on the bladder or urethra.
Serotonin w'as found to produce dose dependent contractions on isolated rat bladder 
muscle strips (Kim et al., 2002). The 5-HT2A receptor antagonist ketanserin, almost 
abolished the facilitatory effects of serotonin in the rat bladder muscles whereas 
propranolol, a non-selective beta blocker and 5-HT 1 receptor antagonist partially 
blocked the effects of serotonin on bladder contractility. Tropisetron, a 5 -HT3 
receptor antagonist failed to inhibit the facilitatory effects o f serotonin. These results 
demonstrated that the 5-HT2 receptor (specifically 5 -H T 2a receptor) was mainly 
responsible for serotonin-induced contraction of the detrusor, whereas the 5-HT 1 
receptor was only partially responsible.
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The effects of 5-HT2A receptor agonist DOI on pudendal nerve reflexes in the 
anaesthetised cat was investigated by Danuser and Thor (1996). Pudendal nerves 
were isolated from both female and male cats where some had undergone a T12-T13 
laminectomy. All the cats were pre-treated with the long lasting peripheral restricting 
5-HT2 receptor antagonist xylamidine, in order to eliminate any peripheral effects of 
DOI on the bladder or vascular smooth muscle. Intravenous administration of DOI 
(0.01-3 mg k g 1) was found to dose dependently increase pudendal reflexes in acute 
spinal cats, but not spinally-intact cats. The group concluded that 5 -HT2 receptors 
facilitated pudendal reflexes through a facilitatory effect mediated in the spinal cord 
of acute spinal cats and these effects were counteracted by inhibitory supraspinal 5- 
HT2 receptors as observed in the spinally-intact cats. In the same study, Danuser and 
Thor (1996) also investigated the effects of DOI on pelvic and hypogastric nerves 
where surprisingly DOI produced no significant effects on the pelvic to hypogastric 
reflex in either spinally-intact or acute spinal cats, thus excluding the involvement of 
5-HT/5-HT2 receptors in bladder contraction o f the cat. The findings from this study 
are interesting as it has been documented elsewhere in the literature that 5-HT/5-HT2 
receptor is able to contract the urinary bladder from cat (Saxena et al., 1985), guinea 
pig (Ambache & Zar, 1970) and rabbit (Longhurst et al., 1984). In the dog, bladder 
contraction was observed following administration of a-methyl serotonin, an agonist 
with selectivity for the 5 -HT2 receptor and its effects were blocked by LY53857 
(Cohen, 1990). In humans, the role of 5-HT2 receptors in the lower urinary tract has 
been demonstrated from studies where the 5 -HT2A receptor antagonist ketanserin was 
found to cause significant decreases in urethral pressure with no significant changes 
on bladder function (Delaere, 1987). It was concluded that ketanserin would be useful
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in mediating bladder emptying due to a reduction in urethral resistance in patients 
with outflow obstruction due to prostatic enlargement.
The involvement o f 5-HT2C receptors in the control of micturition was first 
demonstrated by Steers and de Groat (1989) with the findings confirmed by Guameri 
et al (1996). In the study, intravenous administration of mCPP (100 pg kg'1) inhibited 
rhythmic bladder contraction. Interestingly, following abolishment of somatic muscle 
contractions by administering the neuromuscular blocker pancuronium, mCPP did not 
inhibit bladder activity, thus suggesting a somatic influence on the actions o f mCPP 
on bladder activity. Other 5-HT2C receptor agonists TFMPP and MK212 were also 
found to depress reflex bladder activity. Guameri and colleagues (1996) also 
demonstrated blockade of the inhibitory effect of mCPP on bladder activity by the 
non-selective 5 -HT2 receptor antagonists mesulergine and metergoline. A mechanism 
proposed for these inhibitory actions o f 5-HT2C receptors on micturition is that the 
raphe input to the spinal cord activates segmental inhibitory intemeurons via 5-HT2C 
receptors which in turn suppress the parasympathetic preganglionic neurones 
innervating the bladder. The effects of intravenous administration of 5 -HT2 receptor 
antagonists on the micturition reflex were investigated by Testa et al (2001). 
Mesulergine, ketanserin and SB 242084 had no effects on isovolumetric bladder 
contractions even at the highest dose of 1 mg kg '1. However, when compared to basal 
values, administration of the low dose of mesulergine (10 jig kg'1) and ketanserin (100 
pg kg'1) appeared to decrease the frequency of isovolumetric bladder contractions, 
although no significance was observed when comparisons were made with pre- 
treatment. Furthermore, it was reported that in some animals, mesulergine and SB 
242084 showed a tendency to increase the frequency of bladder contraction. Espey
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and Downie (1995) also reported that i.t. methylsergide (a partially selective 5- 
HT2A/2C receptor antagonist) induced reductions in the volumes at which micturition 
occurred in conscious spinally intact cats. Due to the variable results obtained from 
the antagonist data described above, the use of 5-HT2C receptor antagonists in the 
improvement of bladder control should be approached with great caution.
Studies carried out on guinea pigs (McMurray & Miner, 2005) demonstrated the 
involvement o f 5-HT2C receptors in the control of bladder and urethral function. This 
study found that the selective 5-HT2C receptor agonists Ro 60-0175 and YM348 
significantly increased external urethral sphincter activity as well as inhibiting the 
micturition reflex. The selective 5-HT2C receptor antagonist SB 242084 reversed the 
agonist induced activity on the urethral striated muscle and bladder function. The 5- 
HT2a receptor antagonist MDL 100907 and 5 - H T 2b receptor antagonist SB 204741 
failed to affect the agonist induced responses on bladder and urethral function, thus 
drawing the conclusion that 5-HT2C receptors are involved in mediating both bladder 
and urethral activity of these agonists in the guinea pig.
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1.73 5-HT3 receptors
The 5-HT3 receptor is the only member of the 5-HT superfamily characterised as a 
ligand-gated ion channel (Derkach et al., 1989). It was initially known as the ‘M’ 
receptor because it interfered with responses to morphine on induced gut contractions. 
Ligand-binding and functional studies have shown that the 5 -HT3 receptor is widely 
distributed in central and peripheral nervous tissue and the receptor has been reported 
to reduce alcohol consumption in experimental animals, whilst the antagonists of this 
receptor have been reported to treat anxiety disorders (see Bloom & Morales, 1998). 
The 5-HT3 receptors have also been implicated in several gastrointestinal functions 
including peristalsis, intestinal secretion, sensation, nausea and vomiting (Andrews et 
al., 1990; Gershon et al., 1990).
1.73.1 Receptor distribution
5-HT3 receptors were originally cloned from a neuroblastoma cell line (Maricq et al., 
1991). cDNA encoding a single 5 -HT3 receptor subunit (5-HT3a) was initially 
identified and cloned from several mammalian species including mouse, rat, guinea 
pig and ferret (Mochizuki et al., 2000; Lankiewicz et al., 1998; Isenberg et al., 1993). 
Another subunit, 5 -HT3B was also identified in both rat and human tissue (Davies et 
al., 1999; Dubin et al., 1999; Hanna et al., 2000).
Several radioligand studies have mapped out the distribution of 5 -HT3 receptors in the 
CNS with the highest levels o f the receptor binding sites present in the dorsal vagal 
complex in the brainstem (see Pratt et al., 1990) consisting of the nucleus tractus 
solitarius, area postrema and dorsal motor nucleus of the vagus nerve. However, 
relative to the dorsal vagal nerve, 5 -HT3 receptor distribution is low in the forebrain.
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High levels of the receptor are expressed in the hippocampus, amygdala and 
superficial layers o f the cerebral cortex. Species variation has been found to exist 
with regards to the relative distribution of 5 -HT3 receptor distribution in the forebrain, 
where for example in humans, high levels of 5 -HT3 receptor recognition sites have 
been located within the caudate nucleus and putamen (Abi-Dargham et al., 1993; 
Button et al.y 1993; Parker et al., 1996), with relatively low levels detected within the 
cortical regions (Bames et al.y 1989; Waeber et al.y 1988; Abi-Dargham et al.y 1993; 
Parker et al.y 1996). However, this pattern is reversed in rodents. In most species 
(e.g. mouse, rat, man; Parker et al.y 1996), relative to other forebrain regions, high 
levels of 5 -HT3 receptors have been found to be expressed in the hippocampus.
In peripheral tissues, 5 -HT3 receptors are primarily expressed in the gut wall. Glatzle 
et al (2002) demonstrated 5 -HT3 receptor expression by functionally distinct classes 
of neurones innervating the gastrointestinal tract. 5 -HT3 receptors were also observed 
on the cell surface as well as in the cytoplasm o f the neurones. Furthermore, 5 -HT3 
receptors were found in dense networks of fibers in the myenteric plexus, muscle and 
mucosa and also in the cell bodies and processes o f interstitial cells of Cajal as well as 
in enteroendocrine cells. Few 5 -HT3 receptors were found to be expressed in 
enterochromaffin cells.
5-HT3 receptors exist both as postsynaptic and presynaptic receptors. Postsynaptic 
receptors have been shown to be present on GABAergic intemeurones and are 
thought to mediate fast synaptic transmission in the central nervous system (Sugita et 
al.y 1992; Lambert et al.y 1995). Furthermore, it has been suggested that presynaptic 
5-HT3 receptors modulate the release of several neurotransmitters in the central 
nervous system.
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1.7.3.2 Receptor pharmacology
A large number o f ligands that interact selectively with the 5 -HT3 receptor have been 
identified, thus enabling pharmacological definition of 5 -HT3 receptor evoked 
responses. The most commonly used 5 -HT3 receptor agonists include m-CPBG, 
phenylbiguanide and 2-methyl-5HT. However, highly selective 5 -HT3 receptor 
agonists have not been identified. Conversely, numerous highly potent 5 -HT3 
receptor antagonists have been developed and these include granisetron, ondansetron, 
tropisetron (ICS 205930), zatosetron and MDL 72222. All these 5 -HT3 receptor 
antagonists have non-selective effects occurring at concentrations in excess o f those 
required to antagonize 5 -HT3 receptors by 100-fold or more. These non-selective 
effects of 5 -HT3 receptor antagonists therefore include agonism of 5 -HT4 receptors 
and local anaesthetic-like block o f ligand- and voltage-gated ion channels (Scholtysik 
et al., 1988; Barann et al., 1993; Ye et al., 1997). An interesting phenomenon 
observed for the 5 -HT3 receptor is that inter-species pharmacological differences exist 
for the receptor. This is demonstrated by the fact that the antagonist MDL 72222 
displays considerably lower affinity for the guinea pig variant of the 5 -HT3 receptor 
(Kilpatrick & Tyers, 1992; Lankiewicz et al., 1998). Similarly, the partial 5 -HT3 
receptor agonist m-CPBG differs approximately 300-fold between the rat and rabbit 
5-HT3 receptors (Kilpatrick et al., 1990). Another pharmacologically distinct 
characteristic of the 5 -HT3 receptor is the existence of allosteric modulation of the 
receptor complex. This is demonstrated in studies where alcohol increases the 
potency with which agonists activate the 5 -HT3 receptor complex (Lovinger & Zhou, 
1993; Downie et al., 1995; Parker et al., 1996). Furthermore, some anaesthetic agents 
have also been found to modify the function of the 5 -HT3 receptor (see Parker et al., 
1996).
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1.7.3.3 Signal transduction
5-HT3 receptors are non-selective cation channels that mediate transient inward 
currents and membrane depolarization under physiological conditions (Lambert et al., 
1995; see Barnes & Sharp, 1999). In the CNS, differences have been found to exist 
between the functional properties of the presynaptic and postsynaptic 5-HT3 receptors. 
For example, presynaptic 5-HT3 receptors on striatal synaptosomes are Ca2+- 
permeable ion channels, and the influx of Ca2+ through these channels is responsible 
for the elevation o f intracellular Ca2+ induced by stimulation of 5-HT (Ronde & 
Nichols; 1998). Conversely, postsynaptic 5-HT3 receptors on hippocampal 
intemeurones are blocked by Ca2+ at negative membrane potentials (McMahon & 
Kauer, 1997). Peripherally, the 5-HT3 receptor has been shown to elicit a rapid 
depolarization produced by increased membrane permeability to monovalent cations 
in the gut (Peters & Lambert, 1989). In many enteric neurons, the 5-HT3 receptor also 
mediates a rapidly developing and desensitizing depolarization (Galligan, 1996).
1.73.4 Physiological functions
The 5-HT3 receptor is the only monoamine receptor to be associated with fast synaptic 
transmission in the brain (Sugita et al., 1992). The presence of functional 5-HT3 
receptors in the brain was obtained from behavioural effects of the 5-HT3 receptor 
ligands with much optimism generated towards the search of novel psychotropic 
agents. 5-HT3 receptor antagonists have therefore been forwarded as potential 
therapeutic agents for disorders such as; anxiety, cognitive dysfunction and psychosis 
(see Bentley & Barnes, 1998). 5-HT3 receptors have also been found to play an 
important role in the processing of cardiovascular afferent input at the level of the 
nucleus tractus solitarius (Jeggo et al., 2005).
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In peripheral tissues, 5 -HT3 receptors mediate a number o f neural reflexes involved in 
the physiologic regulation o f gastrointestinal function, including intestinal feedback, 
inhibition of gastric emptying (Raybould & Zittel, 1995) and gastrocolonic reflex 
(Foxx-Orenstein et al., 1996). 5 -HT3 receptors have also been implicated in the 
defence of the gut for example in response to intestinal anaphylaxis (Cooke et al., 
1997; Mourad et al., 1995).
1.73.5 5 -HT3 receptors -  excitatory or inhibitory?
It has been documented that the 5 -HT3 receptor is associated with fast synaptic 
transmission in the brain (Sugita et al., 1992), with fast synaptic depolarisations 
observed. Similarly, in the gut, the 5 -HT3 receptors receptor elicits a rapid 
depolarization produced by increased membrane permeability to monovalent cations 
(Peters & Lambert, 1989). This implies that 5 -HT3 receptors are excitatory as they 
mediate neuronal excitation characterized by depolarization thus increasing neuronal 
excitability and neurotransmitter release both centrally and peripherally.
1.73.6 5 -HT3 receptors and micturition
Pharmacological evidence implicating a role of the 5 -HT3 receptor in micturition was 
provided by a study carried out by Espey and Downie (1995) where intrathecal 
administration o f the 5 -HT3 receptor antagonist zatosetron decreased volume 
threshold in spinally intact conscious cats. Additionally, the so called 5 -HT3 receptor 
agonist 2-methyl increased volume threshold in cats that had undergone complete 
spinal transection. From these results, the authors concluded that spinal 5 -HT3 
receptors were physiologically involved in micturition by mediating inhibitory effects.
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A subsequent study by Espey et al (1998) recorded ascending activity (bladder 
afferent activation) evoked by pelvic nerve stimulation in the thoracic spinal cord of 
anaesthetized cats. The group observed that following intrathecal administration of 5- 
HT3 receptor antagonists zatosetron, tropisetron (ICS 205930) and MDL 72222, pelvic 
evoked neuronal activity was increased in spinally intact cats. These results suggested 
that through 5 -HT3 receptor activation, endogenous serotonin tonically inhibited 
ascending activity in spinally intact cats. This was further confirmed by the decrease 
in volume threshold observed following intrathecal administration o f zatosetron 
(Espey & Downie, 1995). These data therefore support the theory that by increasing 
ascending activity through blockade of spinal 5 -HT3 receptors the levels o f spinal 5- 
HT are decreased. Preganglionic parasympathetic neurones are thereafter activated 
and this result in the excitatory effect observed on micturition. Conversely, activation 
of 5-HT3 receptors by 2-methyl-5-HT depressed ascending activity thus implying that 
spinal 5-HT is increased and activation of the endogenous spinobulbospinal negative 
feedback mechanism results in inhibition of the micturition reflex. Interestingly, 
intrathecal administration of 2-methyl-5-HT increased the pelvic-pudendal reflex 
whereas zatosetron inhibited this reflex (Espey et al, 1998) thus suggesting the 
involvement o f 5 -HT3 receptors in the control of the EUS in the conscious cat. I.v. 
administration of zatosetron and Y 25130 had no effect on isovolumetric bladder 
contractions in anaesthetized rats (Testa et al., 2001). Similarly, i.c.v administration 
of2-methyl-5-HT also had no effect on the cystometry parameters in conscious rats 
(Ishizuka et al., 2002).
50
1.7.4 5-HT4
Activation of the 5-HT4 receptor mediates widespread effects in both central and 
peripheral nervous systems, through the use o f selective agonists and antagonists. 
Centrally, the receptor has been implicated in the regulation of learning and memory, 
cognition and anxiety (Eglen et al., 1995). Activation o f the 5-HT4 receptor 
peripherally has been shown to play a modulatory role in several tissues including 
heart, gastrointestinal tract, adrenal gland and the urinary bladder (Hegde & Eglen,
1996).
1.7.4.1 Receptor distribution
Development o f specific radioligands has enabled mapping of the central distribution 
of the 5-HT4 receptor. Relatively high levels o f 5-HT4 receptors have been identified 
in the nigrostriatal and mesolimbic systems of the brain of various species including 
rat, guinea pig, pig, cow, monkey and humans (Grossman et al., 1993; Waeber et al., 
1993; Domenech et al., 1994; Jakeman et al., 1994; Schiavi et al., 1994; Mengod et 
al., 1996). In the limbic system, the 5-HT4 receptors are localized in the olfactory 
tubercle, frontal cortex, fundus striatus, ventral pallidum, septal region, hippocampus 
and amygdala (see Eglen et al., 1995). It should be noted that species variation exists 
with regards to the distribution of the 5-HT4 receptor, where for example more 
abundant receptors are found in the interpendicular nucleus, habenula, lateral 
substantia nigra, medial hypothalamus and locus coeruleus of the rat compared to the 
guinea pig (Waeber et al., 1993; Jakeman et al., 1994). In the periphery, 5-HT4 
receptors are found to be expressed in rat ileum, colon, bladder and in the atrium 
(Gerard et al., 1995). RT-PCR studies have revealed 5-HT4 receptor expression on
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human endothelial cells and in many blood vessels studied from the pig (Ullmer et al.,
1995).
In situ hybridization histochemistry studies revealed that 5-HT4 receptors were 
located both somatodendritically and axonally in both the rat and guinea pig (Vilaro et 
al., 2005).
1.7.4.2 Receptor pharmacology
The lack of selectivity towards the 5-HT4 receptor restricts in vivo studies of the 
receptor. Agonists such as BIMU1, BIMU8, RS 66331 and RS 56532 have all been 
used as 5-HT4 receptor agonists but unfortunately these compounds also possess equal 
or higher affinity for the 5 -HT3 receptor (Waeber et al., 1993; Schiavi et al., 1994; 
Domenech et al., 1994). This is also the case for compounds such as zacopride, 
renzapride and cisapride (Domenech et al., 1994). However, 5-HT4 receptor agonists 
SC-53116 and SC-49518 possess lower affinity for the 5 -HT3 receptor thus making 
these agonists more selective for the 5-HT4 receptor. Another highly potent, selective, 
partial agonist at 5-HT4 receptors in guinea pig ileum and rat oesophagus is 
ML10302. Additionally, RS 67333 and RS 67506 which exhibit similar high 
affinities are also selective, but are also partial agonists for the 5-HT4 receptor.
Previously, antagonists such as SDZ205557 and DAU6285 were used as 5-HT4 
receptor antagonists but these compounds exhibit similar affinities at the 5 -HT3 
receptor. Numerous compounds have now' been developed that are highly selective at 
the 5-HT4 receptor. GR 113808 has been extensively used to characterize the 5-HT4 
receptor in vitro (Bockaert et al., 1992). However, this compound is rapidly degraded
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in vivo and therefore its analogue GR 125487 is the compound of choice when 
investigating 5-HT4 receptors in vivo (Eglen et al., 1994). Other selective 5-HT4 
receptor antagonists that have been found to be suitable for in vivo studies include RS 
39604 (Hedge et al., 1994), RS 100235, RS 67532 (Bockaert et al., 1992) and SB 
207266 (Wardle et al., 1996).
1.7.4.3 Signal transduction
Activation of 5-HT4 receptors leads to the activation of adenylate cyclase, thereby 
increasing intracellular cAMP levels (Ford & Clarke, 1993). It has been revealed that 
5-HT4 receptor-mediated increase in cAMP levels may lead to phosphorylation of a 
range of target proteins e.g. cAMP-dependent protein kinase A (Fagni et al., 1992). 
This phosphorylation o f the voltage-gated K+ channels leads to their closure. 
Moreover, in dorsal root ganglion cells, 5-HT4 receptor activation is associated with 
an increase in tetrodotoxin-insensitive Na+ current (Cardenas et al., 1997). It should 
be noted that there are differences in the coupling of 5-HT4 receptors between tissues. 
Therefore, in mouse colliculi neurones, compounds may act as full agonists following 
measurements o f intracellular cAMP (Dumuis et al., 1988) whereas in the 
hippocampus, the same compounds act as partial agonists. Additionally, at 5-HT4 
receptors coupled to inward K+ currents in the rat hippocampus, these compounds act 
as antagonists (Chaput et al., 1990).
1.7.4.4 Physiological functions
5-HT4 receptors in the central nervous system have been implicated in the regulation 
of learning and memory, cognition and anxiety (Eglen et al., 1995). Receptor 
distribution in the brain has enabled the effects o f 5-HT4 receptor agonists and
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antagonist assessment in cognitive impairment. Peripherally, activation of the 5-HT4 
receptor plays a modulatory role in several tissues including heart, gastrointestinal 
tract, adrenal gland and urinary bladder (Hegde & Eglen, 1996). In the 
gastrointestinal tract, effects such as motility, peristaltic reflex and secretion have 
been studied in the gut o f different species using various 5-HT4 receptor agonists and 
antagonists (see Hedge & Eglen, 1996). In the cardiovascular system, activation of 5- 
HT4 receptors by 5-HT in humans and pigs induces tachycardia and positive inotropy 
(see Kaumann, 1994). 5-HT4 receptors have also been implicated in the pathogenesis 
of arrhythmias leading to atrial fibrillation and stroke (see Kaumann, 1994). The only 
known endocrine effect o f the 5-HT4 receptor was first demonstrated in the frog 
adrenal gland and later in the human adrenal cortex (Idres et al., 1991; Contesse et al., 
1994; Lefebvre et al., 1993) where coticosterone and aldosterone release was shown 
to be mediated by the 5-HT4 receptor.
1.7.4.5 5-HT4 receptors -  excitatory or inhibitory?
Electrophysiological studies have demonstrated 5-HT4 receptor activation in neurones 
increases excitability (Chaput et al., 1990; Andrade & Chaput, 1991; Roychowdhury 
etal., 1994). In rat hippocampus and mouse colliculi neurones, intracellular 
accumulation of cAMP modulates the activity of protein kinase A which leads to the 
closure of K* channels. The closure o f K* channels results in a reduction in 
repolarization thus increasing neuronal excitability and ultimately, increasing 
neurotransmitter release (Ansanay et al., 1995).
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1.7.4.6 5-HT4 receptors and micturition
Tonini et al (1994) demonstrated a facilitatory role for 5-HT4 receptors in cholinergic 
mediated contractions of the human bladder. The group found that in postganglionic 
cholinergic nerves, 5-HT caused concentration-dependant increases in the amplitude 
of contractions in human isolated detrusor strips in methylsergide and ondansetron 
pretreated tissues. These concentration-dependant increases were antagonized by the 
selective 5-HT4 receptor antagonist GR 113808 in a competitive manner and therefore 
die authors were able to conclude that cholinergic transmission in human isolated 
detrusor muscle was facilitated by 5-HT4 receptors. Another study providing 
evidence for the involvement of 5-HT4 receptors in bladder function was 
demonstrated by Waikar et al (1994). The group found that 5-HT inhibited 
electrically evoked contractions of isolated urinary bladder strips from Rhesus and 
Cynomolgus monkeys. The 5-HT4 receptor antagonists, GR 113808 and DAU 6285 
produced parallel displacement effects of the concentration-effect curves of 5-HT, 
thus suggesting that this inhibitory effect was mediated via activation of 5-HT4 
receptors. In anaesthetized rats, i.v. administration of the 5-HT4 receptor antagonist 
RS 39604 did not affect regular isovolumetric bladder contractions (Testa et al.,
2001). Conversely, the 5-HT4 receptor agonist RS 67506 administered i.c.v. to 
conscious rats was observed to decrease bladder capacity and micturition volume 
(Ishizuka et al., 2002) thus suggesting that in normal conscious rats, at the supraspinal 
level, 5-HT4 receptors can enhance the micturition reflex induced by bladder filling. 
However, further studies need to be carried out in order to deduce the mechanism and 
site of action of these receptors in micturition. Therapeutic applications of the 5-HT4 
receptor in the human urinary bladder have originated from the use of 5-HT4 receptor 
agonists such as cisapride, whose side effect is known to include increased micturition
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frequency/urinary incontinence (Boyd & Rohan, 1994). This effect is thought to be 
due to the strategic placement of 5 -HT4 receptors on cholinergic nerve terminals. 
Similarly, metoclopramide which possesses selectivity for the 5 -HT4 receptor has 
been reported to diminish residual urine volume in a diabetic patient with a 
neurogenic bladder (Nestler et al., 1983) thus suggesting that 5 -HT4 receptor agonists 
may be of value in the treatment of bladder disorders associated with detrusor 
hypomotility such as overflow incontinence.
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1.7.5 5-htsA receptors
The 5-ht5 receptor family consists o f 5-htsA and 5-ht5B receptors which share 
approximately 68% mutual amino acid identity (Plassat et al., 1992; Erlander et al., 
1993). These two 5-hts receptors have been identified in both mouse (Plassat et al., 
1992; Matthes et al., 1993) and rat (Erlander et al., 1993). However in humans, only 
the 5-htsA receptor gene encodes a functional protein whereas the 5-htsB encodes a 
non-functional protein due to its interruption by stop codons. The physiological 
function of the 5-htsA receptor is not well understood due to a lack of specific ligands, 
but it has been implicated in the control o f circadian rhythm, mood disorders and 
schizophrenia and other cognitive disorders.
1.7.5.1 Receptor distribution
mRNA localisation studies in mouse (Plassat et al., 1992; Matthes et al., 1993), rat 
(Erlander et al., 1993) and human (Rees et al., 1994; Pasqualetti et al., 1998) brain 
have revealed evidence for 5-htsA receptor mRNA in cerebral cortex, hippocampus, 
thalamus, hypothalamus, habenula, cerebellum and spinal cord. Additionally, 
immunohistochemical studies in the rat have also confirmed the presence of 5-htsA 
receptor in raphe nuclei (dorsal and median raphe), amygdala and hypothalamus 
(Oliver et al., 2000). In several o f these regions, the receptor is expressed on 
neurones which include cortical and hippocampal pyramidal neurones, purkinje 
neurones, molecular layer intemeurones and Golgi cells of the cerebellum (Geurts et 
al., 2002). Immunolocalisation studies have also confirmed expression of 5-ht5A 
receptor in the suprachiasmatic nucleus (Duncan et al., 2000) in hamsters.
In the periphery, 5-ht5A receptor mRNA expression was observed as very low to 
absent. This was observed following the use o f RT-PCR technique (Rees et al., 1994)
57
where 5-htsA receptor mRNA was found to be absent in human heart, kidney, liver, 
small intestine, spleen and uterus. However, 5-htsA receptor mRNA was observed to 
be present in rat superior cervical ganglion, petrosal ganglion and carotid body (Wang 
et al., 2000).
The 5-ht5A receptor has been shown to be exclusively localized on postsynaptic cells 
in all the regions expressing the receptor (Doly et al., 2004).
1.7.5.2 Receptor pharmacology’
A complication with the 5-htsA receptor is that no selective ligands have been 
identified for the receptor. An additional complicating factor is that pharmacological 
similarities have been observed for the 5-htsA receptor when compared to either 5 -HT7 
or 5-HT 1A receptor. For example, like the 5-HTi A receptor, the 5-HTsA receptor 
displays a high affinity for 5-carboxamidotryptamine (5-CT) and is potently 
antagonized by non-selective 5-HT receptor antagonist methiothepin (see Thomas, 
2006). The only way o f distinguishing between the two receptors however, is through 
the use o f the 5-HTja receptor antagonist WAY 100635 which exhibits low affinity 
for the 5-ht5A receptor. 5-ht5A and 5-HT7 receptors are known to display a 
pharmacological overlap where both receptors share the same rank order of agonist 
potency, 5-CT>5-HT>8-OH-DPAT. They are also both antagonized by 5-HT 
receptor antagonists methiothepin and ritanserin (Thomas et al., 1999, Thomas et al., 
2004). Furthermore, antagonist studies using the selective 5-HT7 receptor antagonist 
SB-269970 have demonstrated moderate high affinity of the compound for the 5-ht5A 
receptor (pKi 7.2). Similarly, the potent 5-HT7 receptor antagonist SB-656104 and 
close analogue o f SB-269970 also displays affinity for the 5-ht5A receptor (pKj 6.7),
58
although this is lower (Forbes et al., 2003; Thomas et al., 2003; Thomas & Hagan, 
2004). Recently, the first selective 5-htsA receptor antagonist SB-699551 has been 
developed (Corbett et al., 2005). This compound is at least 30-fold selective for the 
5-htsA receptor versus the other 5-HT receptor subtypes. What is interesting about 
this compound however is that the pharmacological profile is species dependant 
where it exhibits a high affinity for the human and guinea pig 5-htsA receptor, but low 
affinity for the rat and mouse receptors (see Thomas, 2006).
1.7.5.3 Signal transduction
Radioligand binding studies with the recombinant 5-htsA receptors have provided 
evidence to indicate that the receptors couple to a G-protein. The 5-htsA receptor 
appears to couple preferentially to Gi 0 proteins as agonist-induced activation of the 
receptor inhibits adenylyl cyclase activity in various cell systems (Francken et al., 
1998, 2001; Thomas et al., 2004). Additionally, the receptor has also been reported to 
couple inwardly to rectifying K+ channels (GIRKi) when expressed in oocytes 
(Grailhe et al., 2001). When expressed in C6 glioma cells, the 5-htsA receptor has 
been shown to enhance intracellular Ca2+ signaling (Noda et al., 2003). It should be
noted however that the transduction mechanisms described above have only been
observed for the recombinant 5-htsA receptor, whereas mechanisms by which the 
receptor couples to signaling pathways in native tissues remains to be established.
1.7.5.4 Physiological functions
Tissue localisation of the 5-htsA receptor in the dorsal and median raphe as well as the 
suprachiasmatic nucleus suggests a potential role for the 5-htsA receptor in the control 
of circadian timing. The 5-ht5A receptor has also been implicated as a potential drug
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target to treat mood disorders including anxiety and depression as well schizophrenia 
and other cognitive disorders. It has also been postulated that the 5-ht5A receptor may 
play a role in central motor control, nociception and autonomic function (Doly et al., 
2004).
1.7.5.5 5-htsA receptors -  excitatory or inhibitory?
As mentioned above, it has been reported that the 5-htsA receptor couples inwardly to 
rectifying K+ channels (GIRKi) when expressed in oocytes (Grailhe et al., 2001). It 
was previously reported that activation of GIRK channels causes membrane 
hyperpolarisation and therefore the channels play an important role in the inhibitory 
regulation of neuronal excitability (North & Uchimura, 1989). One can therefore 
speculate that following activation of GIRKi channels by the 5-htsA receptor, 
inhibitory effects are observed on neuronal excitability.
1.7.5.6 5-ht5A receptors and micturition
Spinal motomeurones of the O nuf s nucleus innervating pelvic striated muscles are 
involved in direct control of pelvic function, including micturition via the external 
urethral sphincter. Species variation exists with regards to the location of the O nuf s 
nucleus. In rats, studies have demonstrated that the O nuf s nucleus is located in the 
L5-L6 spinal segments and consists o f two separate nuclei, namely the dorsomedial 
nucleus and the dorsolateral nucleus (McKenna & Nadelhafl, 1986). Xu and 
colleagues (2007) observed intense 5-htsA receptor immunoreactivity in the 
dorsolateral nucleus in both male and female rats. Both light and electron microscopy 
studies revealed labelling o f the dorsolateral nucleus following injections of 
horseradish peroxidase in the external urethral sphincter. Similarly, injections of
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pseudorabies virus into the external urethral sphincter also revealed labelling of the 
dorsolateral nucleus. This labelling study clearly reveals that 5-htsA receptors are 
associated with external urethral sphincter motomeurones in male and female rats on 
the dorsolateral nucleus of the O nuf s nucleus. The external urethral sphincter has 
been found to play a major role in continence by maintaining closure of the urethral 
sphincter. From the results above, it would appear that 5-htsA receptors may be 
selectively involved in the control of continence in both male and female rats.
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1.7.6 5-HT6 receptors
The existence of 5-HT6 receptors was revealed primarily from the use of molecular 
cloning techniques. Cloning o f the 5-HT6 receptor has therefore been demonstrated in 
the rat, human and mouse tissue (Monsma et al., 1993; Ruat et al., 1993; Kohen et al., 
1996, 2001).
1.7.6.1 Receptor distribution
Northern blots have shown that 5-HT6 receptor mRNA appears to be exclusively 
located in the brain, w ith very little evidence for its presence in peripheral tissues. In 
situ hybridization, northern blot analysis, and RT-PCR have revealed the presence of 
the 5-HT6 receptor in the olfactory tubercle, nucleus accumbens, striatum, 
hippocampus and cerebral cortex in the rat brain (Monsma et al., 1993; Ruat et al., 
1993; Ward et al., 1995, Gerard et al., 1997; Grimaldi et al., 1998). Lower levels of 
the receptor have also been detected in the granular layer of the cerebellum, several 
diencephalic nuclei and amygdala (Ward et al., 1995). Additionally, 5-HT6 receptor 
immunoreactivity associated with dendritic processes in striatum and hippocampus of 
the adult rat has been demonstrated using immunocytochemistry (Gerard et al., 1997). 
In the human brain however, highest expression levels of 5-HT6 receptor mRNA were 
found in the caudate nucleus (Kohen et al., 1996). Interestingly, East et al (2002) 
revealed distribution patterns similar to rats, in postmortem samples from 
schizophrenic and normal patients.
Information regarding peripheral distribution of 5-HT6 receptor distribution in 
peripheral tissues is very limited. Northern blot analysis of stomach rat tissue 
detected low expression levels o f 5-HT6 receptors (Ruat et al., 1993). In the guinea
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pig, northern blot analysis revealed a very faint signal of 5-HT6 receptor expression in 
the adrenal glands (Ruat et al., 1993). RT-PCR has also revealed 5-HT6 receptor 
mRNA expression in ex vivo isolated spleen, thymus and peripheral blood 
lymphocytes in rat tissue which would suggest the possibility of the involvement of 5- 
HT6 receptors on immune functions (Stefulj et al., 2000).
Immunocytochemistry studies revealed 5-HT6 receptor-like immunoreactivity was 
associated w ith dendritic processes making synapses with unlabelled axonal synapses 
in both hippocampus and striatum (Gerard et al., 1997). This would therefore suggest 
that 5-HT6 receptors in these regions are predominantly postsynaptic.
1.7.6.2 Receptor pharmacology
The 5-HT6 receptor possesses unique pharmacological profiles as it has high affinities 
for non-selective agents such as tryptamines, methiothepin, lisuride, LSD and 
clozapine. Similarly, the 5-HT6 receptor also exhibits high affinity for tricyclic 
antidepressants as well as a large number of typical and atypical antipsychotic agents 
(Roth et al., 1994). For many years, there was a lack of selective agonists and 
antagonists at the receptor, therefore the non-selective compounds mentioned above 
e.g. clozapine (Glatt et al., 1995) were used to label the 5-HT6 receptor. This meant 
that characterization o f 5-HT6 receptor mRNA in native tissue was difficult as the 
compounds used had selectivity for dopamine receptors, monoamine oxidases as well 
as other 5-HT receptors. To date, three selective 5-HT6 agonists have been developed 
and these include EMDT, LY586713, and WAY-466 (Glennon et al., 2000; Bemotas 
et al., 2004). Several antagonists have also been developed in recent years for the 5- 
HT6 receptor with the first reported antagonists being Ro 04-6790 and Ro 63-0563
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(Sleight et al., 1998). Both these antagonists were reported to be potent at both rat 
and human recombinant 5-HT6 receptors. Additionally, another 5-HT6 receptor 
antagonist SB 271046 (Hirst et al., 2003) was developed, and it is thought that this 
compound may be a significant new tool for the study of 5-HT6 receptor function, due 
to good selectivity for the receptor as well as its low blood clearance, good half life 
and oral bioavailability. The antagonist radioligand [125I]-SB-258585 (Hirst et al., 
2000) was also identified and utilized in characterizing the 5-HT6 receptor.
1.7.6.3 Signal transduction
The 5-HT6 receptor was identified as the first mammalian serotonin receptor to be 
cloned that was coupled to activation of adenylyl cyclase (Monsma et al., 1993; Ruat 
et al., 1993; Kohen et al., 1996; Boess et al., 1997). The recombinant 5-HT6 receptor 
expressed in various artificial expression systems couples to the G stimulatory (Gs 
protein). Subsequent studies using striatal tissues and mouse neuroblastoma have also 
revealed that native 5-HT6 receptors are positively coupled to adenylyl cyclase 
(Schoeffter & Waeber, 1994; Sebben et al., 1994).
1.7.6.4 Physiological functions
Due to the unique pharmacological profile o f the 5-HT6 receptor, primary interest in 
the receptor has been based on the pathology and treatment of depression and/or 
affective disorders such as schizophrenia. Additionally, high levels of the 5-HT6 
receptor have been detected in the hippocampus, and a role of the 5-HT6 receptor in 
memory, especially hippocampal-dependent aspects o f learning and memory has been 
postulated (Perez-Garcia & Meneses, 2005). The 5-HT6 receptor has been shown to 
influence acetylcholine release in the frontal cortex (Riemer et al., 2003) thus
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suggesting a role for the receptor in cognition deficits such as Alzheimer Disease 
(AD). Regarding a role of the 5-HT6 receptor in anxiety or depression, very few 
studies in the literature have explored the role o f 5-HT6 receptor activity in these two 
conditions. Yoshioka et al ( 1998) showed that increased 5-HT in the preffontal cortex 
from conditioned fear is significantly inhibited by treatment with antisense 
oligonucleotides, specific to 5-HT6 mRNA infused i.c.v. In a later study, Hamon et al 
(1999) demonstrated that infusion of antisense oligonucleotides specifically down- 
regulated 5-HT6 receptor expression in the nucleus accumbens with increased anxiety 
observed in the elevated plus maze and the social interaction test. As 5-HT6 receptors 
are present in various limbic areas, it was suggested (Monsma et al., 1993; Roth et al., 
1994) that 5-HT6 receptors play an important role in mediating the actions of 
antipsychotic drugs. It is also known that antipsychotic compounds such as clozapine 
and olanzapine exhibit a strong affinity for 5-HT6 receptors. It has been demonstrated 
that clozapine significantly reduced 5-HT6mRNA in the hippocampus (Frederick & 
Meador-WoodrufT, 1999) and down-regulated 5-HT6 receptors expressed in cultured 
cells (Zhukovskaya & Neumaier, 2000) thus providing evidence for a physiological 
role for 5-HT6 receptors in schizophrenia.
1.7.6.5 5-HT6 receptors -  excitatory or inhibitory?
Due to a lack o f receptor-like immunoreactivity in the soma of excitatory pyramidal 
and granule cell neurones in the hippocampus Gerard and co-workers (1997) 
postulated that 5-HT6 receptors were probably located on the dendrites of these 
neurones. The presence of 5-HT6 receptors in dendrites of the above mentioned cell 
neurones suggest that 5-HT6 receptors may possibly be excitatory on the 
hippocampus. Conversely, Ward and Dorsa (1996) demonstrated 5-HT6 receptor
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expression on dendritic processes of GABAergic neurones terminating in the 
substantia nigra and globus pallidus. The above neurones are thought to exert 
differential modulation (inhibition and dishinhibition, respectively) of basal ganglia in 
the substantia nigra (see Barnes & Sharp, 1999) thus suggesting the receptors mediate 
inhibitory effects.
1.7.6.6 5-HT6 receptors and m icturition
To my knowledge, there is only one study in the literature that has looked at the 
effects of a selective 5-HT6 receptor ligand and its effect on micturition. This study 
was carried out by Testa and colleagues (2001) where they found that i.v. 
administration of the 5-HT6 receptor antagonist Ro 04-6790 was ineffective on regular 
isovolumetric bladder contractions. From these results, the group concluded that 5- 
HT6 receptors are o f little importance for control o f micturition.
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1.7.7 5-HT7 receptors
The 5 -HT7 receptor is the most recently identified member o f the family of G-protein- 
coupled 5-HT receptors. The use of non selective ligands has provided evidence for 
the involvement o f the 5 -HT7 receptor in regulation o f the limbic system, sensory 
processing and circadian rhythms as well as a possible involvement in migraines and 
afferent sympathetic pathways (see Vanhoenacker et al., 2000).
1.7.7.1 Receptor distribution
In the rat and guinea pig, the 5 -HT7 receptor subtype is unique in that both the mRNA 
and receptor binding sites display a similar distribution site, thus suggesting that the 
receptor is expressed very closely to the site of synthesis (Gustafson et al., 1996; 
Stowe & Barnes, 1998). 5 -HT7 receptor expression has been found to be elevated 
within regions o f the thalamus, hypothalamus, cortical regions and hippocampus 
(Gustafson et al., 1996; Stowe & Barnes, 1998).
Alternative splicing in human and rat tissues has produced several 5 -HT7 receptor 
isoforms which include 5-HT7(a), 5-HT7(b), 5-HT7(C). A difference exists between the 
distribution patterns of the human 5-HT7(b) receptor isoforms when compared to the 
rat. In both species, 5-HT7<a) is predominantly found in the spleen, kidney, heart, 
thalamus, hindbrain, hippocampus, cortex, caudate, striatum and cerebellum (Monyer 
& Lambolez, 1995). With the 5-HT7(b) isoform, 31-45% of the human 5-HT7 receptor 
mRNA is present in the caudate, hippocampus and spleen compared to 14-18% in the 
corresponding rat tissues. No differences have been noted with regards to the 
distribution of the 5-HT7(C) receptor isoform in either of the two species.
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1.7.7.2 Receptor pharmacology
Non selective receptor agonists such as [3H]5-HT, [3H]5-CT and receptor antagonists 
such as [3H] risperodine have been used to further characterise the 5-HT7 receptor. 
However at present there are no commercially available selective 5-HT7 receptor 
agonists. SB258719 is the first ‘selective' 5-HT7 receptor antagonist described and 
has been shown to be at least 100-fold more selective for the 5-HT7 receptor 
compared to other 5-HT receptors. In addition, Meiji Seika Kaisha Ltd synthesised 
another ‘selective’ 5-HT7 receptor antagonist DR4004 with a 47-fold selectivity over 
the 5-HT2 receptor and others (Kikuchi et al., 1999). The most selective 5-HT7 
receptor antagonist developed to date is SB-269970 which is known to possess a 
profile greater than 100-fold selectivity for other receptors (except 5-htsA receptors 
which is 50-fold) (see Wesolowska, 2002). Defining the above compounds as 
selective 5-HT7 receptor antagonists should be done with caution as not all 5-HT 
receptor subtypes have been used to determine the receptor binding profile, thus they 
are not ‘truly’ selective for the 5-HT7 receptor. Interestingly, no major 
pharmacological differences have been identified between the different 5-HT7 
receptor isoforms.
1.7.7.3 Signal transduction
The 5-HT7 receptor preferentially activates adenylate cyclase by supposedly coupling 
to Gja (Adham et al., 1998). Stimulation of the 5-HT7 receptor with Gsa  was found to 
mediate the Gs sensitive form of adenylate cyclase i.e. adenylate cyclase 5. 
Interestingly, coupling o f the artificially expressed 5-HT7(a) receptor isoform with Gsa 
not only mediated the Gs sensitive form of adenylate cyclase , but also the Gs 
insensitive forms, adenylate cyclase 1 and adenylate cyclase 8 (Baker et al., 1998). It
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has been postulated that an increase in intracellular calcium may be responsible for 
the 5 -H T 7(a) receptor-mediated activation of adenylate cyclase 1 and adenylate cyclase 
8. However, activation following an increase in phosphatidylinositol turnover or Gj 
activation has been ruled out as factors mediating the above events (Baker et al.,
1998).
1.7.7.4 Physiological functions
The 5-HT7 receptor has been implicated in the regulation of circadian rhythms. This 
is based on studies done using 5-CT and 8-OH-DPAT where both agonists possess 
selectivity at the 5-HT7 receptor (Lovenberg et al., 1993). The expression of mRNA 
for 5-HT7 receptors in the thalamic and limbic structures suggests that the receptors 
may be involved in affective behaviour. Interestingly, a conflict o f interest exists with 
regards to the 5-HT7 receptors and their involvement in schizophrenia. Clinical 
studies carried out on schizophrenic patients have shown a decrease in 5-HT7 mRNA 
in the prefrontal cortex thus suggesting that 5-HT7 receptors may be involved in 
schizophrenia (Vanhoenacker et al., 2000). However, another study reported that no 
differences in 5-HT7 mRNA were observed in the hippocampus of subjects with 
chronic schizophrenia (Erdmann et al., 1996). A possible role for 5-HT7 receptors in 
the treatment of epilepsy has also been deduced as shown in a study where non- 
selective 5-HT receptor antagonists preventing 5-HT-induced activation of adenylate 
cyclase by heterologously expressed 5-HT7 receptors correlated with their ability to 
prevent seizures in mice (Bourson et al., 1997)
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1.7.7.5 5 -HT7 receptors -  excitatory or inhibitory?
Not many studies have been carried out to establish whether 5 -HT7 receptors are 
excitatory or inhibitory on neuronal firing in the central nervous system. However, 5- 
HT7 receptors are thought to mediate the inhibitory effect o f 5-HT on purkinje 
neurones in the cerebellum. This conclusion is drawn from the fact that purkinje 
neuronal activity is inhibited following iontophoretic application of the agonists 8- 
OH-DPAT and ipsapirone (Darrow et al., 1990), of which both possess affinity for the 
5-HT7 receptor. Conversely, a study by Roberts and colleagues (2004) suggested that 
5-HT7 receptor activation exerted a stimulatory rather than inhibitory influence on 
dorsal raphe 5-HT neurons. From these results, it is evident that the excitatory or 
inhibitory effects of the 5 -HT7 receptors is greatly dependant on their location.
1.7.7.6 5 -HT7 receptors and micturition
It is common knowledge that the receptor agonist and antagonists for the 5-HT 1 a/2 
receptors also possess affinity for the 5 -HT7 receptor. These include agonists such as 
8-OH-DPAT and mCPP and antagonists such as WAY 100635, methylsergide 
(Krobert & Levy, 2002), methiothepin and mesulergine (Hagan et al., 2000).
Mesulergine has been used to label 5-HT7 receptors in the rat brain and is therefore 
considered to possess good selectivity for the 5-HT7 receptor. Palea et al (2004) 
found that a correlation existed between the potency for mesulergine in the rat bladder 
(pA2 = 7.27) when compared to the potency of functional 5 -HT7 receptors in the rat 
thalamus. However no correlation was observed when both 5 -HT2A and 5 -HT2C 
receptors were investigated in this study.
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The development of 5 -HT7 receptor antagonists SB-269970 and SB-656104 which are 
from the same chemical series but are structurally distinct has enabled further 
investigation of the role of 5 -HT7 receptors in micturition. Read et al (2003) observed 
inhibition on the micturition reflex following i.c.v. administration of SB-269970 and 
SB-656104. Interestingly, i.t. (L6/S1 region o f spinal cord) and i.v. administration of 
SB-269970 had no significant effects on any o f the bladder variables measured. 
Conclusions drawn from these results were that these antagonists inhibited the 
micturition reflex by blocking central 5 -HT7 receptors. Most importantly, these 
results also confirmed that 5 -HT7 receptors located in the forebrain were involved in 
the control of bladder function, whereas the receptors in the sacral spinal cord were 
not. Interestingly, both compounds displayed no significant effects on the reflex- 
evoked urethral function thus suggesting that central 5 -HT7 receptors were not 
involved in mediating this effect. Surprisingly, central administration of SB-656104 
significantly increased residual volume suggesting there was interference of the 
urethra. This however was not mirrored by the more selective 5 -HT7 receptor agonist 
SB-269970. Overall these findings provide evidence for the involvement of central 5- 
HT7 receptors in the control o f micturition.
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1.8 Representation of the putative supraspinal 5-HTiA 
autoreceptor pathway involving a 5-HT2c receptor
WAY 100635 has been shown to be an antagonist at both the pre- and postsynaptic 
level (Fletcher et al., 1996) and is thus considered to be a full 5-HTiA receptor 
antagonist. Testa et al (1999) observed significant inhibition of rhythmic bladder 
contractions following i.v. administration o f WAY 100635. Interestingly, this 
inhibitory effect of WAY 100635 was antagonized by pretreatment with the 5-HT2 
receptor antagonist mesulergine, whereas the ‘partial agonist’ NAN-190 was 
unaffected. Similar results were reported from interaction studies in rats where 
pretreatment o f WAY 100635 with the 5-HT2A receptor antagonist ketanserin was 
devoid o f inhibitory effects. These results clearly suggest the involvement of 5 -HT2 
receptors. A putative supraspinal 5-HTiA receptor pathway involving the 5 -HT2C 
receptor was proposed as the mechanism responsible for blockade of the effects of 
WAY 100635 on the micturition reflex by mesulergine (see de Groat, 2002).
Although 5-HT iA receptors are universally located in the rat brain, cell clusters 
located in the raphe nuclei have been identified which contain abundant 
somatodendritic 5-HTiA autoreceptors (see Bames & Sharp, 1999). There are several 
studies in the literature providing evidence supporting the idea that WAY 100635 acts 
on supraspinal 5-HTi A receptors unmasking an inhibitory pathway that is tonically 
suppressed by supraspinal serotonergic mechanisms. Therefore in micturition, WAY 
100635 is thought to block 5-HT iA inhibitory autoreceptors in the raphe neuron, 
which in turn enhances neuronal firing and increases the release of 5-HT in the spinal 
cord. An increase in spinal 5-HT activates the endogenous spinobulbospinal negative 
feedback mechanism, thus leading to inhibition o f the micturition reflex. Blockade of
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the effects of WAY 100635 by mesulergine is thought to occur as a result of spinal 5- 
HT activating excitatory 5-HT2C receptors on segmental inhibitory intemeurones 
which in turn suppress parasympathetic preganglionic neurons.
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Figure 1.3 Schematic representation of a putative supraspinal 5-HTja autoreceptor pathway involving a 5-HT2C receptor possibly 
located in the sacral region of the spinal cord in the rat (adapted from de Groat; 2002). WAY 100635 blocks inhibitory 
autoreceptors in the raphe neurones thus enhancing neuronal firing and increasing the release of 5-HT in the spinal cord. Spinal 5- 
HT activates excitatory 5-HT2c receptors on inhibitory intemeurones and suppresses parasympathetic preganglionic firing. The 
transmitter released by the inhibitory intemeurones is still unidentified.
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1.9 Dysfunctions of the lower urinary tract
Several conditions attributed to dysfunctions of the lower urinary tract exist, and these 
are a prevalent clinical problem for the health services in the western world due to the 
significant bother caused to the sufferers. Symptoms associated with lower urinary 
tract dysfunctions include bladder storage symptoms, sensation symptoms or voiding 
symptoms. Bladder storage symptoms include increased daytime frequency of 
voiding, nocturia, urgency and urinary incontinence. Bladder sensation symptoms 
include increased, reduced and absent bladder sensation whereas voiding symptoms 
include slow urinary stream, splitting or spraying of the urinary stream, intermittent 
urinary stream, hesitancy, straining to void, and terminal dribbling. The above 
symptoms are characteristic of the pathological conditions of the lower urinary tract, 
which include overactive bladder syndrome (OABS) affecting bladder function and 
stress urinary incontinence, urge urinary incontinence and mixed urinary incontinence 
affecting urethral function. Most of the conditions named above are prevalent in the 
female rather than the male population. Benign prostatic hyperplasia (BPH) is a 
common pathological condition affecting the male population.
1.9.1 Overactive bladder syndrome (OABS)
Initially, OABS was defined collectively as a condition encompassing bladder storage 
symptoms such as urgency, frequency, urge incontinence and nocturia which were 
thought to ‘occur either singly or in combination’ (Bates et al., 1980). However, this 
definition of OABS was not completely representative of the condition, as individuals 
suffering a single symptom of the named symptoms above, were deemed as having 
OABS even though the underlying causes may not have been bladder related. 
Therefore, the International Continence Society (ICS) proposed a new definition of
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OABS which was described as urinary urgency with or without urge incontinence, 
usually with frequency and nocturia, in the absence o f infection or other obvious 
pathology (see Abrams et al., 2002). This enabled the definition of OABS to be 
definitively characterised by functional disorders o f the lower urinary tract. The 
pivotal symptom of OABS is urgency. Urgency is known to have two components: a 
quantitative component which identifies the episodes o f urgency and can be counted 
and a qualitative component where the individual experiences a sudden desire to void 
with the inability to defer this desire (see Chappie et al., 2005). The symptoms of 
OABS may be triggered by neurogenic etiology where conditions such as multiple 
sclerosis, stroke, diabetes, Alzheimer Disease, spinal stenosis and spinal cord injuries 
all present symptoms for OABS. It is well known that the suprapontine areas exert an 
inhibitory influence on the pontine micturition center, thus enabling urinary 
continence (Fall et al., 1989; 1995). Damage to these areas reduces this inhibitory 
action thus leading to an overactive bladder. Damage to the spinal cord may also 
disrupt voluntary and suprasacral modulation of micturition thus leading to loss or 
changes in sensation o f micturition events as well as sphincter coordination (see 
Mostwin, 2002). Myogenic etiology may be another contributing factor to OABS 
through disorders o f smooth muscle tone. In some cases, bladder tissues from patients 
bear distinct features at the smooth muscle level thus leading to unstable contractions 
(see Moreland et al., 2004). Loss of normal excitatory neural input increases 
signalling between smooth muscle cells thus leading to a state of overactivity.
Smooth muscle function may also be impaired as a result of a partial urethral outlet 
obstruction.
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1.9.2 Urinary incontinence (UI)
The ICS has defined UI as ‘complaint o f any involuntary leakage of urine’ (see 
Abrams et al., 2002). It is a disorder that affects women and men of all ages with a 
higher prevalence in women than men. An estimate of the prevalence of UI in women 
is that 1 in 4 women suffer from the condition, and this prevalence increases with age. 
Although not life threatening, many patients suffering UI affirm to a reduction in their 
quality of life, especially suffering social constraints due to fears o f embarrassing 
situations in the public. Several types of UI have been described in the literature with 
die most common being stress urinary incontinence (SUI), urge urinary incontinence 
(UUI) and mixed urinary incontinence (MUI).
1.9.2.1 Stress urinary incontinence (SUI)
This is defined as the involuntary loss of urine which is associated with physical 
activities such as running, jumping and lifting, or with sneezing and coughing (see 
Abrams et al., 2002). This is the most common type of urinary incontinence in 
women and is uncommon in men except after prostate surgery (Hunskaar et al.,
2000). Symptoms of SUI can be presented as either pure or mixed forms. Pure SUI 
occurs in women between the ages of 25 and 49 years, and decreases with increasing 
age, whereas mixed SUI (symptoms of both SUI and urge urinary incontinence 
[UUI]) increases with increasing age (Hannestad et al., 2000). The main cause for 
SUI is insufficient urethral closure forces associated with displacement of the urethral 
wall e.g. after pregnancy, and this therefore leads to a low urethral closure pressure 
due to the intrinsic sphincter deficiency. Displacement of the bladder neck or urethra 
following a sudden increase in abdominal pressure, may also lead to SUI (Van der 
Vaart et al., 2002; see Viktrup, 2002). These characteristics of SUI are observed in
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pregnancy as well as pelvic trauma during vaginal delivery, and are therefore 
considered as risk factors contributing to the development of SUI. Other risk factors 
include obesity, constipation, smoking, chronic lung disease, neurological disorders, 
pelvic surgery, radiation and medications (see Viktrup, 2002).
1.9.2.2 Urge urinary incontinence (UUI)
This is defined as the complaint of involuntary leakage accompanied or immediately 
preceded by urgency (see Abrams et al., 2002). UUI is mainly characterized by an 
overactive bladder. A distinction between UUI and SUI can be made following 
observations of involuntary detrusor contractions (IDCs) during the filling phase in 
cystometry (see Viktrup, 2002).
1.9.2.3 Mixed urge incontinence (MUI)
This has been defined by the ICS as the complaint of involuntary leakage associated 
with urgency as well as with exertion, effort, sneezing or coughing (see Abrams et al., 
2002) and can therefore be described as a combination of SUI and UUI.
1.93 Benign prostatic hyperplasia (BPH)
BPH is a chronic progressive condition primarily affecting the ageing male 
population. The prevalence of BPH symptoms is 26% in men aged 40 to 49 and 46% 
in men aged 70 and older (Wei et al., 2004) with 90% of men demonstrating evidence 
of BPH by the age of 85 (McConnell et al., 1994). BPH is characterised by abnormal 
and excessive non-malignant growth of the prostate tissue which over time starts 
impinging on the prostatic urethra and the bladder neck, leading to bladder outlet
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obstruction. Bladder outlet obstruction leads to symptoms such as increased urinary 
frequency, urgency, nocturia, weak stream, hesitancy and straining whilst voiding.
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Ligand Receptor
Subtype
5-HT2A 5-HT2B 1
in
Agonists
WAY 161503 V ) - - 8.40
Ro 60-0175 a (2C) 7.44 8.27 8.22
mCPP a (20 7.26 7.39 7.85
D O I a (2A) 9.03 7.55 8.08
BW 723C86a(2B) 7.20 7.33 7.11
Antagonists
Mianserin a <2> 7.74 7.92 8.26
Ketanserina (2a> 8.09 6.13 7.21
MDL 100907 a(2A) 8.73 5.99 7.52
RS 102221 a (20 5.54 5.95 8.30
SB 242084 a (20 6.07 6.84 8.15
a Knight et al., 2004
b Cryan & Lucki, 2000
Table 1.1 pKi (log) values for the agonists and antagonists used in this study.
The affinity values presented in this table are limited to the 5-HT2 
receptor family as this was the focus o f this thesis.
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1.10 Study aims
There is limited pharmacological success with respect to treatment of lower urinary 
tract dysfunctions specifically conditions such as SUI and OABS. However, it has 
been proposed that treatment o f SUI should focus on increasing resistance of the 
striated urethral sphincter and urethral smooth muscle, whereas treatment of OABS 
should focus on improving bladder compliance, hence the proposal for the use of 
compounds selective for the 5 -HT2 receptor in this study. At present, there is very 
limited evidence regarding a role of 5 -HT2 receptors in micturition. The indication 
that 5-HT2 receptors are involved in micturition came from a study by Steers and de 
Groat (1989) where they observed inhibitory effects of the non-selective 5 -HT2 
receptor agonist mCPP on isovolumetric bladder contractions. Surprisingly, this 
inhibitory effect evoked by mCPP was blocked by the neuromuscular blocker 
pancuronium thus suggesting that this inhibition was related to somatic muscle 
contractions. Additionally, de Groat (2002) proposed that 5 -HT2C receptors may be 
physiologically involved in mediating the actions of the 5-HTia receptor. The aim of 
this thesis was therefore to investigate what role is played by 5 -HT2 receptors in 
micturition. The experiments in this thesis set out to address,
1) What role is played by 5 -HT2 receptors in bladder and urethral function in 
urethane anaesthetised female rats following bolus dosing of various selective 
5-HT2a^b/c receptor agonists and antagonists?
2) What role is played by 5 -HT2 receptors in bladder and urethral function in 
urethane anaesthetised female rats following infusion dosing of 5-HT2C 
receptor agonist Ro 60-0175 and 5 -HT2C and 5-HT2A receptor antagonists SB 
242084 and MDL 100907?
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3) Are the effects evoked by the 5 -HT2 receptor agonists mediated centrally or 
peripherally?
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Chapter 2
Methods
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2 Methods
The experiments were carried out under the Animals (Scientific Procedures) Act,
1986. After completion of experiments, animals were killed by an overdose of 
pentobarbitone sodium (i.v.).
2.1 General preparation
Experiments were performed on 230 female Sprague-Dawley rats (200-300g). 
Anaesthesia was induced and maintained during initial surgery with isoflurane (4% in 
100% oxygen which was reduced to 3% in 100% oxygen). The left jugular vein* was 
cannulated for anaesthetic and drug administration. The trachea was cannulated to 
maintain a patent airway. Isoflurane administration was then stopped and anaesthesia 
was maintained for the duration of the experiment with intravenous (i.v.) 
administration of urethane (1.2 g kg*1, i.v.). Supplementary doses of urethane (0.1 g 
kg*1, i.v.) were given as required. The right common carotid artery was cannulated 
with a heparinised cannula (20 units ml*1 heparin in 0.9% w v '1 saline) for the 
measurement of arterial blood pressure and sampling arterial blood gases for analysis. 
Blood pressure was measured using a pressure transducer (Gould Statham P23XL), 
and the heart rate (HR) derived electronically on-line from the blood pressure signal 
using AcqKnowledge version 3.7.3 software (Biopac Systems Inc, USA). The depth 
of anaesthesia was assessed by the stability of blood pressure and heart rate, and by an 
absence o f hindlimb withdrawal in response to paw pinch. Animals were 
spontaneously breathing oxygen enriched air (0.05 -  0.101 min’1) supplied by use of a 
positive pressure pump (Harvard Rodent Ventilator 683). Body temperature was 
monitored by placing the rectal temperature probe underneath the animal and was 
maintained at 37-38 °C using a homeothermic blanket system (Harvard). Blood
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samples were taken from the carotid arterial cannula and blood gases and pH were 
monitored with a Coming pH/blood gas analyser (Model 238). Blood gases were 
maintained between 90-130 mmHg Po2, 40-50 mmHg Pco2 and pH 7.3-7.4. 
Adjustments o f the supplemented oxygen levels were made necessary to maintain 
blood gas and pH balance. The animals were infused (6 ml kg*1 h*1, i.v.) with a 
solution comprising 10 ml plasma substitute (gelofusine), 10 ml distilled water, 0.04 g 
glucose and 0.168 g sodium bicarbonate, to prevent the development of non- 
respiratory acidosis and to maintain blood volume. The rats were placed in a 
stereotaxic frame and the head tilted approximately 10-15° to allow the animal to lie 
in a supine position to prevent the weight of the animal affecting the bladder and 
urethral pressure recordings.
* Some differences in general preparation were employed in experiments carried out 
at Pfizer (chapter 4). The left jugular vein was tri-cannulated. One cannula was used 
for the administration of urethane and the other two cannulae were used for the 
simultaneous infusions o f agonist and vehicle or agonist and antagonist respectively. 
In these experiments, the animals spontaneously breathed room air and the plasma 
substitute solution was not infused. Body temperature was monitored by placing a 
small diameter rectal probe in the oesophagus. The right common carotid artery was 
cannulated for the measurement of arterial blood pressure and for withdrawal of blood 
samples for analysis of plasma concentration of the compounds. Additionally, for 
experiments carried out in this chapter, experiments were performed on the rats whilst 
lying on their backs.
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2.1.1 Measurement of bladder pressure (cystometry method)
The ureters were exposed by retroperitoneal incisions and the proximal end of each 
ureter leading to the kidney was cannulated to prevent the bladder filling with urine 
during the experiments. The distal ends of the ureters were tied to ensure no backflow 
and hence leakage of saline from the bladder. The urinary bladder was exposed by a 
midline laparotomy. A small incision was made in the bladder dome and a single 
cuffed cannula (0.86 mm internal diameter (ID) and 1.52 mm outer diameter (OD)) 
was inserted into the bladder dome. The cannula was secured with a suture around 
the top o f the bladder dome and this was followed by closure o f the abdominal 
incision. The cuffed cannula was connected via a T-piece to a pressure transducer 
(Gould Statham P23XL) to record bladder pressure, and a syringe pump for the 
infusion o f saline (0.9% wv'1) at a rate of 0.1 ml m in'1, to evoke the micturition reflex. 
Backflow through this cannula allowed the bladder to be emptied of residual fluid 
after micturition had occurred (See Figure 2.1 for diagram showing a representation of 
the experimental method used).
For experiments carried out in chapter 4, a double lumen catheter was used and this 
was inserted into the bladder dome. The bladder catheter was constructed from 
polyethylene tubing (ID 1,4mm, OD 1.9mm) inside which two catheters were sealed. 
One catheter was connected to a pressure transducer and was used to record bladder 
pressure and to withdraw residual volume via a syringe on a plastic stopcock attached 
to the transducer. The second catheter was used for bladder infusions and was 
connected to a syringe infusion pump (Kd Scientific).
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The bladder was filled to 80% volume of saline required to evoke a micturition reflex 
(calculated for each animal from the average bladder volume required to evoke the 
micturition response during three sequential cystometric investigations) prior to 
administering the compounds. This approach was adopted following initial 
experiments where no effects on EUS-EMG activity were observed following 
administration o f the 5-HT2C receptor agonist mCPP (300 pg kg'1, i.v) in an empty 
bladder. It was therefore decided following discussions with colleagues that the 
bladder should be filled with 80% volume of saline required to evoke the micturition 
reflex and thereafter administer mCPP 5 minutes later. Hence, it appears that external 
urethral sphincteric activity controlled via a somatic output to the urethral striated 
muscle is dependant on bladder afferents activated by bladder distension.
2.1.2 External urethral sphincter (EUS) -  Electromyography
(EMG) recordings
Two fine copper wire electrodes (0.2 mm diameter) were used to measure the EMG of 
the external urethral sphincter. The tip of an electrode was positioned in the bevel of 
a needle (25G) and the needle was inserted percutaneously approximately 0.5 cm 
lateral and 0.5 cm caudal to the urethral orifice. The needle and wire were advanced 
approximately 0.5cm through the skin and the needle slowly withdrawn leaving the 
wire inserted in the external urethral sphincter. The second electrode was inserted in 
the same position on the contralateral side of the urethral orifice. The electrodes were 
connected to a Neurolog head stage (NL100; Digitimer, Welwyn Garden City, U.K.) 
and the signal was amplified (20 kHz; NL104) and filtered (500 Hz; NL125, and 
displayed on an oscilloscope (Tektronix, 2205).
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2.13 Measurement of urethral pressure
A 1.4 F nylon catheter with a side-mounted microtip transducer located 1 mm from 
die catheter (SPR-671, Millar Instruments inc., Houston, Texas) was inserted into the 
urethra from the urethral orifice. Placement o f the catheter in the mid region of the 
urethra exhibited high frequency oscillations in urethral pressure during urethral 
relaxation (in the voiding phase when the micturition reflex was tested), producing 
oscillations in urethral pressure (see figure 2.2). The microtip transducer catheter was 
connected to a pressure control unit (PCU-2000). Urethral pressure was measured as 
the force per unit area exerted by the wall of the organ (during contraction or 
relaxation) on the side mounted microtip transducer.
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CYSTOMETRY METHOD
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(0.1 ml min'1)
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/ \
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Drainage
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recorded using 
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Figure 2.1 Schematic representation o f the experimental method used. The 
ureters were tied and cut at the level o f the bladder and cannulated at the level o f  the 
kidneys. A single* cuffed cannula connected via a T-piece to a pressure transducer 
and a syringe pump was inserted into the bladder dome. Electrodes used to record 
EUS-EMG activity were inserted on either side o f the urethral orifice. The miliar 
probe was inserted into the urethra from the urethral orifice.
* For experiments carried out in chapter 4, a double lumen cuffed cannula was 
inserted into the bladder dome.
Adapted from Wibberley etal., 2002.
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Figure 2 . 2  A  r e p r e s e n t a t i v e  t r a c e  o f  r e c o r d i n g s  o f  u r e t h r a l  p r e s s u r e  f o l l o w i n g  p l a c e m e n t  o f  t h e  c a t h e t e r  i n  t h e  m i d  r e g i o n  o f  t h e  u r e t h r a .  H i g h  
f r e q u e n c y  b u r s t s  p r e s s u r e  o s c i l l a t i o n s  d u r i n g  u r e t h r a l  r e l a x a t i o n  o n  v o i d i n g  w e r e  o b s e r v e d .
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2.1.4 Cannulation of the right lateral cerebral ventricle
(intracerebroventricular inj ections)
The rat was placed in a stereotaxic apparatus and a stainless steel guide cannula (22 
gauge) was implanted into the right lateral cerebral ventricle. The coordinates used 
from bregma were 4 mm ventral, 1.5 mm lateral and 1 mm posterior. Drugs and 
vehicle solutions (5 pi) were administered through an i.c.v. injection cannula (28 
gauge) attached by a length of polythene tubing to a 25 pi syringe (Hamilton). At the 
end of the experiment, the cannula placement was confirmed by the administration of 
5 pi of 2% pontamine sky blue dye.
2.1.5 Cannulation of the L6-S1 region of the spinal cord
(intrathecal injections)
In these experiments, following cannulation of the bladder and placement of the EMG 
electrodes into the external urethral sphincter, the animal was placed on its front and a 
midline incision was made to expose the vertebral column. Using the last rib as a 
guide (T13 of the vertebral column), a guide cannula (26G, 9.5mm in length; Plastics 
One Inc) was inserted at the level between the L1-L2 vertebrae (L6-S1 region of the 
spinal cord; see figure 2.3). A tail flick or hindlimb reflex established the placement 
of the guide cannula in the spinal cord. The cannula guide was secured in place using 
the tissue adhesive Vetbond. The animal was thereafter turned on to its right side to 
prevent the animal’s weight affecting bladder recordings. Due to the positioning of 
the animal, the miliar probe was not inserted into the urethral orifice and thus urethral 
pressure was not recorded for the intrathecal experiments. Drugs and vehicle (10 pi) 
were administered through an internal cannula (33G) attached via a length of
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polythene tubing to a 50 pi syringe (Hamilton). The location o f the cannula 
placement for the injection site was subsequently confirmed at the end of the 
experiment by administering 10 pi of pontamine sky blue dye and performing a 
laminectomy thereafter.
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Figure 2.3 Schematic representation o f the spinal cord. Histochemical studies have confirmed that 
autonomic nuclei in the lumbosacral spinal cord innervate the lower urinary tract. Additionally, it has 
also been shown that receptors (specifically 5-HTiA) in the L6/S1 region o f the spinal cord have an 
important physiological role in the tonic control o f the descending limb o f the micturition pathway. 
This region o f the spinal cord was therefore chosen in this study to investigate whether 5 -HT2 
receptors are also physiologically involved in the control o f the micturition pathway. Adapted from 
Ziegler, 1988.
93
2.2 Experimental Protocols
2.2.1 Experiments in Chapter 3
5-HT2 receptors in micturition - bolus dosing regimen
Animals were left for 1 hour to stabilise after completion of surgery. A diagram for 
the experimental protocol used is shown in Figure 2.4. The bladder was infused with 
saline until threshold was reached and the micturition reflex was evoked. Saline was 
continuously infused for 15 min to ‘prime’ the system and cause a series of infusion- 
induced micturition reflexes. After ‘priming the system’, the infusion was stopped 
and the bladder emptied. 3 min later, saline was infused into the bladder until 
micturition was evoked, the infusion was discontinued, the bladder was emptied and 
the residual volume was collected and measured. This was repeated until three 
consecutive reflex-evoked bladder contractions of similar volume threshold and 
amplitude were obtained to ensure stability of the response. After a period of 3 min, 
the bladder was filled with 80% volume of saline required to evoke the micturition 
reflex and all variables were recorded for 5 min. The test drug (antagonist) or vehicle 
(saline or 100% DMSO) was administered i.v and all variables were recorded for a 
further 5 min before administering the 5-HT2A/2B/2C receptor agonist or vehicle. Ten 
minutes later, the bladder was emptied and infusion was commenced once more to 
evoke the micturition reflex (a single micturition reflex) in the presence of test drug or 
vehicle. In some experiments, the test drug caused a continuous rise in bladder 
pressure with no obvious contraction observed. In these cases, after a certain period 
of time, a few drops of saline leaked from the urethral opening and once this was 
observed, the infusion was switched off. These responses were taken to indicate that 
the micturition response had been abolished.
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Figure 2.4 Diagram showing the experimental protocol used for the bolus dosing regimen. It should be noted that there is a 1 hour 
stabilization period following surgery.
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2.2.2 Experiments in Chapter 4
5-HT2 receptors in micturition - infusion dosing regimen
Figure 2.5 represents the protocol used for the infusion dosing regimen. Following 
attainment of three consecutive reflex-evoked bladder contractions of similar 
amplitude, the bladder was filled with 80% volume o f saline required to evoke the 
micturition reflex, and all variables recorded for 5 min. Baseline values were 
recorded for EUS-EMG activity, urethral pressure and blood pressure during this 
period. The bladder was emptied and 2 min later a micturition reflex was evoked. 
Three minutes later, test drugs or vehicle were infused into the animal in total volume 
of 100 pi kg'1 min'1 for agonist alone or agonist plus antagonist. Thirty seconds later 
infusion of saline into the bladder was commenced until 80% volume of saline 
required to evoke the micturition reflex was achieved. All variables were recorded for 
a further 5 min. The bladder was thereafter emptied and 2 min later saline was 
infused into the bladder to evoke a micturition reflex in the presence of test compound 
or vehicle. Subsequently, a blood sample was withdrawn from the common carotid 
artery for analysis of the plasma concentrations of the test compounds. 3 min later, 
the bladder was again filled with 80% volume of saline required to evoke the 
micturition reflex and all variables recorded for a further 5 min. A second micturition 
reflex was tested and a second blood sample (0.2 ml) was withdrawn from the animal 
(see subsequent paragraph for details on test drug infusions). This was repeated until 
a total o f 6 micturition reflexes and 6 blood samples were obtained (in the presence of 
vehicle and test compounds) for the duration of each experiment. The compounds or 
vehicles were infused continuously into the animal for a duration of approximately 90 
min.
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Figure 2.5 Diagram showing the experimental protocol used for the infusion dosing regimen. It should be noted that there is 1 hour 
stabilization period after surgery.
* Cumulative dosing was utilized for the agonist infusion where three different doses of the compound were infused (see below) for 
approximately 30 min each dose.
97
The compounds under investigation using the infusion dosing regimen were 5-HT2C 
receptor agonist Ro 60-0175 and 5-HT2C and 5 -HT2A receptor antagonists SB 242084 
and MDL 100907 respectively.
Ro 60-0175 was administered for a duration of approximately 30 min as i.v. infusions 
of 27, 90 and 270 |ig kg'1 min'1 targeting 10, 30 and 100 nM free plasma 
concentration in each rat respectively (see Figure 2.6 showing the cumulative target 
concentrations calculated for Ro 60-0175). As Ro 60-0175 is a selective 5 -HT2C 
receptor agonist (Ki = InM) from cloned rat binding studies (Hemrick-Luecke & 
Evans, 2002), it was decided following in-house discussions at Pfizer with colleagues 
that 10, 30 and 100 x Ki nM (free plasma concentration) would be suitable to 
investigate the selectivity and efficacy of Ro 60-0175 in this study. Therefore, 
following in-house pharmacokinetic/pharmacodynamic (PK/PD) studies in the rat and 
in vitro plasma protein binding (PPB), carried out at Pfizer (Sandwich, UK), 
cumulative infusion doses were simulated, where the low dose o f Ro 60-0175 infused 
at a rate o f 27pg kg'1 m in'1 (targeting 10 nM free plasma concentration) was proposed 
to be selective for 5 -HT2C receptors and the high dose infused at a rate of 270 pg kg'1 
min'1 (targeting 100 nM free plasma concentration) was proposed to be non-selective, 
thus activating other receptors including 5-HT2A- In this study, the duration of 
infusion of each dose of Ro 60-0175 was designed to fit in with the cystometry 
experimental protocol described above.
SB 242084 is an antagonist with high affinity for the 5 -HT2C receptor subtype where 
Ki = 0.94 (~1 nM) at the human 5 -HT2C receptor (Gleason et al., 2001). It was 
established that targeting 3 x Ki (3 nM) plasma concentration would be selective for
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the 5-HT2C receptor. In order to obtain the desired free plasma levels of SB 242084, 
calculations performed by Pfizer Drug Metabolism (PDM) using PK/PD studies and 
PPB determination carried out in-house, concluded that SB 242084 was to be 
administered as a loading dose of 22.5 pg kg'1 min'1 for 15 min, and thereafter 
maintained at a dose of 3.5 pg kg'1 min'1 for the remaining duration of the experiment 
(see Figure 2.7 for simulation graph of target concentration for SB 242084).
MDL 100907 is an antagonist with a high selectivity for the 5 -HT2A receptor where 
Ki = 0.78 (~1 nM) at the human 5 -HT2A receptor (Gleason et al., 2001). Similar to 
SB 242084 above, it was established that targeting 3 x Ki (3 nM) would be an 
effective free plasma concentration of MDL 100907, as this would be selective for the 
5-HT2A receptors. In order to obtain the desired free plasma levels of MDL 100907, 
calculations performed by PDM using PK/PD studies and PPB determination carried 
out in-house, concluded that MDL 100907 was to be administered as a loading dose 
of 16.7 pg kg'1 min'1 for 15 min, and thereafter maintained at a dose o f 0.83 pg kg'1 
min*1 for the remaining duration o f the experiment (see Figure 2.8 for simulation 
graph of target concentration for MDL 100907).
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Figure 2.6 Simulation graph showing cumulative predicted plasma concentrations calculated for Ro 60-0175 (courtesy of PDM; 
Pfizer, Sandwich UK). To achieve target concentrations of 10, 30 and 100 nM for Ro 60-0175, the compound was infused at 3 
cumulative doses of a) 27 pg kg'1 min'1 (-10 nM), b) 90 pg kg'1 min'1 (-30 nM) and c) 270 pg kg'1 min'1 (-100 nM). The duration of 
infusion of each dose of Ro 60-0175 was designed to fit in with the cystometry experimental protocol. Simulations were made using 
previous PK/PD studies in the rat carried out in-house for Ro 60-0175.
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To convert the predicted concentration of Ro 60-0175 from ng/mL (see Figure 2.6 
above) to Free nM, the following formula was used:
ng/mL x 1000 x Free unbound plasma (FUpl) = nM Free 
relative molecular mass (Mr)
Relative molecular mass: 226.7
FUpl obtained from rat plasma protein binding studies: 0.04
* The above calculations, were performed courtesy of colleagues in PDM at Pfizer 
(Sandwich, UK)
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Figure 2 . 7  S i m u l a t i o n  g r a p h  s h o w i n g  t h e  f r e e  p l a s m a  t a r g e t  c o n c e n t r a t i o n  c a l c u l a t e d  f o r  S B  2 4 2 0 8 4  ( c o u r t e s y  o f  P D M ;  P f i z e r ,  S a n d w i c h  
U K ) .  T o  a c h i e v e  a  t a r g e t  c o n c e n t r a t i o n  o f  3 n M  ( 3  x  K i )  f o r  S B  2 4 2 0 8 4 ,  t h e  c o m p o u n d  w a s  i n i t i a l l y  i n f u s e d  a s  a  l o a d i n g  d o s e  a t  a  r a t e  o f  2 2 . 5  
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S i m u l a t i o n s  w e r e  m a d e  u s i n g  p r e v i o u s  P K / P D  s t u d i e s  i n  t h e  r a t  c a r r i e d  o u t  i n - h o u s e  f o r  S B  2 4 2 0 8 4 .
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Figure 2.8 Simulation graph showing the infusion rate calculated for MDL 100907 (courtesy of PDM; Pfizer, Sandwich UK). To 
achieve a target concentration of 3nM (3 x Ki) for MDL 100907, the compound was initially infused as a loading dose at a rate of 16.7 pg 
kg'1 min-1 for 15 minutes and thereafter maintained at a rate o f 0.83 pg kg'1 min'1 for the remaining duration of the experiment. The 
duration of infusion of both the loading dose and maintenance dose of MDL 100907 was designed to fit in with the cystometry experimental 
protocol. Simulations were made using previous PK/PD studies in the rat carried out in-house for MDL 100907.
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2.2.3 Experiments in Chapter §
5-HT2 receptors in micturition - i.c.v and i.t. administration
In these experiments, following attainment of three consecutive reflex-evoked bladder 
contractions of similar amplitude, the bladder was filled with 80% volume of saline 
required to evoke the micturition reflex, and all parameters were recorded for 5 min. 
The agonist or vehicle was thereafter administered i.c.v. (5 pi) or i.t. (10 pi). Ten 
minutes later, the bladder was emptied and infusion was commenced once more to 
evoke the micturition reflex (a single micturition) in the presence of test drugs or 
vehicle (see Figure 2.9).
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Figure 2.9 Diagram showing the experimental protocol used for the i.c.v. and i.t. dosing regimen. It should be noted that there is 1 hour 
stabilization period after surgery.
2.3 Data capture
Arterial blood and bladder pressure were continuously displayed on a chart recorder 
(Grass Instruments) and captured (2000 samples per second) by a MP 100 WSW 
interface (Biopac Systems Inc, USA) to allow data to be acquired and analysed offline 
using Acknowledge version 3.7.3 software (Biopac Systems Inc, USA). Heart rates 
(HR) were derived electronically on-line from the blood pressure signal using the 
Biopac system. The amplified raw EMG signal was captured (2000 samples per 
second) and the input integrated off-line using Acknowledge version 3.7.3 software 
(Biopac Systems Inc, USA). For EUS-EMG activity, the noise levels were verified at 
the end o f the experiment by slowly administering the neuromuscular blocker 
decamethonium bromide (3 mg kg '1, i.v.) to abolish activity. The background noise 
was then determined and subtracted from the measured values. Urethral pressure was 
captured (500 samples per second) and displayed using the Acknowledge version 3.7.3 
software and analysed offline.
For experiments carried out in chapter 4, blood pressure, bladder pressure, urethral 
pressure, raw and integrated EUS-EMG were recorded onto a computer hard disk 
using a CED (Cambridge Electronic Design) 1404 + interface and Spike 2 (version 
5.06) data collection software which was used for off-line analysis. HR was derived 
off-line from the blood pressure signal using the Spike system. Additionally, due to 
Home Office restrictions at Pfizer (Sandwich, UK), no decamethonium was 
administered for experiments carried out in the establishment but rather change in 
EUS-EMG signal was calculated from subtracting baseline EUS-EMG activity pre- 
treatment from EUS-EMG activity post-treatment and percentage changes in EUS- 
EMG signal calculated thereafter.
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2.4 Analysis of results
Saline infusion into the bladder evoked large-amplitude bladder contractions with 
corresponding urethral relaxations and bursts of the EUS-EMG each of which 
represents a micturition reflex (Maggi et al., 1986; see Figure 2.10). The following 
variables were measured on the micturition reflex; volume threshold (ml) - defined as 
the volume o f saline required to elicit voiding, pressure threshold (mmHg) -  the 
bladder pressure recorded at the start o f a micturition contraction, and residual volume 
- expressed as a percentage of the total volume infused (see Figures 2.10 and 2.11).
As mentioned in the previous section, background noise was subtracted from the 
measured integrated EUS-EMG activity. The total integrated EUS-EMG activity 
using the root mean square of the raw EUS-EMG was used for analysis as it produced 
waveforms that were more easily analyzable than the noisy raw EMG signal.
Baseline values of the area under the curve of the rectified EUS-EMG signal were 
analysed over a 1 min period before administration of test drug or vehicle and for 5 
min after drug/vehicle administration. It should be noted that these baseline variables 
were recorded whilst the bladder was filled with 80% volume of saline required to 
elicit a micturition reflex. The percentage change of the total integrated EUS-EMG 
signal following deduction of background noise was calculated thereafter. Similarly, 
the mean baseline variables for urethral pressure, blood pressure and heart rate were 
also measured over a 1 min period before addition of test drug/vehicle with post- 
treatment effects measured for 5 min thereafter.
For experiments carried out in chapter 4, raw EUS-EMG activity was rectified and 
smoothed (0.1s time constant) using Spike 2 functions. The resulting baseline EUS- 
EMG activity was analysed as described in the paragraph above.
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2.5 Statistical analysis
Changes in all the above variables were measured after drug administration and all 
values are expressed as A mean (%) ± s.e.mean or A mean ± s.e.mean. Drug evoked 
changes on the micturition reflex were compared to control reflexes (calculated mean 
of the variables measured for the 3 control micturition reflexes) using unpaired 
Student’s t-test. Changes in mean integrated EUS-EMG activity, urethral pressure, 
blood pressure and heart rate caused by the test drugs were compared with time 
matched vehicle controls (*), antagonist + agonist (#) or antagonist alone (+) using 
two-way analysis of variance and the least significant difference test (Sokal & Rohlf, 
1969). Values of P<0.05 were considered to be statistically significant for all the 
statistical tests performed.
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Figure 2.10 Urethane anaesthetised female rats: traces showing changes in bladder 
and urethral pressures, raw and integrated urethral striated muscle (EUS-EMG 
activity) during intravesical infusion of saline into the bladder (the distension evoked 
micturition reflex). Arrow denotes onset of saline infusion into the bladder.
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Figure 2.11 Rat cystometry method, trace showing distension evoked micturition reflex and the measurements taken.
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2.6 Drugs and solutions
Drugs and chemicals were obtained from the following sources: 8,9-Dicloro-2,3,4,4a- 
tertrahydro-1 H-pyrazinol[ 1,2,-a]quinoxaline-5(6//)-one hydrochloride (WAY- 
161503), (aS)-6-Chloro-5-fluoro-a-methyl-lH-indole-l-ethanamine fumarate (Ro 60- 
0175), a-methyl-5-(2-thienylmethoxy)-l H-indole-3-ethanamine (BW 723C86), 
ketanserin, mianserin and 8-[5-(5-amino 2,4-dimethoxyphenyl) 5-oxopentyl]-l,3,8- 
triazaspiro[4,5] decane-2,4-dione (RS 102221) from Tocris Cookson Ltd., 
Avonmouth, Bristol, U.K; urethane, decamethonium bromide, l-(3-Chlorophenyl) 
piperazine hydrochloride (mCPP) and (2,5-dimethoxy-4-idophenyl)-2-aminopropane 
hydrochloride (DOI) from Sigma Aldrich Chemicals, Poole , Dorset, U.K; isoflurane 
from Abbots Labs, Queenborough, Kent, U.K; gelofusine from Braun Medical Ltd, 
Aylesbury, Bucks, U.K; sodium chloride, glucose, sodium bicarbonate from 
Merck/BDH, Poole, Dorset, U.K; heparin from CP Pharmaceuticals from CP 
Pharmaceuticals Ltd, Wrexham, U.K. 2-amino-4-(4-fluoronaphth-l-yl)-6- 
isopropylpyrimidine (RS 127445) and 6-Chloro-2,3-dihydro-5-methyl-N-[6-[(2- 
methyl-3-pyridinyl)oxy]-3-pyridinyl]-1 H-indole-1 -carboxyamide dihydrochloride 6- 
Chloro-5-methyl-l-[[2-(2-methylpyrid-3-yloxy)pyrid-5-yl]carbamoyl]indoline 
dihydrochloride (SB 242084) were a gift from Pfizer Global Research and 
Development, Sandwich, Kent, UK; a-anilino-N-2-m-chlorophenoxypropylacetamide 
(BW501C67) was a gift from Wellcome Research Laboratories, Beckenham, Kent; 
and R-(+)-a- (2,3-dimethoxyphenyl)-l -[2-(4-fluorophenylethyl)]-4-piperidinem 
ethanol (MDL 100907) was a gift from Merrill Dow, Cincinnati, Ohio. mCPP, 
WAY-161503, Ro 60-0175, DOI, BW723C86 and BW501C67 were dissolved in
0.9% w v '1 saline. Mianserin, ketanserin, * MDL 100907, RS 102221, * SB 242084 
and RS 127445 were dissolved in 100% DMSO for i.v. bolus doses. All i.v. bolus
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doses were administered in a 0.1 ml volume followed by a flush of 0.1 ml saline. All 
i.c.v. doses were administered in a 5 t^l volume over a 20 s period whereas all i.t. 
doses were administered in a 10 |il volume over the same time period. All drugs were 
given as their salts.
* For i.v. infusion studies (chapter 4), MDL 100907 and SB 242084 were dissolved in 
a mixture comprising 50% cremaphor, 40% tetraglycol and 10% ethanol (CTE) to 
give a final concentration of 4% of the mixture when made up to the required volume 
in saline.
112
Chapter 3
Effects of i.v. bolus doses of 5-HT2 
receptor agonists and antagonists on the 
urethra and the micturition reflex
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3.1 Introduction
It has been established that central 5-HT containing pathways play an important role in 
the control o f micturition (see Ramage, 2006). The major receptor subtypes that have 
been identified to play a role in this pathway are 5-HTiA (Lecci et al., 1992; Testa et al., 
1999; Conley et al., 2001) at both supraspinal and spinal levels (Kakizaki et al., 2001; 
Seeker et al., 2003; Yoshiyama et al., 2003) and 5 -HT7 receptors which act only at the 
supraspinal level (Read et al., 2003). Interestingly, data from these experiments would 
imply that 5-HT containing neurones play an excitatory role in the control o f micturition. 
This contradicts the established view that 5-HT pathways are inhibitory. To get round 
this contradiction, a 5-HT2C receptor pathway has been proposed, which excites 
inhibitory intemeurones controlling the parasympathetic preganglionic neurones 
innervating the bladder (see de Groat, 2002). This would indicate that activation o f 5- 
HT2C receptors would cause inhibition o f the micturition reflex as reported by Steers and 
de Groat (1989) using the so called archetypical 5 -HT2C receptor agonist mCPP which is 
fairly non selective between the 5 -HT2 receptor subtypes (see Barnes & Sharp, 1999). 
Further, this hypothesis would imply that 5 -HT2C receptor antagonists would have an 
excitatory action on the micturition reflex. However, this has not yet been examined 
although the selective 5-HT2A receptor antagonist ketanserin (see Barnes & Sharp, 1999) 
has been reported to inhibit iso volumetric bladder contractions (Testa et al., 2001). 
Further, in the paper by Steers and de Groat (1989), it was also suggested that 5 -HT2C 
receptor activates “somatic muscle contraction” i.e. the EUS. In this respect, in the cat, 
5-HT2 receptors have also been implicated in the control o f the EUS (Danuser & Thor, 
1996).
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The aim o f  the present study was therefore to investigate the role o f  5 -HT2 receptor 
subtypes in the control o f  micturition in urethane anaesthetized female rats, by examining 
the effects o f  intravenous administration o f various 5 -HT2 receptor agonists and 
antagonists on bladder and urethral responses evoked by saline infusion into the bladder. 
The effects o f these agonists and antagonists on cardiovascular regulation were also 
investigated.
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3.2 Results
Baseline values for all variables are shown in Tables 3.4-3.8.
3.2.1 Vehicle Control
Administration o f  5-HT2 receptor antagonist vehicle (0.9% w v '1 saline or 100% DMSO;
i.v; n = 5) followed 5 minutes later by the 5-HT2 receptor agonist vehicle (0.9% w v'1 
saline; i.v; n = 5) evoked no significant changes in baseline EUS-EMG signal, urethral 
pressure and bladder distension caused by infusion o f  saline at a rate o f  0.1 ml m in '1 
(micturition reflex). Baseline MAP and HR were also unaffected.
3.2.2 5-HT2 receptor agonists i.v.
3.2.2.1 WAY 161503 (5-HT2C)
Traces showing the effects o f WAY 161503 (300 pg kg '1, i.v; n = 5) on changes in EUS- 
EMG signal, urethral pressure and the micturition reflex are shown in Figure 3.1a. 
Administration o f  WAY 161503 evoked EUS-EMG activity and significantly (P < 0.05) 
increased the EUS-EMG signal by 179 ± 17%. This was associated with a significant 
increase in urethral pressure reaching a maximum o f 13 ± 2%. However, when compared 
to vehicle control, this increase was found to be significant only at one time point, 2 min 
(Figure 3.1b). The increase observed on EUS-EMG activity was found to be significant 
between 2 and 3 min. The onset o f  appearance o f  EUS-EMG activity was 28 ± 11s. This 
evoked increase in EUS-EMG activity was observed to be ongoing up to 10 min, at
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which point the bladder was thereafter emptied and EUS-EMG activity ceased. In some 
experiments however, EUS-EM G activity continued over the period o f  evoking the 
micturition reflex.
WAY 161503 attenuated the micturition reflex causing a significant increase in volume 
threshold (55 ± 13%), pressure threshold (25 ± 11% ) and residual volume (121 ± 35%; 
Figure 3.1c). However, W AY 161503 had no significant effect on the reflex-evoked 
urethral relaxation (data not illustrated). The mean area o f  integrated EUS-EMG burst 
that accompanied the bladder contraction tested in the presence o f  WAY 161503 was also 
unaffected. This was found to be the case with all the other experiments carried out 
throughout this study (except i.v. mCPP; see below), thus the reflex-evoked urethral 
relaxation and mean area o f integrated EUS-EMG burst in the presence o f compounds 
were not analysed any further.
WAY 161503 significantly increased MAP by 21 ± 1 mmHg, whereas HR was 
unaffected.
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Figure 3.1a Traces showing the effects o f WAY 161503 (300 jig kg '1, i.v.) on A baseline urethral pressure and EUS-EMG activity and B 
bladder and urethral pressures and raw urethral striated muscle. * denotes onset o f saline infusion into the bladder.
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Figure 3.1b U r e t h a n e  a n a e s t h e t i s e d  f e m a l e  r a t s :  a  c o m p a r i s o n  o f  t h e  e f f e c t s  o f  
v e h i c l e  ( D M S O  +  s a l i n e )  a n d  W A Y  1 6 1 5 0 3  o n  p e r c e n t a g e  c h a n g e s  ( A )  i n  e x t e r n a l  
u r e t h r a l  s p h i n c t e r  ( E U S )  E M G  s i g n a l ,  u r e t h r a l  p r e s s u r e  ( U P )  a n d  m e a n  a r t e r i a l  b l o o d  
p r e s s u r e  ( M A P ) .  E a c h  p o i n t  r e p r e s e n t s  t h e  m e a n  v a l u e  a n d  v e r t i c a l  b a r s  s h o w  t h e  
s . e . m e a n .  C h a n g e s  c a u s e d  b y  W A Y  1 6 1 5 0 3  w e r e  c o m p a r e d  w i t h  D M S O  +  s a l i n e  
c o n t r o l  u s i n g  t w o - w a y  a n a l y s i s  o f  v a r i a n c e  f o l l o w e d  b y  t h e  l e a s t  s i g n i f i c a n t  
d i f f e r e n c e  t e s t .  *  P <  0 . 0 5 ,  * * *  P < 0 . 0 0 1 .
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Figure 3.1c Urethane anaesthetised female rats: a comparison o f  the effects o f vehicle 
(DMSO + saline) and WAY 161503 on percentage changes (A) in volume threshold, pressure 
threshold and residual volume. Each bar represents mean value and vertical bars show the 
s.e.mean. Changes caused by WAY 161503 were compared with DMSO + saline control 
using Student’s unpaired t test. * P< 0.05, *** P<0.001.
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3.2.2.2 Ro 60-0175 (5-HT2C)
Traces showing the effects o f  Ro 60-0175 (300 |ig kg"1, i.v; n = 5) on changes in EUS- 
EMG signal, urethral pressure and the micturition reflex are shown in Figure 3.2a. Ro 
60-0175 (n = 5) evoked EUS-EM G activity and significantly increased the EUS-EMG 
signal by 154 ± 15%. This was associated with a significant increase in urethral pressure 
o f 23 ± 2%  (Figure 3.2b) which was maintained and thus found to be significant at all 
time points for the duration o f the experiment. The onset o f appearance o f  EUS-EMG 
activity was 36 ± 13s and this was paralleled by the increase in urethral pressure. Similar 
to WAY 161503 (see above), this evoked increase in EUS-EMG activity was observed to 
be ongoing up to 10 min. W hen the bladder was emptied to begin testing the micturition 
reflex, the EUS-EM G firing usually stopped. However, just like WAY 161503, in some 
experiments EUS-EMG activity was observed to be ongoing whilst testing the micturition 
reflex, see Figure 3.2a.
Ro 60-0175 also attenuated the micturition reflex causing a significant increase in volume 
threshold (71 ± 15%) and pressure threshold (90 ± 33%; Figure 3.2c), and although 
residual volume was increased, it was found not to be significant overall.
Ro 60-0175 significantly increased MAP by 14 ± 1 mmHg and decreased HR by -13 ± 2 
beats/min.
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Figure 3.2b Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and Ro 60-0175 on percentage changes (A) in external urethral sphincter 
(EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Each 
point represents the mean value and vertical bars show the s.e.mean. Changes caused by Ro 
60-0175 were compared with DMSO + saline control using two-way analysis of variance 
followed by the least significant difference test. * P< 0.05, ** P <0.01, *** P<0.001.
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Figure 3.2c Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and Ro 60-0175 on percentage changes (A) in volume threshold, pressure 
threshold and residual volume. Each bar represents mean value and vertical bars show the 
s.e.mean. Changes caused by Ro 60-0175 were compared with DMSO + saline control 
using Student’s unpaired t test. * P< 0.05, ** P<0.01, NS non-significant.
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3.2.2.3 mCPP (5-HT2C)
Traces showing the effects o f  mCPP (300 pg kg '1, i.v; n = 5) on changes in EUS-EMG 
signal, urethral pressure and the micturition reflex are shown in Figure 3.3a. Saline and 
mCPP (n = 5) evoked EUS-EM G activity and significantly increased the EMG signal by 
166 ± 17%. This was associated with a significant increase in urethral pressure o f 24 ± 
3% (Figure 3.3b) which although the increase observed on urethral pressure was parallel 
with the appearance o f  EUS-EMG activity; it did not reach significance until after 5 min. 
The onset o f  appearance o f  EUS-EMG activity was 20 ± 5s and the duration o f EUS- 
EMG firing was between 5-8 min.
mCPP completely blocked the micturition reflex causing a continuous rise in bladder 
pressure resulting after 5 min in the appearance o f  a few drops o f  saline leaking from the 
urethral orifice. Such responses were taken to indicate that the micturition reflex had 
been abolished (see Figure 3.3a). As there was no obvious bladder contraction following 
administration o f  mCPP, both the reflex-evoked urethral relaxation and mean area o f 
integrated EUS-EMG burst that accompanied the bladder contraction were found to be 
markedly reduced or not present at all, as seen in Figure 3.3a.
Baseline MAP and HR were unaffected by mCPP.
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Figure 3.3a Traces showing the effects of mCPP (300 pg kg '1, i.v.) on A baseline urethral pressure and EUS-EMG activity and B bladder and 
urethral pressures and raw urethral striated muscle. * denotes onset o f saline infusion into the bladder.
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Figure 3.3b Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(saline + saline) and mCPP on percentage changes (A) in external urethral sphincter 
(EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). 
Each point represents the mean value and vertical bars show the s. e. mean. Changes 
caused by mCPP were compared with saline + saline control using two-way analysis of 
variance followed by the least significant difference test. * P< 0.05, ** P <0.01.
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3.2.2.4 Comparisons made between 5-HT2c receptor agonists; 
W AY 161503, Ro 60-0175 and mCPP
Direct statistical comparisons made between all three 5-HT2C receptor agonists (WAY 
161503, Ro 60-0175 and mCPP) showed no significant differences on EUS-EMG 
activity, urethral pressure and the micturition reflex (Figure 3.4a & 3.4b).
However, significant differences were observed when comparing the effects o f both 
mCPP and W AY 161503 on blood pressure (Figure 3.4a). HR was unaffected.
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Figure 3.4a Urethane anaesthetised female rats: a comparison of the effects of 5-HT2c 
receptor agonists WAY 161503, Ro 60-0175 and mCPP on percentage changes (A) in external 
urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure 
(MAP). Each point represents the mean value and vertical bars show the s. e. mean. Changes 
caused by WAY 161503, Ro 60-0175 and mCPP were compared with saline or DMSO + 
saline control using two-way analysis of variance followed by the least significant difference 
test. *, # P<0.05, ** P<0.01, *** PcO.OOl. (*), compared to saline or DMSO + saline, (#), 
compared to DMSO + WAY 161503.
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Figure 3.4b Urethane anaesthetised female rats: a comparison o f the effects o f 5-HT2C 
receptor agonists W AY 161503, Ro 60-0175 and mCPP on percentage changes (A) in 
volume threshold, pressure threshold and residual volume. Each bar represents mean 
value and vertical bars show the s.e.mean. Changes caused by WAY 161503, Ro 60- 
0175 and mCPP were compared with DMSO + saline control using Student’s unpaired t 
test. * P<0.05, ** P<0.01, *** P 0 .0 0 1 , NS non-significant.
mCPP was not included as part o f the reflex data as the reflex was completely abolished 
with no obvious bladder contraction observed hence unable to measure any o f the bladder 
variables.
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3.2.2.5 DOI (5-HT2A)
Traces showing the effects o f DOI (100 fig kg '1) on changes in EUS-EMG signal, 
urethral pressure and the micturition reflex are shown in Figure 3.5a. DOI (30, 50 and 
lOOpg kg '1, n = 3/5) in separate experiments increased baseline EUS-EMG signal activity 
by 139 ± 27%, 224 ± 36% and 198 ± 15% respectively (Figure 3.5b). However, these 
increases were found not to be dose related on the EUS-EMG signal. The 3 doses o f DOI 
had no significant effect on urethral pressure (Figure 3.5b). Onset o f  appearance o f EUS- 
EMG activity following administration o f DOI (30, 50 and 100 (ig kg '1) was 48 ± 9s, 46 ± 
6s and 17 ± 3 s respectively. This evoked increase in EUS-EMG activity was observed to 
be ongoing up to 10 min. W hen the bladder was emptied to test the micturition reflex, 
EUS-EMG firing usually stopped, but again in some experiments EUS-EMG was 
observed to be ongoing whilst testing the micturition reflex in the presence o f all three 
doses o f DOI.
On the micturition reflex, both 30 and lOOpg kg '1 DOI were found to be excitatory, 
causing a significant decrease in volume threshold (-27 ± 5% and -35 ± 7% respectively; 
Figure 3.5c), but again showing no dose relationship.
Only the high dose o f  DOI (100 pg k g '1) significantly increased MAP by 21 ± 1 mmHg 
(Figure 3.5b). Overall, DOI at all three doses had no effect on HR.
131
30
Before After
£
S '
10
6
i
w
p
w
e
&
1 min
0 J
30 n
100 fig kg-1 DO I I.v.
10
-10 1 min
Figure 3.5a Trace showing the effects o f DOI (100 pg kg '1, i.v.) on A baseline urethral pressure and EUS-EMG activity and B bladder 
and urethral pressures and raw urethral striated muscle. * denotes onset o f saline infusion into the bladder.
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Figure 3.5b Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and DOI on percentage changes (A) in external urethral sphincter (EUS) 
EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Each point 
represents the mean value and vertical bars show the s. e. mean. Changes caused by DOI were 
compared with DMSO + saline control using two-way analysis of variance followed by the 
least significant difference test. * P< 0.05, ** P <0.01, *** PO.OOl.
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Figure 3.5c Urethane anaesthetised female rats: a comparison o f  the effects o f vehicle 
(DMSO + saline) and DOI on percentage changes (A) in volume threshold, pressure 
threshold and residual volume. Each bar represents mean value and vertical bars show 
the s.e.mean. Changes caused by DOI were compared with DMSO + saline control using 
Student’s unpaired t test. * P< 0.05, ** P<0.01, NS non-significant.
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3.2.2.6 BW 723C86 (5-HT2B)
BW723C86 (300 pg kg"1, i.v; n = 5) had no significant effect on baseline EUS-EMG 
signal, MAP and HR (Figure 3.6a). Although BW723C86 appeared to cause an increase 
in urethral pressure between 4 and 5 min, this was found not to be significant overall 
(Figure 3.6a).
On the micturition reflex, BW723C86 significantly increased pressure threshold (30 ± 
9%; Figure 3.6b)
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Figure 3.6a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and BW723C86 on percentage changes (A) in external urethral sphincter 
(EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Each 
point represents the mean value and vertical bars show the s. e. mean. Changes caused by 
BW723C86 were compared with DMSO + saline control using two-way analysis of variance 
followed by the least significant difference test.
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Figure 3.6b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and BW723C86 on percentage changes (A) in volume threshold, 
pressure threshold and residual volume. Each bar represents mean value and vertical 
bars show the s.e.mean. Changes caused by BW723C86 were compared with DMSO + 
saline control using Student’s unpaired t test. *** P<0.001, NS non-significant.
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3.2.3 5-HT2 receptor antagonists i.v.
3.2.3.1 Mianserin (5-H T 2A/2b/2c)
Mianserin (300 pg k g '1, i.v; n = 5) had no significant effect on baseline EUS-EMG signal, 
urethral pressure and the micturition reflex (Figure 3.7a and 3.7b).
Although mianserin appeared to cause an increase in MAP (see Figure 3.7a), this was 
found not to be significant overall. Mianserin had no effect on HR.
3.2.3.2 Ketanserin (5-HT2a)
Ketanserin (100 pg kg*1, i.v; n = 5) had no significant effect on baseline EUS-EMG 
signal and urethral pressure (Figure 3.8a).
On the micturition reflex, ketanserin was inhibitory, with a significant increase observed 
on volume threshold (27 ± 3%) and pressure threshold (11 ± 4%; Figure 3.8b), but had no 
effect on residual volume.
Ketanserin had no effect on either MAP or HR.
3.2.3.3 MDL 100907 (5-HT2A)
MDL 100907 (30 pg kg*1, i.v; n = 5) and saline had no significant effect on baseline 
EUS-EMG signal and urethral pressure (Figure 3.9a).
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On the micturition reflex, M DL 100907 was inhibitory, with a significant increase 
observed on volume threshold (65 ± 15%; Figure 3.9b) but not pressure threshold or 
residual volume.
MDL 100907 significantly increased MAP by 14 ± 1 mmHg (Figure 3.9a). HR was 
unaffected.
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Figure 3.7a Urethane anaesthetised female rats: a comparison of the effects of mianserin and 
vehicle (saline) on percentage changes (A) in external urethral sphincter (EUS) EMG signal, 
urethral pressure (UP) and mean arterial blood pressure (MAP). Each point represents the 
mean value and vertical bars show the s. e. mean. Changes caused by mianserin and vehicle 
were compared with DMSO + saline control using two-way analysis of variance followed by 
the least significant difference test.
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Figure 3.7b Urethane anaesthetised female rats: a comparison o f the effects o f 
mianserin and vehicle (saline) on percentage changes (A) in volume threshold, pressure 
threshold and residual volume. Each bar represents mean value and vertical bars show 
the s.e.mean. Changes caused by mianserin and saline were compared with DMSO + 
saline control using Student’s unpaired t test. NS non-significant.
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Figure 3.8a Urethane anaesthetised female rats: a comparison of the effects of ketanserin 
and vehicle (saline) on percentage changes (A) in external urethral sphincter (EUS) EMG 
signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Each point 
represents the mean value and vertical bars show the s.e.mean. Changes caused by 
ketanserin and vehicle were compared with DMSO + saline control using two-way analysis 
of variance followed by the least significant difference test.
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Figure 3.8b Urethane anaesthetised female rats: a comparison o f the effects o f 
ketanserin and vehicle (saline) on percentage changes (A) in volume threshold, pressure 
threshold and residual volume. Each bar represents mean value and vertical bars show 
the s.e.mean. Changes caused by ketanserin and saline were compared with DMSO + 
saline control using Student’s unpaired t test. * P<0.05, ** P<0.01, NS non-significant.
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Figure 3.9a Urethane anaesthetised female rats: a comparison of the effects of MDL 100907 
and vehicle (saline) on percentage changes (A) in external urethral sphincter (EUS) EMG 
signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Each point 
represents the mean value and vertical bars show the s. e. mean. Changes caused by MDL 
100907 and vehicle were compared with DMSO + saline control using two-way analysis of 
variance followed by the least significant difference test. ** P<0.01.
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Figure 3.9b Urethane anaesthetised female rats: a comparison o f  the effects o f MDL 
100907 and vehicle (saline) on percentage changes (A) in volume threshold, pressure 
threshold and residual volume. Each bar represents mean value and vertical bars show 
the s.e.mean. Changes caused by MDL 100907 and saline were compared with DMSO + 
saline control using Student’s unpaired t test. ** P<0.01, NS non-significant.
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3.2.4 Effect of 5-HT2 receptor antagonists on agonist 
responses
3.2.4.1 Mianserin (5-HT2) and WAY 161503 (5-HT2C)
Mianserin (100 and 300 ng kg '1, i.v; n = 5) blocked the effects o f  WAY 161503 (n = 5) 
on baseline EUS-EMG signal. The low dose o f  mianserin failed to block the effects o f 
WAY 161503 on urethral pressure whereas the high dose prevented the WAY 161503 
evoked increase on urethral pressure (Figure 3.10a).
On the micturition reflex, only the high dose (300 pg kg '1) o f mianserin significantly 
attenuated the ability o f WAY 161503 to increase residual volume (12 ± 23%), but not 
the increases in volume and pressure threshold (Figure 3.10b).
Both doses o f mianserin (100 and 300 pg k g '1) significantly attenuated the pressor effect 
o f WAY 161503 on MAP (8 ± 1 and 7 ± 1 mmHg respectively compared with 21 ± 1 
mmHg). HR was unaffected.
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Figure 3.10a U r e t h a n e  a n a e s t h e t i s e d  f e m a l e  r a t s :  a  c o m p a r i s o n  o f  t h e  e f f e c t s  o f  v e h i c l e  
( D M S O  +  s a l i n e )  a n d  p r e - t r e a t m e n t  o f  W A Y  1 6 1 5 0 3  w i t h  m i a n s e r i n  o n  p e r c e n t a g e  c h a n g e s  
(A) i n  e x t e r n a l  u r e t h r a l  s p h i n c t e r  ( E U S )  E M G  s i g n a l ,  u r e t h r a l  p r e s s u r e  ( P )  a n d  m e a n  a r t e r i a l  
b l o o d  p r e s s u r e  ( M A P ) .  E a c h  p o i n t  r e p r e s e n t s  t h e  m e a n  v a l u e  a n d  v e r t i c a l  b a r s  s h o w  t h e  
s .  e .  m e a n .  C h a n g e s  c a u s e d  b y  m i a n s e r i n  a n d  W A Y  1 6 1 5 0 3  w e r e  c o m p a r e d  w i t h  D M S O  +  
s a l i n e  c o n t r o l  u s i n g  t w o - w a y  a n a l y s i s  o f  v a r i a n c e  f o l l o w e d  b y  t h e  l e a s t  s i g n i f i c a n t  d i f f e r e n c e  
t e s t .  * , #  P < 0 . 0 5 ,  * * , # #  P < 0 . 0 1 ,  * * * , # # #  P < 0 . 0 0 1 .  ( * ) ,  c o m p a r e d  t o  D M S O  +  S a l i n e ,  ( # ) ,  
c o m p a r e d  t o  D M S O  +  W A Y  1 6 1 5 0 3 .
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Figure 3.10b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and pre-treatment o f WAY 161503 with mianserin on percentage 
changes (A) in volume threshold, pressure threshold and residual volume. Each bar 
represents mean value and vertical bars show the s.e.mean. Changes caused by mianserin 
and WAY 161503 were compared with DMSO + saline control using Student’s unpaired 
t test. *,# P<0.05, ** P<0.01, NS non-significant. (*), compared to DMSO + Saline, (#), 
compared to DMSO + WAY 161503.
148
3.2.4.2 RS 102221 (5-HT2C) and WAY 161503 (5-HT2C)
RS 102221 (30 jig k g '1, i.v; n = 3) blocked the effects o f WAY 161503 (n = 3) on 
baseline EUS-EMG activity, whereas in the presence o f the high dose o f  RS 102221 (500 
pg k g 1; i.v; n = 5), the effects o f  WAY 161503 tended to be potentiated, although non 
significant when compared to WAY 161503 alone (299 ± 36%). RS 102221 (100 pg kg' 
\  i.v; n = 4) also failed to block the effects o f WAY 161503 on baseline EUS-EMG 
activity (Figure 3.1 la). All three doses o f RS 102221 failed to block the WAY 161503 
evoked increase in urethral pressure (14 ± 2%, 8 ± 1% and 11 ± 1%, respectively). Onset 
o f appearance o f  EUS-EMG firing following administration o f WAY 161503 pre-treated 
with RS 102221 (100 and 500 pg kg '1) was 23 ± 5 and 26 ± 5s respectively and again this 
increase in EUS-EMG activity was observed to be ongoing up to 10 min, where on 
emptying the bladder to begin testing the micturition reflex, EUS-EMG firing stopped.
For the micturition reflex, only the highest dose o f RS 102221 (500 pg kg '1) significantly 
decreased the effects o f WAY 161503 on volume threshold (4 ± 12%), and significantly 
reversed the increase in residual volume to a decrease (-14 ± 23%; Figure 3.11b).
Only the highest dose o f  RS 102221 (500 pg kg '1) significantly decreased the pressor 
effects o f WAY 161503 on MAP (7 ± 1 mmHg compared with 21 ± 1 mmHg). HR was 
unaffected.
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Figure 3.11a Urethane anaesthetised female rats: a comparison o f the effects of vehicle 
(DMSO + saline) and pre-treatment of WAY 161503 with RS 102221 on percentage 
changes (A) in external urethral sphincter (EUS) EMG signal, urethral pressure (P) and 
mean arterial blood pressure (MAP). Each point represents the mean value and vertical 
bars show the s.e.mean. Changes caused by RS 102221 and WAY 161503 were 
compared with DMSO + saline control using two-way analysis of variance followed by 
the least significant difference test. *,# P<0.05, **,### P<0.01, *** PO.OOl. (*), 
compared to DMSO + Saline, (#), compared to DMSO + WAY 161503.
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Figure 3.11b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and pre-treatment o f WAY 161503 with RS 102221 on percentage 
changes (A) in volume threshold, pressure threshold and residual volume. Each bar 
represents mean value and vertical bars show the s.e.mean. Changes caused by RS 
102221 and WAY 161503 were compared with DMSO + saline control using Student’s 
unpaired t test. *,# P<0.05, **,## P<0.01, ***P<0.001, NS non-significant. (*), 
compared to DMSO + Saline, (#), compared to DMSO + WAY 161503.
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3.2.4.3 RS 102221 (5-HT2C) and mCPP (5-HT2C)
RS 102221 (500 pg k g '1, i.v; n  = 5) failed to block the effects o f mCPP (n = 5) on 
baseline EUS-EMG signal (533 ± 84%) and urethral pressure (19 ± 3%; Figure 3.12a). 
The effects observed on EUS-EMG activity following pre-treatment o f mCPP with RS 
102221 tended to be potentiated, although non significant when compared to mCPP 
alone. Onset o f appearance o f  EUS-EMG firing following administration o f mCPP pre­
treated with RS 102221 was 11 ± 3s and this evoked increase in EUS-EMG activity was 
observed to be ongoing up to 10 min, where on emptying the bladder to begin testing the 
micturition reflex EUS-EMG firing stopped.
RS 102221 failed to interfere with the ability o f  mCPP to block the micturition reflex.
Pre-treatment o f  mCPP with RS 102221 now caused a significant decrease in MAP (-15 
± 2 mmHg; Figure 3.12a). HR was unaffected.
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Figure 3.12a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and pre-treatment of mCPP with RS 102221 on percentage changes 
(A) in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean 
arterial blood pressure (MAP). Each point represents the mean value and vertical bars 
show the s. e. mean. Changes caused by RS 102221 and mCPP were compared with 
DMSO + saline control using two-way analysis of variance followed by the least 
significant difference test. * P<0.05, ** PO.01.
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3.2.4A  SB 242084 (5-HT2C) and Ro 60-0175 (5-HT2C)
SB 242084 (30 pg k g '1, i.v; n = 5) blocked the effects o f Ro 60-0175 (n = 5) on baseline 
EUS-EMG signal (Figure 3.13a) but not the evoked increase in urethral pressure (27 ± 
3%; Figure 3.13a).
On the micturition reflex, the inhibitory effects o f Ro 60-0175 were blocked and in fact 
SB 242084 now significantly reversed the effects o f  Ro 60-0175 on volume threshold 
from an increase to a decrease (-53 ± 1 6 ; Figure 3 .13b).
SB 242084 significantly potentiated the pressor effects o f Ro 60-0175 on MAP (31 ± 2 
mmHg compared with 14 ± 1 mmHg). HR was unaffected.
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Figure 3.13a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and pre-treatment of Ro 60-0175 with SB 242084 on percentage changes (A) 
in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial 
blood pressure (MAP). Each point represents the mean value and vertical bars show the 
s. e. mean. Changes caused by SB 242084 and Ro 60-0175 were compared with DMSO + saline 
control using two-way analysis of variance followed by the least significant difference test. *,# 
P<0.05, ** P<0.01, ***, P<0.001. (*), compared to DMSO + Saline, (#), compared to DMSO 
+ Ro 60-0175.
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Figure 3.13b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and pre-treatment o f  Ro 60-0175 with SB 242084 on percentage changes 
(A) in volume threshold, pressure threshold and residual volume. Each bar represents mean 
value and vertical bars show the s.e.mean. Changes caused by SB 242084 and Ro 60-0175 
were compared with DMSO + saline control using Student’s unpaired t test. *, P<0.05, ** 
P<0.01, ###, P 0 .0 0 1 , NS non-significant. (*), compared to DMSO + Saline, (#), compared 
to DMSO + Ro 60-0175.
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3.2.4.5 Ketanserin & MDL 100907 (5-HT2A) and W AY 161503 (5- 
HT2C)
Pre-treatment with either ketanserin (30 and 100 pg kg '1, i.v; n = 5) or MDL 100907 (30 
pg kg '1, i.v; n = 5) blocked the effects o f  WAY 161503 (n = 5) on baseline EUS-EMG 
signal but not on urethral pressure (9 ± 1%, 14 ± 1% and 7 ± 1% respectively; Figure 
3.14a).
On the micturition reflex, the low dose o f ketanserin (30 pg kg '1) significantly potentiated 
the effects o f WAY 161503 on volume threshold (153 ± 33%) and tended to increase the 
effects o f WAY 161503 on pressure threshold (61 ± 17%). The effect o f WAY 161503 
on residual volume now became highly variable and was found not to be significant. The 
high dose o f ketanserin (100 pg kg '1) failed to block the effects o f WAY 161503 on 
volume threshold (81 ± 13%), pressure threshold (53 ± 14%) and residual volume (92 ± 
18%). Similarly, MDL 100907 (30 pg kg '1) failed to block the effects o f WAY 161503 
on volume threshold (92 ± 23%) and pressure threshold (83 ± 24%) and again the effects 
on residual volume were again highly variable (see Figure 3.14b for graphs).
The low dose (30 pg kg '1) o f ketanserin failed to attenuate the pressor (25 ± 3 mmHg) 
effect o f WAY 161503 on MAP whereas the high dose (100 pg kg '1) and 30 pg kg '1 dose 
o f MDL 100907 significantly attenuated the pressor response evoked by WAY 161503 
on MAP (5 ± 1 mmHg and 4 ± 1 mmHg respectively compared with 21 ± 1 mmHg; 
Figure 3.14a). HR was unaffected.
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Figure 3.14a Urethane anaesthetised female rats: a comparison of the effects o f vehicle 
(DMSO + saline) and pre-treatment of WAY 161503 with ketanserin or MDL 100907 on 
percentage changes (A) in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) 
and mean arterial blood pressure (MAP). Each point represents the mean value and vertical 
bars show the s.e.mean. Changes caused by ketanserin, MDL 100907 and WAY 161503 were 
compared with DMSO + saline control using two-way analysis of variance followed by the 
least significant difference test. *,# P<0.05, **,## P<0.01, ***,### P<0.001. (*), compared to 
DMSO + Saline, (#), compared to DMSO + WAY 161503.
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Figure 3.14b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and pre-treatment o f WAY 161503 with ketanserin or MDL 100907 on 
percentage changes (A) in volume threshold, pressure threshold and residual volume. 
Each bar represents mean value and vertical bars show the s.e.mean. Changes caused by 
ketanserin, MDL 100907 and WAY 161503 were compared with DMSO + saline control 
using Student’s unpaired t test. *,#,+ P<0.05, ** P<0.01, *** P 0 .0 0 1 , NS non­
significant. (*), compared to DMSO + Saline, (#), compared to DMSO + WAY 161503. 
(+), compared to ketanserin + saline.
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3.2.4.6 Ketanserin & MDL 100907 (5-HT2A) and Ro 60-0175 (5- 
HT2C)
Pre-treatment with either ketanserin or MDL 100907 (30 pg kg '1, i.v; n = 5) blocked the 
effects o f Ro 60-0175 (n = 5) on baseline EUS-EMG signal but not urethral pressure (9 ± 
1 and 11 ± 2 % respectively compared with 23 ± 2; Figure 3.15a).
On the micturition reflex, both ketanserin and MDL 100907 failed to block the inhibitory 
effects o f  Ro 60-0175 on volume threshold (61 ± 5 and 63 ± 6% compared with 71 ±
15%) and pressure threshold (50 ± 3 and 44 ± 6% compared with 90 ± 33%; Figure 
3.15b). The tendency o f  Ro 60-0175 to increase residual volume was now non existent.
Both ketanserin and MDL 100907 failed to block the pressor effect o f  Ro 60-0175 on 
MAP (16 ± 2 and 24 ± 1 mmHg respectively compared with 14 ± 1 mmHg). HR was 
unaffected.
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Figure 3.15a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and pre-treatment of Ro 60-0175 with ketanserin or MDL 100907 on 
percentage changes (A) in external urethral sphincter (EUS) EMG signal, urethral pressure 
(UP) and mean arterial blood pressure (MAP). Each point represents the mean value and 
vertical bars show the s.e. mean. Changes caused by ketanserin, MDL 100907 and Ro 60-0175 
were compared with DMSO + saline control using two-way analysis of variance followed by 
the least significant difference test. * P<0.05, ** P<0.01, *** P<0.001.
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Figure 3.15b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and pre-treatment o f Ro 60-0175 with ketanserin or MDL 100907 on 
percentage changes (A) in volume threshold, pressure threshold and residual volume. 
Each bar represents mean value and vertical bars show the s.e.mean. Changes caused by 
ketanserin, MDL 100907 and Ro 60-0175 were compared with DMSO + saline control 
using Student’s unpaired t test. * P<0.05, ** P<0.01, *** P<0.001, NS non-significant.
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3.2.4.7 RS 127445 (5-HT2B) and Ro 60-0175 (5-HT2C)
Pre-treatment with RS 127445 (300 pg kg'1, i.v; n = 5) failed to block the effects o f Ro 
60-0175 on baseline EUS-EMG signal (218 ± 30% compared with 179 ± 17%; Figure 
3.16a). Interestingly, RS 127445 reversed the Ro 60-0175 evoked increase in urethral 
pressure to a non significant decrease (-11 ± 4%; Figure 3.16a). The onset o f appearance 
o f EUS-EMG firing following pre-treatment o f Ro 60-0175 with RS 127445 was 19 ± 2s. 
This evoked increase in EUS-EMG activity was observed to be ongoing up to 10 min at 
which time the bladder was emptied to test the micturition reflex and EUS-EMG firing 
stopped.
On the micturition reflex, RS 127445 failed to have a significant effect on Ro 60-0175 
evoked responses on both volume and pressure threshold. Interestingly, even though Ro 
60-0175 alone had no significant effect on residual volume due to high variability, pre­
treatment o f with RS 127445 reduced this variability, thus causing a significant increase 
in residual volume (64 ±11% ; Figure 3.16b).
RS 127445 failed to block the pressor effects o f Ro 60-0175 on MAP (25 ± 2 mmHg 
compared with 14 ± 1 mmHg). HR was unaffected.
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Figure 3.16a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and pre-treatment of Ro 60-0175 with RS 127445 on percentage changes 
(A) in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean 
arterial blood pressure (MAP). Each point represents the mean value and vertical bars 
show the s.e. mean. Changes caused by RS 127445 and Ro 60-0175 were compared with 
DMSO + saline control using two-way analysis of variance followed by the least 
significant difference test. * P<0.05, ** PO.01, ***,### P0.001. (*), compared to 
DMSO + Saline, (#), compared to DMSO + Ro 60-0175.
164
2 0 0 i
qi g .1 5 0 -
I  ?  1 0 0 -
> "§ 50H
£  0 
-50J
Q)
<a  2
(A O
0) SZ  
Q - (D 
<  }=
150-i 
—  100- 
50- 
0
-50J
250-i
ro  s ?
€  ®  1 5 0
'55 E
<U 3
" o  50
^  >
■DM SO  + Saline i.v. (n = 5)
□DM SO  + 300 pg kg'1 Ro 60-0175 i.v. (n = 5)
30 fig kg'1 RS 127445 + 300 jig kg" Ro 60-0175 i.v. (n = 5)-1
*
-50J
Figure 3.16b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and pre-treatment o f Ro 60-0175 with RS 127445 on percentage 
changes (A) in volume threshold, pressure threshold and residual volume. Each bar 
represents mean value and vertical bars show the s.e.mean. Changes caused by RS 
127445 and Ro 60-0175 were compared with DMSO + saline control using Student’s 
impaired t test. * P<0.05, ** P<0.01, *** P 0 .0 0 1 , NS non-significant.
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3.2.4.8 Ketanserin & MDL 100907 (5-HT2A) and DOI (5-HT2A)
Both ketanserin (30 pg kg '1, i.v; n = 5) and MDL 100907 (30 pg kg '1, i.v; n = 3) blocked 
the ability o f DOI (n = 3/5) to evoke EUS-EMG activity (Figure 3.17a). Pre-treatment of 
DOI with the 5-HT2A receptor antagonists now tended to increase urethral pressure, but 
these increases were found not to be significant (Figure 3.17a).
On the micturition reflex, both 5-HT2A receptor antagonists significantly reversed the 
effects o f DOI on volume threshold from a decrease to an increase (43 ± 15% and 90 ± 
43% respectively; Figure 3.17b). Interestingly, administration o f DOI alone had no 
significant effect on pressure threshold but pre-treatment o f DOI with ketanserin caused a 
significant increase o f 63 ± 22% (Figure 3.17b).
Ketanserin and MDL 100907 failed to interfere with the pressor effect evoked by DOI on 
MAP (14 ± 1 mmHg and 24 ± 3 mmHg respectively compared with 21 ± 1 mmHg;
Figure 3.17a). HR was unaffected.
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Figure 3.17a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and pre-treatment of DOI with ketanserin or MDL 100907 on percentage 
changes (A) in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean 
arterial blood pressure (MAP). Each point represents the mean value and vertical bars show the 
s. e. mean. Changes caused by ketanserin, MDL 100907 and DOI were compared with DMSO + 
saline control using two-way analysis of variance followed by the least significant difference 
test. * P<0.05, ** P<0.01, *** P0.001.
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Figure 3.17b Urethane anaesthetised female rats: a comparison o f the effects o f vehicle 
(DMSO + saline) and pre-treatment o f DOI with ketanserin or MDL 100907 on percentage 
changes (A) in volume threshold, pressure threshold and residual volume. Each bar represents 
mean value and vertical bars show the s.e.mean. Changes caused by ketanserin, MDL 100907 
and DOI were compared with DMSO + saline control using Student’s unpaired t test. *,# 
P<0.05, **,## P<0.01, NS non-significant. (*), compared to DMSO + Saline, (#), compared 
to DMSO + DOI.
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999999
300 jig kg'1 Ro 60-0175 bolus i.v. (n = 3)
Sample no. Time (min) Measured [Free Plasma] 
nM
1 (0 * 0 0.5 49
2 10 15
Table 3.1 Summary o f  measured free plasma concentrations o f 5 -HT2C receptor agonist 
Ro 60-0175. Blood samples were taken at 30s and lOmin following administration o f Ro 
60-0175.
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CJai cliovubiculai cl tccts 1' s e l e c t i v i t y
Overall Vol
Thres
Pressure
Thres
Residual
Vol
Blood
Pressure
Heart
Rate
WAY161503 5-HT2C agonist TTT T (13) inhibited t t TT TTT TT 4—4
Ro 60-0175 5-HT2C agonist T T T t t (23) inhibited T t TT 4—4 T (14) i (13)
mCPP 5-HT2C agonist t t t t t  (24) abolished x x x x XXXX XXXX 4—4 4—4
DOI 5-HT2A agonist T T T 4—4 excited I 4 - + TT (21) 4—4
BW723C86 5-HT2B agonist 4—4 4—4 inhibited 4 - + T 4 — > 4—4 4—4
Mianserin 5HT2A/2B/2c antagonist 4—4 4—4 no effect 4 - 4 4—4 4—4 4 - 4 f 4 - 4
Ketanserin 5HT2A/1d;
a,H ,
antagonist 4—4 4—4 inhibited T T 4—4 4—4 4 - 4
MDL 100907 5-HT2A antagonist 4 — * 4—4 inhibited T 4 - 4 4—4 _  T ( 1 4 ) 4—4
WAY161503 
Mianserin 
100 & 300
blocked T unaffected TT TT 4—4 attenuated 
(8 & 7)
4—4
WAY161503 
RSI02221 
(30, 100 & 500)
only low dose 
blocked
T unaffected block high 
dose only
4—4 4—4 block high 
dose only
4—4
mCPP 
RSI02221 
(500)
no block, tended to 
potentiate T unaffected abolished XXXX XXXX XXXX i  (-15) 4—4
Ro 60-0175 
SB 242084 5-HT2C antagonist blocked T unaffected blocked i 4—4 4—4
potentiate 
T T T  (31) 4—4
WAY161503 
Ketanserin 30 
Ketanserin 100
blocked
blocked
T unaffected 
T unaffected
potentiates 
no effect
T T T
TT
TT
TT
<-► variable 
TT T
T
atten <-►
4—4
4—4
WAY161503 
MDL 1000907 blocked T unaffected no effect TT TT <-*• variable atten <-*• 4 - 4
Ro 60-0175 
Ketanserin 30 blocked T unaffected no effect TT TT 4 - 4 blocked 4—4
Ro 60-0175 
MDL 100907 blocked T unaffected no effect TT TT 4—4 blocked 4—4
Ro 60-0175 
RS 127445 5-HT2B antagonist T T T blocked no effect TT TT 4—4 no effect 4—4
DOI 
Ketanserin 30 blocked unaffected reversed T TT T variable t t  (14) 4—4
DOI 
MDL 100907 30 blocked unaffected reversed .  TT T variable 4—4 t t  (24) 4—4
Table 3.2 Summary of 5-HT2 receptor agonist and/or antagonist evoked responses on EUS-EMG, urethral pressure, micturition reflex and cardiovascular effects
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AE xperim ental G roup n O nset tim e o f  E U S-EM G  activity (s)
300 pg kg*1 WAY 161503 i.v. 5 28± 11
300 pg kg '1 Ro 60-0175 i.v. 5 36 ± 13
300 pg kg '1 mCPP i.v. 5 20 ±5
30 pg kg '1 DOI i.v. 3 48 ± 9
50 pg kg '1 DOI i.v. 3 46 ± 6
100 pg kg '1 DOI i.v. 5 17 + 3
B
100 pg kg '1 RS 10 2221 + 
WAY 161503 i.v.
4 23 + 5
500 pg kg '1 RS 10 2221 + 
WAY 161503 i.v.
5 26 + 5
500 pg kg '1 RS 10 2221 + 
mCPP i.v.
5 11+3
C
30 pg kg '1 RS 127445 + 5 19 + 2
Ro 60-0175 i.v.
Table 3.3 Summary o f onset times o f appearance o f EUS-EMG activity following A 
WAY 161503, Ro 60-0175, mCPP and DOI (i.v.); B pre-treatment o f WAY 161503 and 
mCPP with RS 102221 (i.v.); C pre-treatment o f Ro 60-0175 with RS 127445 (i.v.). All 
values are expressed as means ± sem. No statistical differences were observed when 
comparisons were made between the different groups.
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3.3 Discussion
The present data demonstrate that, with the exception o f BW723C86, all the 5 -HT2 
receptor agonists tested, mCPP, WAY 161503, Ro 60-0175 and DOI when given i.v. 
caused activation o f the external urethral sphincter (EUS) in urethane anaesthetized rats 
with a primed (i.e. 80% full) urinary bladder. In addition, with the exceptions o f DOI and 
BW723C86, they all increased urethral pressure and inhibited the micturition reflex. In 
this latter respect DOI had an excitatory effect, while BW723C86 was ineffective on the 
micturition reflex. The three agonists mCPP (see Bonhaus et al., 1997) WAY 161503 
(Cryan & Lucki, 2000) and Ro-60-0175 (Martin et al., 1998) are considered to be 
selective for 5 -HT2C receptors. If  taken alone these agonist data would suggest that 
activation o f 5 -HT2C receptors causes external urethral sphincter activation, urethral 
contraction and the inhibition o f micturition. It should be noted that an increase in 
urethral pressure could involve both the urethral smooth muscle and striated muscle due 
to the structural link o f  both urethral muscle types. Further, the present data confirm the 
observations by Steers & De Groat (1989) that mCPP activates the external urethral 
sphincter. However, the suggestion by these authors that the inhibition o f isovolumetric 
contractions by mCPP is caused by activation o f the EUS is unfounded. The present data 
indicate that this is a separate action, as although mCPP completely inhibited the 
micturition reflex, the other agonists increased EUS-EMG in a similar fashion but only 
attenuated the micturition reflex.
To confirm whether the evoked responses caused by mCPP, WAY 161503 and Ro 60- 
0175 on the micturition variables involved activation o f 5-HT2c receptors; the effects o f
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these agonists was studied in the presence o f the selective 5-HT2C receptor antagonists.
RS 102221 (Bonhaus et al., 1997) failed to block the mCPP evoked responses on the 
EUS and the micturition reflex. In fact, the mCPP-evoked EUS-EMG activity tended to 
be potentiated. This may simply reflect the lack o f selectivity o f mCPP; for instance, 
mCPP is a partial agonist at 5 -HT2A receptors (Grotewiel et al., 1994) as well as ‘other’ 
receptors. To confirm that these effects were in fact mediated by 5 -HT2 receptors another 
selective 5 -HT2C receptor agonist, WAY 161503, was tested against the non-selective 
5 -HT2 receptor antagonist mianserin (see Bonhaus et al., 1995). Both doses o f mianserin 
blocked the ability o f  WAY 161503 to evoke EUS-EMG activity but mianserin had little 
effect on the inhibitory action o f WAY 161503 on the micturition reflex. However, the 
high dose o f mianserin did block the ability o f WAY 161503 to increase residual volume 
and to significantly increase urethral pressure. Thus these data are at least consistent with 
the view that external urethral sphincter activation involves 5 -HT2 receptors. To further 
clarify if  the 5 -HT2C receptor subtype was responsible for this action o f WAY 161503 
experiments were carried out again in the presence o f the RS 102221. Once more the 
same dose (500 pg kg*1) that had failed to block the effects o f mCPP also failed to affect 
the effects o f WAY 161503 on EUS-EMG and urethral pressure, although it blocked all 
the inhibitory actions o f WAY 161503 on the micturition reflex. Further, this high dose 
o f RS 102221, as for mCPP, tended to potentiate the effects o f WAY 161503 on the 
EUS-EMG. Nevertheless, the lowest dose did block WAY 161503-evoked EUS-EMG 
activity but not the increase in urethral pressure or the inhibitory action on the micturition 
reflex. This would indicate that the increase in EUS activity by these agonists is separate 
from the ability o f these drugs to inhibit micturition. The failure o f  the high doses to
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affect the evoked EUS-EMG is difficult to explain, although RS 102221 was reported to 
have inconsistent actions on 5-HT2C receptor mediated effects (Bonhaus et al., 1997).
For instance, RS 102221 failed to block the classical 5HT2C receptor mediated effect of 
hypolocomotion (Bonhaus et al., 1997) evoked by mCPP at any dose. Thus the present 
data extend and confirm that the use o f RS 102221, at least in vivo, to characterise 
5-HT2C receptor mediated effects needs to be dealt with caution as the combined data 
suggest RS 102221 is having other unknown actions. However, overall the present data 
are still consistent with the view that 5-HT2C receptors are involved in EUS-EMG 
activation and have an inhibitory action on the micturition reflex. This was further 
confirmed by studying the effects o f Ro 60-0175, which is considered to have at least 
500x greater selectivity for 5-HT2C over 5-HT2A and 5-HT 2b receptors (see Barnes & 
Sharp 1999), in the presence o f the highly selective 5-HT2C receptor antagonist SB 
242084 (Kennett et al., 1997). It should be noted however that in vitro studies have 
recently revealed Ro 60-0175 possesses greater selectivity for both human and rat 5-HT2b 
receptors than previously thought (Ki = 2.4 nM; Kimura et al., 2004) therefore caution 
needs to be applied again when characterising 5-HT2C receptor mediated effects. The Ro 
60-0175 evoked EUS-EMG and inhibitory effects on the micturition reflex were now 
blocked but not the increase in urethral pressure, implying that the evoked increase in 
urethral pressure is most likely to be mediated by another 5 -HT2 receptor subtype, 
possibly 5-HT2B receptors. However, in this respect it is surprising that the 5 -HT2B 
receptor agonist BW723C86 (Kennett et al., 1996) did not affect urethral pressure 
although there was tendency for it to increase this variable. This might again be related to 
lack of expected selectivity in vivo. Indeed in vitro data gives conflicting data on
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BW723C86’s selectivity for 5-HT2B receptors, either lOOx over 5-HT2A/2C (Porter et al., 
1999) or none (Knight et al., 2004). Confirmation that 5-HT2B receptors are responsible 
for the increase in urethral pressure by these agonists is the present observation that pre­
treatment with the selective 5-HT2B receptor antagonist RS 127445 (Bonhaus et al., 1999) 
completely blocked the ability o f Ro 60-0175 to increase urethral pressure without 
affecting the evoked increase in EUS-EMG and inhibition o f the micturition reflex. This 
again indicates that increases in both urethral pressure and EUS activity are not linked.
The ability o f DOI, which shows some selectivity for 5-HT2A receptors (Porter et al.,
1999; Knight et al., 2004), to increase EUS-EMG, implies that 5-HT2A receptors are also 
involved in this action. DOI also has an excitatory action on the micturition reflex 
implying that this is a function o f 5-HT2A receptors. These conclusions are supported by 
the observations that DOI in the presence o f the selective 5-HT2A receptor antagonists, 
ketanserin (see Bonhaus et al., 1997) or MDL 100907 (Kehne et al., 1996) failed to 
evoke EUS-EMG activity and reversed the excitatory action o f DOI on the micturition 
reflex to inhibition. This latter effect would be consistent with DOI, at the dose used in 
the present study, having an additional action on 5-HT2C receptors. Thus the 5-HT2C 
receptor mediated effect o f DOI is overridden by its 5-HT2A receptor agonist action on 
the micturition reflex. In this respect, DOI might be expected to also have a residual 
action on the external urethral sphincter. However, DOI only had a tendency to increase 
urethral pressure in the presence o f these 5-HT2A receptor antagonists, which is 
presumably due to a weak action on 5-HT2B receptors as the selectivity o f DOI between 
the 5-HT2 receptor subtypes is very low (Porter et al., 1999).
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wOverall the data suggest that both 5-HT2A and 5-HT2C receptors are involved in activation 
of the EUS. Thus to investigate if  any 5-HT2A receptor component was involved in the 
effects o f WAY 161503 on the external urethral sphincter, studies were carried out in the 
presence o f the 5-HT2a receptor antagonists. Surprisingly the WAY 161503 evoked 
EUS-EMG was blocked by these antagonists but not the increase in urethral pressure. 
Further, the inhibitory action o f WAY 161503 on the micturition reflex was unaffected, 
although the low dose o f ketanserin tended to potentiate this action o f WAY 161503 by 
probably blocking a weak excitatory 5-HT2A receptor agonist action o f WAY 161503.
The failure o f these antagonists to interfere with the WAY 161503 inhibitory action on 
the micturition reflex further confirms the conclusion that 5-HT2C receptors play an 
inhibitory role in the control o f micturition. Consistent with this conclusion is the 
observation that both ketanserin and MDL 100907 also failed to interfere with the 
inhibitory effects o f Ro 60-0175 on the micturition reflex, although again blocking the 
ability o f Ro 60-0175 to evoke EUS-EMG activity. Interestingly, although ketanserin did 
not interfere with the ability o f Ro 60-0175 to evoke an increase in urethral pressure,
MDL 100907 did prevent Ro 60-0175 evoking a significant increase in urethral pressure 
by increasing the variability o f Ro 60-0175’s action on this micturition variable. This 
latter observation implies that even at the low dose o f MDL 100907 there might be some 
weak 5-HT2B receptor actions. Thus overall the data indicate that both 5 -HT2A and 5- 
HT2C receptors are involved in mediating the ability o f these agonists to activate the 
external urethral sphincter. The relationship between these two 5-HT receptor subtypes 
remains to be determined in this action although on the micturition reflex they have an 
opposing action.
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The present data examining the effects o f ketanserin and MDL 100907 alone on the 
micturition reflex indicate that 5-HT2A receptors may play a physiological tonic 
excitatory role in micturition as these antagonists caused increases in the volume 
threshold and ketanserin also caused an increase in the pressure threshold. However 
these antagonists had no effect on the reflex evoked EUS-EMG activity indicating that 
these receptors are not involved in this part o f the micturition pathway. In this respect, 
ketanserin has previously been reported to inhibit bladder isovolumetric contractions 
(Testa et al., 2001). However, the involvement o f 5 HT2A receptors in the reflex control 
o f micturition may be considered a minor one as a similar dose to that o f ketanserin o f a 
5 -HT7 receptor antagonist completely blocked the reflex (Read et al., 2003). Further, 
Testa et al., (2001) found that the selective 5 -HT2C receptor antagonist SB 242084 
(Kennett et al., 1997) and the so-called classical 5 -HT2C receptor antagonist mesulergine, 
which again according to binding data shows poor selectivity for this receptor (see 
Bonhaus et al., 1997; Knight et al., 2004) also failed to affect the micturition reflex 
(Testa et al., 1999, 2001). The failure o f the non-selective antagonist mianserin to affect 
the micturition reflex in the present study is somewhat surprising, however mianserin is 
known to bind to both a i- and <X2-adrenoceptors, to histamine Hj receptors and to 5-HTiD 
receptors (see Marek et al., 2003) and these receptor especially a-adrenoceptors are 
known to play a role in micturition (see Michel & Vrydag, 2006).
5 -HT2 receptors are also known to play a role in central and peripheral regulation o f 
blood pressure. Activation o f central 5 -HT2A receptors causes sympathoexcitation and 
vasopressin release (see Ramage, 2001) and, peripherally, vasoconstriction (see Kaumann
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& Levy, 2006) all leading to a rise in blood pressure. The role o f 5-HT2C receptors in 
central cardiovascular regulation is poorly understood, although there is some evidence to 
suggest that they may cause sympathoexcitation and thus a rise in blood pressure 
(Knowles & Ramage, 2000). In the peripheral cardiovascular system 5-HT2C receptors 
have not been found (see Kaumann & Levy, 2006). Consistent with this is that DOI, in 
the present experiments, caused an increase in blood pressure as did the so called 
selective 5-HT2C receptor agonists, WAY 161503 and Ro 60-0175. However, the 
classical 5-HT2C receptor agonist mCPP had no effect on blood pressure and neither did 
the selective 5-HT2B receptor BW723C86. This latter observation is consistent with 
previous observations with BW723C86 (Knowles & Ramage, 2000), although high doses 
of BW723C86 given centrally caused a fall in blood pressure, which was believed to be 
mediated by 5-HT2B receptors (Knowles & Ramage, 2000). The pressor action o f WAY 
161503 was observed to be attenuated by mianserin or RS 102221 at a high dose. These 
pre-treatments at least confirm that the action o f WAY 161503 is at least mediated by 5- 
HT2 receptors. Pre-treatment with the selective 5-HT2a receptor antagonists, ketanserin at 
100 but not 30 pg kg"1 and MDL 100907 (30 pg kg '1) attenuated the rise in blood 
pressure caused by WAY 161503, implying that the pressor effect caused by this agonist 
is mainly mediated by 5 -HT2A receptors. This would imply that RS 102221 at the high 
dose used in the present study is also blocking 5 -HT2A receptors, although why this 
antagonist at this high dose (500 pg kg"1) fails to interfere with EUS-EMG evoked by 
WAY 161503 still remains unclear (see above). Interestingly, the same dose o f MDL 
100907 that attenuated the pressor effect o f WAY 161503 failed to block the pressor 
effects o f Ro 60-0175. However, this rise in blood pressure evoked by Ro 60-0175 could
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be due to activation o f  central 5-HT2C receptors and that Ro 60-0175 is more selective for 
5 -HT2C over 5 -HT2A receptors. However, in the presence o f the 5-HT2C selective 
antagonist SB 242084 the pressor effect o f Ro 60-0175 was potentiated. This may simply 
reflect the fact that Ro 60-0175 no longer evoked a bradycardia and thus there was no 
simultaneous reduction in cardiac output counteracting the evoked rise in blood pressure. 
This therefore still indicates that Ro 60-0175’s pressor action is not mediated by 5-HT2C 
receptors but by 5 -HT2A receptors. However, why would an effective 5-HT2A receptor 
blocking dose o f MDL 100907 fail to interfere with pressor response o f Ro 60-0175? In 
fact MDL 100907 also tended to potentiate this response. This could be because MDL 
100907 is interfering with 5-HT2B receptors as indicated by a tendency for a reduction in 
the evoked increase in urethral pressure caused by Ro 60-0175 in the presence o f MDL 
100907 (see above). Thus the interference with the 5-HT2B receptor depressor action 
would further explain the potentiation o f the pressor response. In this respect Ro 60-0175 
tended to have a larger pressor effect in the presence o f the selective 5 -HT2B receptor 
antagonist but it was not significant. In addition, Ro 60-0175 at the dose chosen may 
have a more potent action than WAY 161503 at 5 -HT2A receptors and the dose o f MDL 
100907 was not enough to interfere with Ro 60-0175’s pressor action. In this respect, the 
DOI evoked pressor action, which is considered to be mainly 5 -HT2A receptor mediated, 
was not attenuated by this low dose o f MDL 100907. However, the rise in blood pressure 
could now be evoked by DOI acting on 5 -HT2C receptors. Further it might also be 
expected that the WAY 161503 pressor action would be potentiated by MDL 100907, as 
W AY-161503 caused an increase in urethral pressure, a putative 5-HT2B receptor agonist 
mediated action. A possible explanation for not observing this for WAY 161503 as for
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Ro 60-0175 is that Ro 60-0175 has a more potent agonist action on 5-HT2B receptors and 
although the effects o f Ro 60-0175 are larger in increasing urethral pressure (a putative 5- 
H T 2b receptor mediated action) it is not significant. Again the data are to a degree 
consistent with the view that activation o f 5-HT2A or 5-HT2c receptors causes a rise while 
activation o f 5 - H T 2b  receptors causes fall in blood pressure. In this respect, mCPP in the 
presence o f R S-102221 (500 pg kg '1) now caused a fall in blood pressure which would be 
at least consistent with a possible 5 - H T 2b  receptor action. However the surprising poor 
selectivity o f these 5-HT2 receptor ligands for the different 5-HT2 receptor subtypes and 
the fact that all 3 subtypes are involved in cardiovascular regulation make it difficult to 
obtain a clear view o f the function o f these receptors in cardiovascular regulation.
In the case o f a 5-HT2a receptor agonist given intravenously the evoked increase in blood 
pressure observed could be due to vascular smooth contraction and/or central 
sympathoexcitation plus the release o f vasopressin which also causes peripheral 
vasoconstriction (see Ramage, 2001). If  the rise in blood pressure is due to a peripheral 
action; direct vasoconstriction and/or vasopressin release, it may be expected that a reflex 
baroreceptor mediated bradycardia to be associated with the evoked rise in blood 
pressure. However all 5-HT2 receptor agonists tested in the present study, which evoked 
a rise in blood pressure, with the exception o f mCPP, displayed no change in heart rate, 
which is a characteristic effect o f 5-HT2 receptor agonists (see Ramage, 2001). A further 
complicating effect to understanding the cardiovascular changes caused by 5-HT2a 
receptor agonists is that DOI given i.v. or centrally to the hindbrain fails to cause 
sympathoexcitation o f the sympathetic supply to the heart (Ramage & Daly, 1998),
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although it activates all other vascular sympathetic outputs. Moreover the physiological 
role o f these receptors in cardiovascular regulation is also poorly understood as the 5 -HT2 
receptor antagonist had very little effect overall on resting blood pressure (see Ramage, 
2001). In the present study, however the selective 5 -HT2A receptor antagonist MDL 
100907 caused a significant increase in blood pressure and mianserin also tended to 
increase blood pressure although in all cases heart rate was unaffected, while ketanserin 
had no effect. This is somewhat surprising as blockade o f 5 -HT2 receptor would be 
expected to cause a fall in blood pressure and this is the first report o f a 5 -HT2 receptor 
antagonist causing an increase in blood pressure (see Ramage, 2001). The failure to see 
this trend with ketanserin may be related to its ability to block ai-adrenoceptors (Ramage, 
1985). A possible explanation for this increase in blood pressure could be related to 
blockade o f 5-HT2B receptors which could be under tonic activation; however the 
selective 5-HT2B receptor antagonist RS 127445 given before agonist challenge did not 
affect resting blood pressure, so the mechanism by which MDL 100907 increases blood 
pressure may be unrelated. Thus, as with micturition all 5 -HT2 receptor subtypes seem to 
be involved in cardiovascular regulation and with the seeming lack o f selectivity o f these 
ligands and the fact that these receptors activate different parts o f the cardiovascular 
system that have opposing/interacting actions makes it difficult again to clearly 
understand the precise function o f the individual 5 -HT2 receptor subtypes in this system.
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3.4 Conclusion
It can be concluded that 5 -HT2A/2C receptors activate the external urethral sphincter 
(EUS); however there is no evidence that these receptors are involved in the reflex 
regulation o f this muscle during micturition. In addition, activation o f 5-HT2B receptors 
can cause an increase in urethral pressure and this effect still occurs when the evoked 
EUS-EMG activity is blocked thus indicating that 5-HT2B receptor are causing 
contraction o f the urethral smooth muscle. Again in the present experiments urethral 
pressure was unaffected by the agonists whilst testing the micturition reflex thus the 
physiological role o f these receptors cannot as yet be elucidated. Finally, 5-HT2C 
receptor activation causes cause inhibition o f the micturition reflex; again the 
physiological role is not clear, although hypothesised to be important in the 5-HTiA 
receptor mediated pathway which is known to be involved in micturition (see Ramage, 
2006). Additionally, data from chapter 4 infusion experiments would suggest that 5- 
HT2C receptors are physiologically involved in inhibition o f the micturition reflex. 
However there is some evidence in the present and other studies (see above) that 5-HT2a 
receptors play a small excitatory role in the control o f micturition. The physiological role 
o f 5 -HT2 receptor subtypes in cardiovascular regulation is also unclear from the present 
experiments as it is from the literature (see Ramage 2001). However, activation o f 
5-HT2a/2c receptors causes a pressor response, while activation o f 5-HT2B receptors 
causes a depressor response. Another problematic aspect o f studying the function o f 
5 -HT2 receptor subtypes in vivo is the seemingly poor selectivity o f ligands used to study 
these receptors.
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Experimental
group
n EUS-EMG 
(with bladder filled to 80% VT)
Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
pV
Test
pV
A
%
Onset
s
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A Baseline
bpm
Test
bpm
A
Saline + Saline 5 0.26 ± 0.02 0.30 ±0.01 - - 22 ±2 21 ±0.4 - 125 ±3 127 ± 1 - 329 ± 12 338 ±4 -
DMSO + Saline 5 0.26 ± 0.04 0.26 ± 0.02 - - 22 ±2 22 ±2 - 125 ±3 125 ±3 - 329 ± 12 336 ±2 -
300 pg kg'1 
WAY 161503
5 0.26 ± 0.04 0.44 ± 0.02 179 ± 17 28 ± 11 22 ±2 25 ± 1 13 ± 2 119 ± 8 127 ± 1 21 ± 1 336 ±9 338 ±4 1 ± 1
300 yig kg'1 
Ro 60-0175
5 0.28 ± 0.03 0.74 ± 0.06 154 ± 15 36 ± 13 22 ±2 27 ± 1 23 ±2 116 ± 4 131 ±2 14 ± 1 346 ± 10 335 ±2 -13 ± 2
300 pg kg'1 
mCPP
5 0.42 ±0.10 1.00 ±0.10 166 ± 17 20 ±5 19 ± 2 23 ± 1 24 ±3 140 ±4 140 ±3 0.1 ±2 363 ± 11 342 ±3 -21 ±3
30 pg kg'1 DOI 3 0.40 ± 0.06 1.00 ±0.10 139 ±27 48 ±9 24 ±2 27 ± 1 11 ± 1 121 ±5 134 ± 1 13 ± 1 369 ± 12 371 ±2 4 ± 2
50 pg kg'1 DOI 3 0.37 ± 0.07 1.00 ±0.10 224 ± 36 46 ±6 21 ± 1 26 ±4 5 ± 1 111 ± 10 120 ±2 10 ± 1 377 ± 12 362 ±4 -16 ± 3
100 pg kg'1 DOI 5 0.56 ±0.12 2.00 ±0.10 198 ± 15 17 ± 3 20 ±2 21 ± 1 4 ± 2 121 ±8 142 ±3 21 ± 1 337 ±30 341 ±7 1 ±2
300 pg kg'1 
BW723C86
5 0.34 ± 0.02 0.41 ±0.01 23 ±3 24 ± 1 5 ± 1 116 ± 4 123 ± 1 6 ± 1 349 ±9 335 ±2 -12 ± 2
Table 3.4a 5 -HT2 receptor agonist i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in external urethral
sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental
Group
Volume threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
%
Test
%
A
%
Saline + Saline 5 0.27 ±0.01 0.26 ±0.05 - 9 ±0.5 8 ± 1 - 58 ± 10 55 ± 11 -
DMSO + Saline 5 0.42 ± 0.06 0.42 ± 0.06 - 9 ± 1 9 ± 1 “ 43 ±9 43 ±9 -
300 pg kg'1 
WAY 161503
5 0.33 ± 0.09 0.49 ±0.12 55 ± 13 8 ±0.5 10± 1 25 ± 11 31 ±6 61 ±4 121 ±35
300 pg kg'1 
Ro 60-0175
5 0.30 ± 0.06 0.48 ± 0.07 71 ± 15 10± 1 18 ± 3 90 ±33 36 ±9 71 ±8 142 ±61
300 pg kg'1 mCPP 5 0.29 ±0.01 - - 10± 1 - - 43 ± 12 - -
30 pg kg'1 DOI 3 0.38 ±0.03 0.28 ± 0.02 -27 ±5 10± 1 10 ± 1 -4 ±6 38 ± 14 38 ± 14 8 ± 19
50 pg kg'1 DOI 3 0.31 ±0.09 0.23 ± 0.08 -22 ± 17 11 ±3 9 ± 2 -20 ±4 53 ± 14 30 ±7 -12 ± 8
100 pg kg'1 DOI 5 0.31 ±0.06 0.22 ± 0.06 -35 ±7 12 ± 1 9 ± 1 -19 ± 4 32 ±8 31 ±5 20 ±28
300 pg kg'1 
BW723C86
5 0.40 ± 0.06 0.49 ± 0.05 27 ± 13 9 ± 1 11 ± 1 30 ±9 22 ±7 35 ±5 116 ±65
Table 3.4b 5 -HT2 receptor agonist i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in volume threshold,
pressure threshold and residual volume
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Experimental
group
n EUS-EMG 
(with bladder filled to 80% VT)
Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
pV
Test
pv
A
%
Onset
s
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A Baseline
bpm
Test
bpm
A
300 pg kg'1 
Mianserin
5 0.56 ± 0.02 0.54 ± 0.02 24 ±4 25 ± 1 2 ± 1 112 ± 8 137 ± 2 24 ±3 335 ± 10 347 ± 10 13 ± 2
30 pg kg'1 
SB 242084
5 0.40 ± 0.05 0.43 ±0.14 18 ± 1 17 ± 0.2 -0.4 ± 1 100 ± 5 109 ± 1 8 ± 1 347 ± 12 351 ± 3 4 ± 1
100 pg kg'1 
Ketanserin
5 0.36 ±0.07 0.36 ±0.02 20 ±2 21 ± 1 4 ± 1 110 ± 5 111 ± 0.2 1 ±0.3 369 ±6 366 ± 1 -3 ± 1
30 pg kg'1 
MDL 100907
5 0.36 ±0.06 0.41 ±0.02 24 ± 1 25 ± 1 3 ±0.5 115 ± 5 131 ± 1 14 ± 1 356 ± 14 344 ±3 -12 ± 3
Table 3.5a 5 -HT2 receptor antagonist i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in external urethral
sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental
Group
Volume threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
%
Test
%
A
%
300 |ig kg'1 
Mianserin
5 0.31 ±0.07 0.37 ± 0.06 27 ± 17 10 ± 1 10 ± 2 11 ± 14 33 ± 1 45 ± 10 42 ±32
30 ng kg'1 
SB 242084
5 0.28 ± 0.05 0.32 ± 0.02 23 ± 12 9 ± 0.5 9 ± 1 5 ± 10 35 ± 6 31 ± 10 -10 ± 18
100 |a.g kg'1 
Ketanserin
5 0.27 ± 0.02 0.34 ± 0.04 27 ±4 11 ± 1 12 ± 1 11 ±4 43 ±4 61 ±4 51 ±23
30 ng kg'1 
MDL 100907
5 0.25 ± 0.03 0.41 ±0.06 65 ± 15 8 ± 1 11 ±2 32 ±24 30 ±5 54 ± 11 89 ±35
Table 3.5b 5 -HT2 receptor antagonist i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in volume threshold,
pressure threshold and residual volume
1 8 6
Experimental
group
n EUS-EMG 
(with bladder filled to 80% VT)
Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
pV
Test
pV
A
%
Onset
s
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A Baseline
bpm
Test
bpm
A
100 pg kg'1 
Mianserin ± WAY
5 0.38 ± 0.06 0.40 ±0.01 24 ± 1 28 ± 1 15 ± 2 122 ±6 131 ±2 8 ± 1 319 ± 26 330 ±5 7 ± 1
300 pg kg'1 
Mianserin + WAY
5 0.42 ±0.12 0.46 ± 0.03 24 ±4 25 ± 1 7 ± 2 121 ±5 128 ±2 7 ± 1 364 ± 11 344 ±3 -17 ± 2
30 pg kg'1 
RS 102221 + 
WAY
3 0.33 ± 0.03 0.43 ± 0.03 28 ±0.5 31 ± 1 14 ±2 105 ± 10 126 ± 1 21 ±2 342 ± 29 330 ±4 -17 ± 3
100 pg kg'1
RS 102221 + 
WAY
4 0.28 ± 0.03 0.91 ±0.14 186 ±30 23 ±5 25 ±3 27 ± 1 8 ± 1 115 ± 11 148 ± 16 18 ± 2 366 ± 13 376 ±2 3 ± 1
500 pg kg'1 
RS 102221 + 
WAY
5 0.28 ± 0.02 1.20 ± 0.10 299 ± 36 26 ±5 20 ±4 22 ± 1 11 ± 1 108 ±3 116 ± 1 7 ± 1 375 ± 11 367 ±3 -7 ± 1
500 pg kg'1 
RS 102221 + 
mCPP
5 0.42 ± 0.06 2.00 ± 0.20 533 ± 84 11± 3 17 ± 2 19 ± 1 19 ± 3 133 ±5 118 ± 2 -15 ± 2 364 ±8 352 ±3 -20 ±4
30 pg kg'1 
SB 242084 + 
Ro 60-0175
5 0.24 ±0.11 0.29 ±0.01 15 ± 2 20 ± 0.2 27 ±3 107 ±6 142 ± 1 31 ±2 396 ± 29 380 ± 1 -12 ± 1
Table 3.6a 5-HT2C receptor antagonists on agonist responses i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in
external urethral sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental Group Volume threshold Pressure Thres lold Ftesidual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
%
Test
%
A
%
100 jj.g kg'1 
Mianserin + WAY
5 0.41 ±0.06 0.45 ± 0.06 25 ± 10 9 ± 1 10 ± 1 11 ± 14 44 ±4 57 ±4 38 ±20
300 ng kg'1 
Mianserin + WAY
5 0.32 ± 0.05 0.37 ± 0.08 19 ± 13 11 ± 1 13 ± 1 21 ±11 44 ± 10 50 ± 11 12 ±23
30 ng kg'1 
RS 102221 + WAY
3 0.38 ±0.13 0.70 ±0.21 90 ± 15 9 ± 1 7 ± 2 54 ±8 33 ±12 64 ±7 125 ±48
100 i^g kg'1
RS 102221 + WAY
4 0.24 ±0.1 0.38 ±0.1 56 ± 12 10 ± 2 14 ± 3 40 ±5 48 ±6 58 ±9 13 ± 4
500 i^g kg'1 
RS 102221 + WAY
5 0.22 ±0.05 0.23 ± 0.05 4 ± 12 8 ±0.5 8 ± 1 4 ± 13 43 ±9 32 ±5 -14 ±23
500 i^g kg'1 
RS 102221 + mCPP
5 0.30 ± 0.02 8 ±0.5 35 ± 10
30 jag kg'1 
SB 242084 + 
Ro 60-0175
5 0.30 ± 0.03 0.20 ± 0.02 -53 ± 16 8 ± 1 10 ± 1 10 ± 9 37 ±5 90 ±40 39 ± 15
Table 3.6b 5-HT2C receptor antagonists on agonist responses i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A)
in volume threshold, pressure threshold and residual volume
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Experimental
group
n EUS-EMG 
(with bladder filled to 80% VT)
Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
tiV
Test
tiV
A
%
Onset
s
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A Baseline
bpm
Test
bpm
A
30 ng kg' 
Ketanserin + 
WAY
5 0.48 ± 0.1 0.46 ± 0.02 21 ±3 23 + 1 9+1 124+11 150 + 2 25 + 3 369 + 3 345 + 3 -20 + 3
100 tig kg'1 
Ketanserin + 
WAY
5 0.38 ± 0.06 0.43 ± 0.01 17 ± 4 19+1 14+1 120 + 9 124 + 3 5+1 344 + 8 334 + 2 -9+1
30 ng kg'1 
MDL 100907 + 
WAY
5 0.58 ± 0.08 0.58 ± 0.03 27 ±3 29+1 7+1 138 + 9 144 + 2 4+1 365 + 10 340 + 3 -22 + 3
30 tig kg'1 
Ketanserin + 
Ro 60-0175
5 0.22 ± 0.01 0.30 ± 0.03 20 + 0.1 22 ± 0.3 9+1 95 ± 0.3 111+2 16 + 2 390+ 15 356 + 3 -34 + 2
30 |ig kg'1 
MDL 100907 + 
Ro 60-0175
5 0.22 ± 0.02 0.40 ± 0.01 15 + 0.1 17 + 0.2 11+2 102 + 2 121 ±2 18 + 2 369+ 18 344 + 3 -22 + 3
30 tig kg'1 
Ketanserin + DOI
5 0.34 ± 0.06 0.40 ± 0.02 19+1 21 ± 1 11+2 137 + 9 151 ± 1 14+1 335 + 10 346 + 3 8 + 2
30 tig kg'1 
MDL 100907 + 
DOI
3 0.40 ± 0.06 0.47 ± 0.03 25 ± 0.5 27 + 0.3 7+1 112 + 4 139+1 24 + 3 360+1 363 + 2 2+1
Table 3.7a 5-HT2a receptor antagonists on agonist responses i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in
external urethral sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental Group Volume threshold Pressure Thres lold Flesidual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
%
Test
%
A
%
30 ng kg'1 
Ketanserin + WAY
5 0.41 ±0.1 1 ± 0.33 153 + 33 8+1 13 + 2 61 ± 17 36+11 55+11 104 + 81
100 \xg kg'1 
Ketanserin + WAY
5 0.29 + 0.1 0.51+0.10 81 ± 13 10+ I 15 + 2 53+14 42 + 6 74 + 6 92+18
30 ng kg'1 
MDL 100907+ WAY
5 0.25 ± 0.04 0.50 + 0.13 92 + 23 8+1 15 + 2 83 + 24 31+5 58 + 8 166+120
30 |ig kg'1 
Ketanserin + Ro 60-0175
5 0.22 ± 0.02 0.58 + 0.05 61+5 8+1 17+1 50 + 3 53 + 7 64 + 7 12+17
30 \ig kg'1 
MDL 100907+ Ro 60-0175
5 0.34 + 0.11 0.83 + 0.17 63 + 6 8+ I 14+1 44 + 6 61+9 68+13 -19 + 41
30 |ag kg'1 
Ketanserin + DOI
5 0.37 + 0.06 0.54 + 0.12 43 + 15 8 + 0.5 14 + 3 63 + 22 31+7 61+5 135 + 49
30 (j-g kg'1 
MDL 100907 + DOI
3 0.32 + 0.10 0.54 + 0.1 90 + 43 10+1 18 + 6 82 + 63 51+8 74 + 4 49+19
Table 3.7b 5-HT2A receptor antagonists on agonist responses i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) 
in volume threshold, pressure threshold and residual volume
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Experimental
group
n EUS-EMG 
(with bladder filled to 80% VT)
Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
pV
Test
l*V
A
%
Onset
s
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A Baseline
bpm
Test
bpm
A
30 pg kg'1 
RS 127445 + 
Ro 60-0175
5 0.46 ± 0.02 1.40 ± 0.1 218 ± 30 19 ± 2 12 ± 2 10 ±0.2 -11 ±4 122 ±5 152 ± 1 25 ±2 356 ±5 333 ±8 -19 ± 6
Table 3.8a 5-HT2B receptor antagonist on agonist responses i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) 
in external urethral sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
Experimental Group Volume thresho d Pressure Thres lold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
%
Test
%
A
%
30 pg kg'1 
RS 127445 + Ro 60-0175
5 0.40 ± 0.04 0.66 ± 0.05 39 ±6 11 ± 1 21 ±5 43 ±7 27 ±9 72 ±4 64 ± 11
Table 3.8b 5-HT2B receptor antagonist on agonist responses i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) 
in volume threshold, pressure threshold and residual volume
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Chapter 4
5-HT2 receptor agonists and antagonists 
(infused i.v.) and their effects on the 
urethra and the micturition reflex
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4.1 Introduction
In the previous chapter, it was established that all three 5-HT2 receptor subtypes are 
involved in the control o f bladder and urethral function. Experiments revealed that 5- 
HT2A/2C receptors caused activation o f the external urethral sphincter, whilst 5-HT2b 
receptors increased urethral pressure, probably by contracting urethral smooth muscles. 
Additionally, on the micturition reflex, 5-HT2c receptors were observed to be inhibitory 
whereas 5-HT2A receptors were excitatory. The experiments carried out in chapter 3 also 
revealed poor selectivity o f the agonists for 5-HT2 receptors especially when trying to 
distinguish between the 5-HT2A and 5-HT2c receptor subtype.
By utilizing an intravenous infusion dosing regimen, experiments carried out in this 
chapter made it possible to obtain free plasma concentrations o f the compounds that 
would be selective for a particular 5-HT2 receptor subtype. Ro 60-0175 was chosen as 
the compound o f choice in this study as it is known as the most selective commercially 
available 5-HT2c receptor agonist. Therefore carrying out initial pharmacokinetic and 
pharmacodynamic studies o f Ro 60-0175 enabled accurate calculations that would be 
adequate for the compound to act selectively on 5-HT2c receptors only. Discussions with 
Pfizer colleagues as well as data collected in-house indicated that free plasma 
concentrations o f Ro 60-0175 at 10 nM would be selective for the 5-HT2c receptor (see 
Methods) whereas the other two higher concentrations (30 and 100 nM) chosen would 
activate both 5-HT2c and 5-HT2A receptors. Furthermore, data indicated (see Methods) 
that targeting 3 nM free plasma concentration for the 5-HT2c receptor antagonist SB 
242084 and 5-HT2A receptor antagonist MDL 100907 would be selective for their
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respective receptor subtypes. Therefore, by targeting the above free plasma 
concentrations, it would be possible to determine if  both receptors 5-HT2A and 5-HT2C or 
just one was involved in the activation o f the external urethral sphincter. Performing this 
selectivity study also provided further evidence for an inhibitory and excitatory role for 
5 -HT2C and 5 -HT2A receptors on the micturition reflex respectively. Experiments in this 
chapter were also carried out to further investigate the urethral pressure increases 
observed in chapter 3, as well as the involvement o f 5 -HT2 receptors in cardiovascular 
regulation.
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4.2 Results
Table 4.1 summarises the measured free plasma concentrations o f 5 -HT2C receptor 
agonist Ro 60-0175, 5-HT2C receptor antagonist SB 242084 and 5 -HT2A receptor 
antagonist MDL 100907 administered as infusion doses i.v., compared to simulated target 
concentrations in anaesthetised female rats.
Baseline values for all variables are shown in Tables 4.4-4.9.
4.2.1 Vehicle control
Intravenous infusion o f saline (0.9% wv , n = 5) or 4% CTE vehicle for 5 -HT2 receptor 
antagonists (See Drugs and Solutions section 2.6) (n = 5) evoked no significant changes 
in baseline EUS-EMG signal and urethral pressure or volume threshold, pressure 
threshold and residual volume caused by infusion o f saline at a rate o f 0.1 ml m in'1 
(Figure 4.1a & 4.1b). Baseline MAP and HR were also unaffected.
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Figure 4.1a Urethane anaesthetised female rats: a comparison between the effects of infusion of saline alone and saline + 4% CTE on percentage 
changes (A) in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Baseline variables were recorded 
for a duration of 5 min whilst the bladder was filled to 80% volume of saline required to elicit a micturition reflex. Panel (1) shows baseline variables recorded 
at 20-25 min after start of infusion of both saline alone and saline + 4% CTE, Panel (2) shows variables at 50-55 min after start of infusion of the two vehicles 
and Panel (3) shows variables at 80-85 min after start of infusion of the two vehicles. Each point represents the mean value and vertical bars show the s.e.mean.
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Figure 4.1b Urethane anaesthetised female rats: a comparison of the effects of infusion of saline alone and saline + 4% CTE on percentage changes (A) in 
volume threshold, pressure threshold and residual volume. Two micturition reflexes were tested during each infusion dose (~ 30 min for each infusion dose). 
Panel (1) shows variables recorded following testing the micturition reflex after 12 and 27 min infusions of both saline alone and saline + 4% CTE, Panel (2) shows 
variables recorded following testing the micturition reflex after 42 and 57 min infusions of the two vehicles and Panel (3) shows variables recorded following 
testing the micturition reflex after 72 and 87 min infusions of the two vehicles. Each bar represents the mean value and vertical bars show the s.e.mean.
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4.2.2 5-HT2c receptor agonist
4.2.2.1 I.v. infusion of Ro 60-0175 in saline
Traces showing the effects o f Ro 60-0175 (27, 90 and 270 pg kg*1 m in'1; i.v.) on changes 
in EUS-EMG signal, urethral pressure and the micturition reflex are shown in Figure 
4.2a. Infusion o f Ro 60-0175 (27 and 90 pg kg '1 m in'1; n = 6) evoked no significant 
changes in baseline EUS-EMG signal and urethral pressure. Infusion o f the high dose of 
Ro 60-0175 (270 pg kg '1 m in'1, i.v; n = 5) evoked EUS-EMG activity and significantly 
increased the EUS-EMG signal by 144 ± 11%. The onset o f appearance o f EUS-EMG 
activity following infusion o f the high dose o f Ro 60-0175 was 92 ± 25s. Mean urethral 
pressure was unaffected (Figure 4.2b).
On the micturition reflex, Ro 60-0175 (27 pg kg '1 m in '1) was inhibitory with a significant 
increase observed on volume (68 ± 10%; reflex 1) and pressure threshold (21 ± 8%; 
reflex 1; Figure 4.2c). In contrast, administration of both 90 pg kg '1 m in'1 (-24 ± 14%; 
reflex 2) and 270 pg kg '1 m in'1 (-51 ± 11% and -45 ± 12%; reflex 1 & 2) Ro 60-0175 
were observed to be excitatory on the micturition reflex with significant decreases on 
volume threshold (Figure 4.2c).
None o f the three doses o f Ro 60-0175 had any significant effect on baseline MAP and 
HR.
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Figure 4.2a Urethane anaesthetized female rat: Traces showing the effects of simultaneous infusions (i.v.) of Ro 60-0175 in saline on A baseline 
variables; urethral pressure and EUS-EMG signal (with the bladder filled to 80% volume of saline required to elicit a micturition reflex) and B bladder 
distension-evoked micturition reflex showing bladder pressure (P Bladder), urethral pressure (P Urethra) and EUS-EMG. A, Baseline variables:- Panel 
(1) shows baseline variables during control period, Panel (2) shows variables at 20-25 min after start of infusion of Ro 60-0175 (27 pg kg'1 min'1) and 
saline, Panel (3) shows variables at 50-55 min after start of infusion of both first dose Ro 60-0175 and saline and Panel (4) shows variables at 80-85 min 
after start of infusion of both first dose of Ro 60-0175 and saline. B, Micturition reflex:- Panel (1) -  control reflex tested prior to start of infusion of Ro 60- 
0175 and saline, Panel (2) - reflex tested at 27 min after start of infusion of Ro 60-0175 and saline, Panel (3) - reflex tested at 57 min after start of infusion 
of Ro 60-0175 and saline and Panel (4) - reflex tested at 87 min after start of infusion of Ro 60-0175 and saline. * denotes onset of saline infusion into the 
bladder.
(The large signal recorded for P Urethra in A Panel 4 was biological rather than signal noise).
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Figure 4.2b Urethane anaesthetised female rats: a comparison of the effects of infusion of Ro 60-0175 and vehicle (saline) on percentage changes (A) in 
external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Baseline variables were recorded for a duration 
of 5 min whilst the bladder was filled to 80% volume of saline required to elicit a micturition reflex. Panel (1) shows baseline variables recorded at 20-25 min 
after start of infusion of both Ro 60-0175 (27 pg kg*1 min'1) and saline, Panel (2) shows variables at 50-55 min after start of infusion of first dose of Ro 60-0175 
and saline and Panel (3) shows variables at 80-85 min after start of infusion of first dose of Ro 60-0175 and saline. Each point represents the mean value and 
vertical bars show the s.e.mean. Changes caused by Ro 60-0175 were compared with saline control using two-way analysis of variance followed by the least 
significant difference test. * PO.05.
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Figure 4.2c Urethane anaesthetised female rats: a comparison of the effects of infusion of vehicle (saline) and Ro 60-0175 on percentage changes (A) in 
volume threshold, pressure threshold and residual volume. Two micturition reflexes were tested during each infusion dose (~ 30 min duration for each infusion 
dose). Panel (1) shows variables recorded following testing the micturition reflex after 12 and 27 min infusions of both saline and Ro 60-0175 (27 pg kg'1 min'1), 
Panel (2) shows variables recorded following testing the micturition reflex after 42 and 57 min infusions of saline and Ro 60-0175 (90 pg kg'1 min'1) and Panel (3) 
shows variables recorded following testing the micturition reflex after 72 and 87 min infusions of saline and Ro 60-0175 (270 pg kg'1 min'1). Each bar represents 
the mean value and vertical bars show the s.e.mean. * P<0.05, ** P<0.01, *** PO.OOl, NS non-significant.
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4.2.2.2 4% CTE and Ro 60-0175
Infusion of Ro 60-0175 (27 and 90 jig kg’1 m in'1; n  = 5) in the presence o f vehicle for 5- 
HT2 receptor antagonists (4% CTE) evoked no significant changes in baseline EUS-EMG 
signal and urethral pressure. However, infusion o f the high dose o f Ro 60-0175 (270 pg 
kg’1 min’1, n = 5) in the presence o f 4%  CTE evoked EUS-EMG activity and significantly 
increased the EUS-EMG signal by 1093 ±141%  (Figure 4.3b). The onset o f appearance 
o f EUS-EMG activity following infusion o f the high dose o f Ro 60-0175 in the presence 
o f 4% CTE was 83 ± 14s.
On the micturition reflex, Ro 60-0175 (27 pg kg’1 min’1) in the presence o f 4% CTE was 
inhibitory, with a significant increase observed on volume threshold (59 ± 8%; reflex 2) 
and pressure threshold (55 ± 19%; reflex 1; Figure 4.3c). Interestingly, a significant 
increase was also observed on residual volume (105 ± 27%; reflex 2) at this dose. Unlike 
Ro 60-0175 in the presence of saline, Ro 60-0175 (90 pg kg’1 min’1) in the presence o f 
4% CTE had no significant effect on volume threshold, but instead evoked a significant 
increase in pressure threshold (33 ± 15%; reflex 1). The high dose o f Ro 60-0175 (270 
pg kg’1 min’1) caused a significant decrease in volume threshold (-43 ± 9 and -50 ± 10%; 
reflex 1 & 2) and a significant increase in pressure threshold (46 ± 22 and 53 ± 22%; 
reflex 1 & 2) which was interesting as the effect on pressure threshold was not observed 
following infusion o f  Ro 60-0175 with saline (see above).
Only the high dose o f Ro 60-0175 (270 pg kg*1 min*1) with 4% CTE caused a significant 
increase in MAP by 19 ± 1 mmHg (Figure 4.3b). HR was unaffected.
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4.2.3 Effect of 5-HT2 receptor antagonists on agonist
responses
4.2.3.1 SB 242084 (5-HT2C) and Ro 60-0175 (5-HT2C)
Traces showing the effects o f Ro 60-0175 (270 pg kg*1 min*1; i.v.) plus SB 242084 (22.5; 
3.5 pg kg '1 min*1; i.v.) on changes in EUS-EMG signal, urethral pressure and the 
micturition reflex are shown in Figure 4.3a. Ro 60-0175 (27 and 90 pg kg*1 m in'1; n = 
3/5) in the presence o f SB 242084 (22.5; 3.5 and 67.5; 3.5 pg kg*1 m in'1; n = 3/5) evoked 
no significant changes in baseline EUS-EMG signal and urethral pressure. Further, both 
doses o f SB 242084 failed to block the highest infusion dose o f Ro 60-0175 (270 pg kg*1 
min'1) evoked increase in baseline EUS-EMG signal (1381 ± 129% and 1259 ± 88%; 
Figure 4.3b). The onset o f appearance o f EUS-EMG activity following infusion of both 
doses o f SB 242084 and the high dose o f Ro 60-0175 was 100 ± 27 (low dose) and 113 ± 
16 s (high dose) respectively. Urethral pressure was unaffected (Figure 4.3b).
The low dose o f SB 242084 (22.5; 3.5 pg kg*1 min*1) blocked the inhibitory effect o f the 
lowest infusion dose o f Ro 60-0175 (27 pg kg*1 min*1) on the micturition reflex. Ro 60- 
0175 now had an excitatory effect on the micturition reflex causing a significant decrease 
in volume threshold (-29 ± 6%; reflex 2) and residual volume (-28 ± 12%; reflex 2). This 
excitatory effect on the micturition reflex was also observed at 90 and 270 pg kg '1 min*1 
of Ro 60-0175 in combination with the low dose o f SB 242084 resulting in decreases in 
volume threshold similar to those seen with Ro 60-0175 plus CTE vehicle (Figure 4.3c). 
Similarly, the high dose o f SB 242084 (67.5; 3.5 pg kg '1 m in '1) significantly decreased 
the Ro 60-0175 (27 pg kg '1 m in'1) evoked increase in volume threshold (-16 ± 5%; reflex
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1), and now resulted in a significant decrease in pressure threshold (-19 ± 6%; reflex 1) 
and residual volume (-36 ± 19 and -45 ± 23%; reflex 1 & 2; Figure 4.3c). Interestingly, 
although the middle infusion dose o f Ro 60-0175 (90 pg kg '1 min"1) alone had no effect 
on volume threshold and residual volume, in the presence o f SB 242084 (22.5; 3.5 pg kg' 
1 m in 1), there were now excitatory actions observed, with decreases in volume threshold 
(-40 ± 6 and -44 ± 6%; reflex 1 & 2) and residual volume (-46 ± 1 4  and -48 ± 13%; reflex 
1 & 2). Surprisingly, the low dose o f SB 242084 failed to affect the increase in pressure 
threshold (21 ± 11 and 24 ± 4%; reflex 1 & 2). Again, with the high dose o f SB 242084 
(67.5; 3.5 pg kg '1 m in '1) and the middle infusion dose o f Ro 60-0175 (90 pg kg'1 m in'1), 
volume threshold (-42 ± 7 and -40 ± 5%; reflex 1 & 2) and residual volume (-62 ± 6%; 
reflex 1) were reduced. A similar effect was also observed in the presence o f the low 
dose o f SB 242084 (22.5; 3.5 pg kg '1 m in '1) and the highest dose o f Ro 60-0175 (270 pg 
kg '1 m in'1) where volume threshold (-46 ± 1 0  and -47 ± 10%; reflex 1 & 2) was observed 
to be decreased. Again, this dose o f SB 242084 failed to affect the increase in pressure 
threshold (57 ± 13  and 65 ± 15%; reflex 1 & 2). Similarly, the high dose o f SB 242084 
(67.5; 3.5 pg kg '1 m in '1) failed to block the excitatory effect o f Ro 60-0175 (270 pg kg '1 
m in'1) on volume threshold (-55 ± 5 and -60 ± 3%; reflex 1 & 2). Although markedly 
reduced when compared to Ro 60-0175 alone, SB 242084 (67.5; 3.5 pg kg '1 min'1) again 
failed to block the increase in pressure threshold in response to the high dose Ro 60-0175 
on pressure threshold (7 ± 11%; reflex 2; see figure 4.3c for graphs).
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Both doses o f SB 242084 failed to block the pressor effects o f Ro 60-0175 (270 pg kg'1 
min'1) on MAP (20 ± 0.3 (low dose) and 20 ± 1 mmHg (high dose) respectively; Figure 
4.3b). HR was unaffected.
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Figure 4.3a Urethane anaesthetized female rat: Traces showing the effects of simultaneous infusions (i.v.) of Ro 60-0175 and SB 242084 (22.5; 3.5 pg kg'1 
min'1) on A baseline variables; urethral pressure and EUS-EMG signal (with the bladder filled to 80% volume of saline required to elicit a micturition reflex) and B 
bladder distension-evoked micturition reflex showing bladder pressure (P Bladder), urethral pressure (P Urethra) and EUS-EMG. A, Baseline variables:- Panel (1) 
shows baseline variables during control period, Panel (2) shows these at 20-25 min after start of infusion of both Ro 60-0175 (27 pg kg'1 min'1) and SB 242084, Panel 3 
shows these at 50-55 min after start of infusion of first dose Ro 60-0175 and SB 242084 and Panel (4) shows these at 80-85 min after start of infusion of first dose of 
Ro 60-0175 and SB 242084. B, Micturition reflex:- Panel (1) -  control reflex tested prior to start of infusion of Ro 60-0175 and SB 242084, Panel (2) -  reflex tested 
27 min after start of infusion of Ro 60-0175 and SB 242084, Panel (3) -  reflex tested 57 min after start of infusion of Ro 60-0175 and SB 242084 and Panel (4) -  reflex 
tested 87 min after start of infusion of Ro 60-0175 and SB 242084. * denotes onset of saline infusion into the bladder
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Urethane anaesthetised female rats: a comparison of the effects of infusion of Ro 60-0175 and SB 242084 on percentage changes (A) in 
external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Baseline variables were recorded for a duration of 
5 min whilst the bladder was filled to 80% volume of saline required to elicit a micturition reflex. Panel (1) shows baseline variables recorded at 20-25 min after 
start of infusion of both Ro 60-0175 (27 pg kg'1 min'1) and SB 242084 (22.5; 3.5 & 67.5; 3.5 pg kg'1 min'1), Panel (2) shows variables at 50-55 min after start of 
infusion of first dose of Ro 60-0175 and SB 242084, and Panel (3) shows variables at 80-85 min after start of infusion of first dose of Ro 60-0175 and SB 242084. 
Each point represents the mean value and vertical bars show the s.e.mean. Changes caused by Ro 60-0175 and SB 242084 were compared with vehicle using two- 
way analysis of variance followed by the least significant difference test. * PO.05, ** PO.01, *** P0.001.
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Figure 4.3c Urethane anaesthetised female rats: a comparison of the effects of infusion of Ro 60-0175 and SB 242084 on percentage changes (A) in volume 
threshold, pressure threshold and residual volume. Two micturition reflexes were tested during each infusion dose (~ 30 min duration for each infusion dose). Panel 
(1) shows variables recorded from testing the micturition reflex at 12 and 27 min after start of infusion of both Ro 60-0175 (27 pg kg 1 min ') and SB 242084 (22.5; 
3.5 and 67.5; 3.5 pg kg'1 min'1), Panel (2) shows variables recorded from testing the micturition reflex at 42 and 57 min after start of infusion of first dose of Ro 60- 
0175 and SB 242084 and Panel (3) shows variables recorded from testing the micturition reflex at 72 and 87 min after start of infusion of first dose of Ro 60-0175 
and SB 242084. Each bar represents the mean value and vertical bars show the s.e.mean. Changes caused by Ro 60-0175 and SB 242084 were compared with 
vehicle using Student’s unpaired t-test. *,# P<0.05, **,## P<0.01, ***, ### PO.OOl, NS non-significant.
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4.23.2 MDL 100907 (5-HT2A) and Ro 60-0175 (5-HT2C)
Traces showing the effects o f Ro 60-0175 (27, 90 and 270 jag kg '1 m in '1; i.v.) plus MDL 
100907 (16.7; 0.83 pg kg '1 m in'1; i.v.) on changes in EUS-EMG signal, urethral pressure 
and the micturition reflex are shown in Figure 4.4a. Ro 60-0175 (27 and 90 pg kg'1 min* 
!; n = 5) in the presence o f MDL 100907 (n = 5) evoked no significant changes in 
baseline EUS-EMG signal and urethral pressure. MDL 100907 significantly blocked the 
effects o f high dose o f Ro 60-0175 (270 pg kg '1 m in'1) on baseline EUS-EMG signal 
(Figure 4.4b).
On the micturition reflex, MDL 100907 failed to block the Ro 60-0175 (27 pg kg '1 m in '1) 
evoked increase in volume and pressure threshold and residual volume. Although the 
middle infusion dose o f Ro 60-0175 (90 pg kg '1 m in'1) had no significant effect on 
volume threshold and residual volume, a combination o f Ro 60-0175 and MDL 100907 
was now inhibitory with significant increases observed on volume threshold (97 ± 28%; 
reflex 2) and residual volume (62 ± 13%; reflex 2). MDL 100907 failed to affect the Ro 
60-0175 (90pg kg '1 m in '1) evoked increase in pressure threshold (93 ± 30 and 70 ± 20%; 
reflex 1 & 2). MDL 100907 significantly blocked the excitatory effect o f the highest 
dose o f Ro 60-0175 (270pg kg '1 m in '1) on volume threshold (83 ± 29 and 72 ± 22%; 
reflex 1 & 2), but again failed to block the inhibitory effect o f Ro 60-0175 on pressure 
threshold (42 ± 12 and 43 ± 14%; reflex 1 & 2). Interestingly, although Ro 60-0175 (270 
pg kg '1 min*1) alone had no significant effect on residual volume, the combination of Ro 
60-0175 and MDL 100907 caused a significant increase in residual volume by 103 ± 42% 
(reflex 1; see figure 4.4c for graphs).
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A combination o f MDL 100907 and Ro 60-0175 at 27 or 90 pg kg '1 m in'1 now caused a 
significant decrease in MAP by -16 ± 0.4 and -16 ± 1 mmHg respectively, whilst MDL 
100907 significantly attenuated the pressor effects o f the highest dose infusion of Ro 60- 
0175 (270 pg kg'1 m in '1) on MAP (-17 ± 0.3 mmHg; Figure 4.4b). HR was again 
unaffected.
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Figure 4.4a Urethane anaesthetized female rat: Traces showing the effects of simultaneous infusions (i.v.) of Ro 60-0175 and MDL 100907 (16.7; 0.83 
pg kg'1 m in1) on A baseline variables; urethral pressure and EUS-EMG signal (with the bladder filled to 80% volume of saline required to elicit a micturition 
reflex) and B bladder distension-evoked micturition reflex showing bladder pressure (P Bladder), urethral pressure (P Urethra) and EUS-EMG. A, Baseline 
variables:- Panel (1) shows baseline variables during control period, Panel (2) shows these at 20-25 min after start of infusion of both Ro 60-0175 (27 pg kg'1 
min'1) and MDL 100907, Panel 3 shows these at 50-55 min after start of infhsion of both Ro 60-0175 and MDL 100907 and Panel (4) shows these at 80-85 min 
after start of infusion of both Ro 60-0175 and MDL 100907. B, Micturition reflex:- Panel (1) -  control reflex tested prior to start of infusion of Ro 60-0175 and 
MDL 100907, Panel (2) -  reflex tested 27 min after start of infusion of Ro 60-0175 and MDL 100907, Panel (3) -  reflex tested 57 min after start of infusion of 
Ro 60-0175 and MDL 100907 and Panel (4) -  reflex tested 87 min after start of infusion of Ro 60-0175 and MDL 100907.
* denotes onset of saline infusion into the bladder.
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Figure 4.4b Urethane anaesthetised female rats: a comparison of the effects of infusion of Ro 60-0175 and MDL 100907 (16.7; 0.83 pg kg'1 min'1) on 
percentage changes (A) in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Baseline variables 
were recorded for a duration of 5 min whilst the bladder was filled to 80% volume of saline required to elicit a micturition reflex. Panel (1) shows baseline 
variables recorded at 20-25 min after start of infusion of both Ro 60-0175 (27 pg kg'1 min'1) and MDL 100907, Panel (2) shows variables at 50-55 min after start 
of infusion of first dose Ro 60-0175 and MDL 100907, and Panel (3) shows variables at 80-85 min after start of infusion of first dose Ro 60-0175 and MDL 
100907. Each point represents the mean value and vertical bars show the s.e.mean. Changes caused by Ro 60-0175 and MDL 100907 were compared with 
vehicle using two-way analysis of variance followed by the least significant difference test. *, # P<0.05, **, ## P<0.01, ***, ### P0.001.
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Figure 4.4c Urethane anaesthetised female rats: a comparison of the effects of infusion of vehicle (saline + 4% CTE), Ro 60-0175 and MDL 100907 on percentage 
changes (A) in volume threshold, pressure threshold and residual volume. Each bar represents the mean value and vertical bars show the s.e.mean. For the micturition 
reflex the first reflex was tested ~ 15 minutes after onset of infusion of each dose of Ro 60-0175 and the second reflex was tested -30 minutes later (6 reflexes were 
tested in total i.e. 2 reflexes for each dose of Ro 60-0175 infused). Changes caused by Ro 60-0175 and MDL 100907 were compared with saline and 4% CTE control 
using Student’s unpaired t-test. *,# P<0.05, **,## PO.Ol, *** PO.OOl, NS non-significant.
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4.2.4 SB 242084 (5-HT2c recep to r  a n tagon ist)
Infusion of SB 242084 (* 22.5, 3.5 and 67.5, 3.5 fig kg'1 min'1, i.v; n = 5) evoked no 
significant changes in baseline EUS-EMG signal, urethral pressure or the micturition 
reflex (Figure 4.5a & 4.5b).
The low infusion dose of SB 242084 (22.5; 3.5 pg kg*1 min*1) caused a transient 
decrease in MAP (-4 ± 1 mmHg) which was found to be significant at the first minute 
but returned back to baseline soon after (Figure 4.5a). Even though the highest 
infusion dose of SB 242084 (67.5 pg kg'1 min*1) caused a decrease in MAP (Figure 
4.5a), this was found to be non-significant. Neither of the two doses of SB 242084 
had any effect on HR.
* Doses of SB 242084 (both alone or as a combination with Ro 60-0175) were 
administered as loading doses of 22.5 and 67.5 pg kg"1 min'1 for 15 min and a 
maintenance dose of 3.5 pg kg'1 min"1 thereafter.
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4.2.5 MDL 100907 (5-HT2a receptor antagonist)
Infusion of MDL 100907 alone (*1.67, 0.83; 5.01, 0.83 and 16.7, 0.83 fig kg'1 min'1; 
i.v; n = 5) evoked no significant changes in baseline EUS-EMG signal and urethral 
pressure (Figure 4.6a).
On the micturition reflex, only the lowest infusion dose of MDL 100907 (1.67, 0.83 
pg kg'1 min'1) caused a significant increase in volume threshold (30 ±11%; reflex 2; 
Figure 4.6b), whereas the other two infusion doses had no significant effects on 
pressure threshold and residual volume.
All three doses of MDL 100907 caused significant decreases in MAP of -11 ± 0.2, -16 
± 2 and -25 ± 0.4 mmHg respectively with increasing dose (Figure 4.6a) but were 
ineffective on HR.
* Doses of MDL 100907 (both alone and as a combination with Ro 60-0175) were 
administered as loading doses of 1.67, 5.01 and 16.7 pg kg'1 min*1 for 15 minutes and 
a maintenance dose of 0.83 pg kg'1 min'1 thereafter.
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Figure 4.5a Urethane anaesthetised female rats: a comparison of the effects of infusion of SB 242084 and vehicle (saline + 4% CTE) on percentage 
changes (A) in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood pressure (MAP). Baseline variables were recorded 
for a duration of 5 min whilst the bladder was filled to 80% volume of saline required to elicit a micturition reflex. Panel (1) shows baseline variables recorded at 
20-25 min after start of infusion of both SB 242084 (22.5; 3.5 pg kg-1 min'1) and vehicle and Panel (2) shows variables at 50-55 min after start of infusion of both 
SB 242084 and vehicle. Each point represents the mean value and vertical bars show the s.e.mean. Changes caused by SB 242084 were compared with vehicle 
using two-way analysis of variance followed by the least significant difference test. * P<0.05.
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Figure 4.5b Urethane anaesthetised female rats: a comparison of the effects of infusion of SB 242084 and vehicle (saline + 4% CTE) on percentage changes (A) 
in volume threshold, pressure threshold and residual volume. Two micturition reflexes were tested for each infusion dose (~ 30 min duration for each infusion dose). 
Panel (l) shows variables recorded from testing the micturition reflex at 12 and 27 min after start of infusion of both SB 242084 (22.5; 3.5 pg kg"1 min"1) and vehicle 
and Panel (2) shows variables from testing the micturition reflex at 42 and 57 min after start of infusion of SB 242084 and vehicle. Each bar represents the mean value 
and vertical bars show the s.e.mean. Changes caused by SB 242084 were compared with vehicle using Student’s unpaired t-test. NS non-significant.
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Figure 4.6a Urethane anaesthetised female rats: a comparison of the effects of infusion of MDL 100907 and vehicle (saline + 4% CTE) on percentage changes (A) 
in external urethral sphincter (EUS) EMG signal, urethral pressure (?) and mean arterial blood pressure (MAP). Baseline variables were recorded for a duration of 5 min 
whilst the bladder was filled to 80% volume of saline required to elicit a micturition reflex. Panel (1) shows baseline variables recorded at 20-25 min after start of infusion 
of both MDL 100907 (1.67; 0.83 pg kg'1 min1) and vehicle, Panel (2) shows variables at 50-55 min after start of infusion of first dose of MDL 100907 and vehicle and 
Panel (3) shows variables at 80-85 min after start of infusion of first dose of MDL 100907 and vehicle. Each point represents the mean value and vertical bars show the 
s.e.mean. Changes caused by MDL 100907 were compared with vehicle control using two-way analysis of variance followed by the least significant difference test. * 
P<0.05, ** P<0.01, *** P0.001.
218
A r
esi
dua
l 
 ^p
res
sur
e 
 ^v
olu
me
 
vol
um
e 
(%)
 
thr
esh
old
 (
%) 
thr
esh
old
 (
%)
(1 ) 1 j67 m; k g '1 m m '
M D L  100907
200-1
1 2  m i n 2 7
oo-
ooJ
150-.
00 -
 N S50-  N S
-50J
(2) 5 j01 h ; k g '1 m in '1 MDL, 
1 00907
(3) 16.7 fjg kg'* m m '1 M D L  
1 009 07
4 2 m in
N S
5 7  mm
N S
72  mm
N S
8 7  mm
r N S
r N S I------- 1 i—  N SJ fn N S ■X
I—  N S — I
■■Saline + 4% CTE i.v. (n = 5) 
CZ3MDL 100907 + Saline I.v. (n = 5)200*1
100-
100-
Figure 4.6b Urethane anaesthetised female rats: a comparison of the effects of infusion of MDL 100907 and vehicle (saline + 4% CTE) on percentage 
changes (A) in volume threshold, pressure threshold and residual volume. Two micturition reflexes were tested for each infusion dose (~ 30 min duration for each 
infusion dose). Panel (1) shows variables recorded from testing the micturition reflex at 12 and 27 min after start of infusion of both MDL 100907 (1.67; 0.83 pg kg'1 
min1) and vehicle, Panel (2) shows variables from testing the micturition reflex at 42 and 57 min after start of infusion of MDL 100907 and vehicle and Panel (3) 
shows variables from testing the micturition reflex at 72 and 87 min after start of infusion of MDL 100907 and vehicle. Each bar represents the mean value and 
vertical bars show the s.e.mean. Changes caused by MDL 100907 were compared with vehicle using Student’s unpaired t-test. *P<0.05, NS non-significant.
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Ro 60-0175 
27, 90,270 pg kg'1 min'1 (n = 5)
SB 242084 
22.5; 3.5 pg kg'1 min'1 (n = 5)
MDL 100907 
16.7; 0.83 pg kg'1 min'1 (n = 3)
Target [Free 
Plasmal nM
10 30 100 3 3
Measured 
[Free Plasma] 
nM
8 31 110 5 5 4 15 5 3
Table 4.1 Summary of the measured free plasma concentrations of 5-HT2C receptor agonist Ro 60-0175, 5-HT2C receptor antagonist SB 
242084 and 5-HT2A receptor antagonist MDL 100907 administered as infusion doses i.v.
2 2 0
Drug & treatment Receptor
selectivity
EUS EMG Urethral pressure Micturition Reflex Cardiovascular effects
Overall VolT Pressure T Residual Blood Heart
Vol Pressure Rate
Ro 60-0175 (sal)
27 pg kg"1 min'1 4—► 4—► inhibitory TT T 4—► 4—4 4—►
90 pg kg"1 min"1 5-HT2C agonist 4—► 4—► excitatory (?) 4 4—4 4—► ^ - 4 4—►
270 fag kg'1 min"1 T 4—► excitatory 4 4 4—► 4—► 4—4 4—►
Ro 60-0175
(4% CTE)
27 pg kg"1 min"1 «—► 4—► inhibitory TTT T T t 4—4 4—►
90 fig kg"1 min'1 4—4 4—► excitatory (?) 4—► T 4—► 4—4 4—►
270 pg kg"1 min"1 TTT 4—► excitatory 4 4 T t 4—► TTT 4—►
SB 242084 
22.5; 3.5 pg kg"1 min"1 
67.5; 3.5 pg kg'1 min"1
5-HT2C antagonist 4—► 
4—►
4—► 
4—►
no effect 4—► 
4—►
4—►
4—►
4—► 
4—►
4—► 
4—►
4—► 
4— y
MDL 100907
1.67; 0.83 pg kg'1 min'1 5-HT2a antagonist 4—► 4 -+ Inhibitory (?) T 4—► 4—> 1 4—►
5.01; 0.83 pg kg'1 min'1 4—► 4—► no effect 4—► 4—► 4—► J" ■1’ 'i 4—>
16.7; 0.83 pg kg"1 min"1 4—► 4—► no effect 4—► 4—> 4—► t t 4—►
Table 4.2a Summary of 5 -HT2 receptor agonist and/or antagonist evoked responses (following i.v. infusions) on EUS-EMG, urethral 
pressure, micturition reflex and cardiovascular effects
2 2 1
Drug & treatment Receptor
selectivity
EUS EMG Urethral pressure Micturition Reflex Cardiovascular effects
Overall VolT Pressure T Residual Blood Heart
Vol Pressure Rate
Ro (27) + SB (22.5; 3.5) 4 - 4 4—4 excitatory 1 4—4 11 4—4 4—4
Ro (90) + SB (22.5; 3.5) 4—4 4—4 excitatory 11 T 1 4 - 4 4—4
Ro (270) + SB (22.5; 3.5) TTT 4—4 excitatory 11 TTT 4—4 TT 4—4
Ro (27) + SB (67.5; 3.5)
Ro (90) + SB (67.5; 3.5) 4—4 4—4 excitatory 1 1 11 4 - 4 4—4
Ro (270) + SB (67.5; 3.5) 4—4 4—4 excitatory 11 4—4 1 4—4 4—4
TTT 4 - 4 excitatory 11 T 4—4 TT 4 - 4
Ro (27) + MDL (16.7; 0.83) 4—4 4—4 no effect 4—4 4—4 4—4 J, J, 4—4
Ro (90) + MDL (16.7; 0.83) 4 - 4 4 - 4 inhibitory T T T i 4—4
Ro (270) + MDL (16.7; 0.83) blocked 4—4 inhibitory T TT T !• i* i 4—4
Table 4.2b Summary of the effects of i.v. infusion of Ro 60-0175 + SB 242084 and Ro 60-0175 + MDL 100907 on EUS-EMG activity, 
urethral pressure, micturition reflex and cardiovascular effects.
2 2 2
Experimental Group n Onset time of EUS-EMG activity 
(s)
Ro 60-0175 ± Saline 
(270 pg kg'1 min'1)
5 92 ±25
Ro 60-0175 +4%  CTE 
(270 pg kg'1 min'1)
5 83 ± 14
Ro; 270 pg kg'1 min'1 
+ SB 242084 
(22.5; 3.5 pg kg'1 min'1)
5 100 ±27
Ro; 270 pg kg'1 min'1 
+ SB 242084 
(67.5; 3.5 pg kg'1 min'1)
3 113 ± 16
Table 4.3 Summary of onset times of appearance of EUS-EMG activity 
following Ro 60-0175 + saline, Ro 60-0175 + 4% CTE, Ro 60-0175 + SB 242084 
(22.5; 3.5 and 67.5; 3.5 pg kg'1 min'1). All values are expressed as mean ± sem. No 
statistical differences were observed when comparisons were made between the 
different groups.
223
4.3 Discussion
Infusion of both the low and middle dose of Ro 60-0175 did not evoke any EUS-EMG 
activity, whereas the highest dose evoked EUS-EMG activity. Additionally, none of 
the three doses of Ro 60-0175 had any effect on urethral pressure in contrast to the 
increase seen after bolus doses. On the micturition reflex, the low dose of Ro 60-0175 
was found to be inhibitory, however as the dose was gradually increased, volume 
threshold decreased but pressure threshold remained elevated. It should be noted that 
on the micturition reflexes, differences were observed on pressure threshold following 
infusion of Ro 60-0175 and saline and Ro 60-0175 and 4% CTE. Infusion of Ro 60- 
0175 with 4% CTE was observed to cause significant increases in pressure threshold, 
whereas infusion of Ro 60-0175 with saline was ineffective on pressure threshold.
This is interesting as it suggests the possibility that CTE may have caused a greater 
access of Ro 60-0175 to the receptor sites that when activated resulted in an increase 
in pressure threshold. Reflex evoked EUS-EMG activity and urethral relaxations 
were observed to be unaffected following infusions of Ro 60-0175, as reported for 
bolus doses in chapter 3. Ro 60-0175 has been characterized with full agonist 
efficacy on the 5-HT2C receptor (Ki = 1 nM) as compared to the 5-HT2A receptor (Ki 
= 32 nM; Hemrick-Luecke & Evans, 2002) in cloned rat binding studies and is 
therefore described as a 5-HT2C receptor preferring agonist (Millan et al., 1997).
Thus it would be expected that the low dose effects are mediated by 5-HT2C receptors 
and the high dose effects are mediated by 5-HT2A receptors. This data would 
therefore be consistent with the view that activating 5-HT2C receptors has an 
inhibitory action on the micturition reflex whereas EUS-EMG activation is mediated 
via the 5-HT2A receptor (as this effect was only seen with the highest infusion rate of 
Ro 60-0175). To further confirm these conclusions, infusion of these three doses of
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Ro 60-0175 was studied in the presence of 5-HT2C or 5-HT2A receptor antagonists SB 
242084 or MDL 100907 respectively. The antagonists were given as initial loading 
dose followed by maintenance infusions (see Methods, Chapter 2). Both doses of SB 
242084 failed to block the highest infusion dose of Ro 60-0175 evoked EUS-EMG 
activity. Interestingly, the inhibitory action of the low dose of Ro 60-0175 on the 
micturition reflex was blocked; with a tendency to now observe an excitatory action, 
which at least for volume threshold became more prominent as the dose increased. 
This would be consistent with the view that 5-HT2A receptors are excitatory on the 
micturition reflex (Chapter 3) and with the MDL 100907 infusion data showing a 
significant increase in volume threshold, at least with the lower dose of MDL 100907. 
Moreover, the effects of Ro 60-0175 on volume threshold were not paralleled by 
similar effects on pressure threshold, which was only significantly blocked by the 
higher dose of SB 242084. It is possible for volume threshold to change 
independently of pressure threshold as volume threshold changes reflect changes in 
compliance of the bladder i.e. smooth muscle resting tone. Thus an increase in 
pressure threshold would more than likely indicate central inhibition of the reflexes, a 
decrease in bladder compliance on an increase in EUS tone, whereas an increase in 
volume threshold would reflect changes in one or more of the following, sympathetic 
drive, parasympathetic drive and/or a direct effect on smooth muscle tone or a 
peripherally or centrally-mediated reduction in bladder afferent sensitivity. Thus 
peripheral activation of 5-HT2A receptors on bladder smooth muscle would be 
expected to decrease volume threshold. However, the present data does not support 
an action of Ro 60-0175 activating central 5-HT2A receptors, which are believed to be 
excitatory on the micturition reflex, but peripheral 5-HT2A receptors on bladder 
smooth muscle. It could be considered that the initial reversal of volume threshold
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occurs following blockade of the 5-HT2C receptor inhibitory action, which would 
potentiate the underlying 5-HT2A receptor mediated increase in bladder tone. This 
would explain why it occurs at lower doses of SB 242084 compared with inhibition of 
the increase in pressure threshold which is affected by 5-HT2C receptor activation. 
Further, data from the blood pressure changes indicate that SB 242084 at the doses 
chosen failed to affect the evoked rise in blood pressure by Ro 60-0175, which is 
mediated by peripheral 5-HT2A receptors causing constriction of vascular smooth 
muscle (see Chapter 5). This would also indicate that the doses chosen for SB 242084 
do not interfere with 5-HT2A receptors as indicated by Pfizer in house calculations. 
Moreover, the failure of SB 242084 at the high dose infusion alone to affect any other 
variables being measured indicates that 5-HT2C receptors are not physiologically 
involved in micturition in the anaesthetised rat as proposed by de Groat (2002), (see 
introduction).
Conversely, the selective 5-HT2A receptor antagonist MDL 100907 caused blockade 
of the highest infusion dose Ro 60-0175 evoked increase in EUS-EMG activity. In 
addition, Ro 60-0175 in the presence of MDL 100907 failed to evoke a decrease in 
volume threshold, with the evoked increase in pressure threshold unaffected. MDL 
100907 alone had no effect on resting variables and little effect on the micturition 
reflex apart from a small increase in volume threshold at the lowest dose. Thus this 
data demonstrates that in the rat, activation of 5-HT2A receptors causes EUS-EMG 
activity, and confirms the view that activation of central 5-HT2C receptors have a 
small inhibitory role on the micturition reflex. However, there is little or no evidence 
from the present infusion study that either of these receptors play a physiological role 
in micturition. Interestingly, infusion of MDL 100907 did cause a slow time related
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and thus dose related fall in blood pressure suggesting that these receptors may 
receive a central tonic excitatory drive. However, why the bolus dose of MDL 
100907 increased blood pressure remains to be determined, although this may again 
relate to a high free plasma concentration being obtained, that blocks other receptor 
subtypes.
As urethral pressure was observed to be unaffected in the present data, it would 
appear that neither 5-HT2A nor 5-HT2C receptors are responsible in mediating this 
effect. Data from the previous chapter suggested the involvement of 5-HT2B receptors 
in mediating the increases observed in urethral pressure, as the 5-HT2B receptor 
antagonist RS 127445 reversed the Ro 60-0175 evoked increase in urethral pressure. 
Although there is no evidence in the literature examining a physiological role for 5- 
HT2B receptors in the control of urethral smooth muscle function, these receptors have 
been implicated in gastric smooth muscle contraction (Kitazawa et al., 2006). Indeed 
the 5-HT2B receptor subtype is highly expressed in the rat stomach fundus and has 
been proposed as being functional in mediating gastric smooth muscle contractions. 
The actions of the 5-HT2B receptor on gastric smooth muscle are thought to occur via 
Gq-coupled activation of phospholipase C and intracellular calcium mobilization 
(Kelly & Sharif, 2006). It is therefore possible that 5 -HT2B receptors cause urethral 
smooth muscle contraction via a mechanism similar to that mediating gastric smooth 
muscle contraction. However, in the present study, it would appear that slow 
infusions of Ro 60-0175 at the specified doses failed to activate 5-HT2B receptors and 
the mechanism mediating urethral smooth muscle contraction.
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Overall, the present data suggests that in the rat 5-HT2A receptors are involved in 
activation of the external urethral sphincter and excitation of the micturition reflex 
whereas 5-HT2C receptors are inhibitory on the micturition reflex. Additionally, 
neither 5-HT2A nor 5-HT2C receptors were found to be involved in mediating urethral 
pressure increases as previously observed in chapter 3 although the bolus data suggest 
that the actions on urethral pressure are mediated via 5-HT2B receptors. Conclusions 
that 5-HT2A receptors are involved in activation of the EUS is in agreement with 
previous studies carried out in the cat where it was found that 5-HT2A receptor 
agonists facilitated EUS activity, where i.v. administration of the 5-HT2A receptor 
agonist DOI was observed to increase pudendal reflexes (Thor & Katofiasc, 1995; 
Danuser et al., 1995).
There has been speculation as to the specific role played by the external urethral 
sphincter in the rat i.e. is it mainly involved in micturition or continence. Indeed an 
increase in external urethral sphincter activity is representative of urethral sphincter 
contraction thus aiding in continence. Tracer studies have also revealed that 
injections of Pseudorabies vims into the external urethral sphincter infect the pontine 
storage center which directly projects to the Onuf s nucleus and innervates the 
external urethral sphincter via the pudendal nerve. However, whilst in the guinea pig 
and humans the external urethral sphincteric activity is completely inhibited 
immediately prior to urethral relaxation and bladder emptying, this does not occur in 
the rat, but rather high frequency bursts in EUS-EMG activity are observed during 
urethral relaxation (Walters et al., 2006). These observations in the rat demonstrate a 
favourable role for the external urethral sphincter in enabling efficient voiding to
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occur, whereas in the guinea pig and humans the external urethral sphincter is mainly 
involved in continence.
On the micturition reflex, the inhibitory effect of 5-HT2C receptors and excitatory 
effects of 5-HT2A receptors concur with that of the previous chapter. Additionally, 
these inhibitory effects are in agreement with previous published data by Steers & de 
Groat (1989) and Guameri et al (1996) in rat studies. Moreover, a similar inhibitory 
action of 5 -HT2C receptor agonists on micturition in guinea pigs (McMurray & Miner, 
2005) was also observed therefore suggesting that the mechanism for micturition in 
both species may be very similar with an influence on both parasympathetic and 
sympathetic outputs to the bladder.
4.3.3 Is there evidence of ‘desensitisation’ following continuous infusion
of 5 -HT2A/2C receptor ligands
Considerations as to the possibility of desensitisation should be taken into account in 
the present study due to the fact that the protocol utilized a continuous infusion dosing 
regimen. Evidence for desensitisation is mainly demonstrated by a decrease in 
compound efficacy. Although poorly understood, several mechanisms have been 
postulated as giving rise to desensitisation. These include a change or loss of the 
receptors, exhaustion of mediators, increased metabolic degradation and physiological 
adaptation (Rang et al., 1995). Continuous intravenous infusion of 5-HT2A/2C receptor 
ligands in the present experiments failed to provide evidence for desensitisation of the 
5-HT2 receptors. Measures of free plasma concentrations of compounds remained 
elevated with no decline observed even towards the end of the experiment 90 min 
later from start o f infusion. Moreover, compound efficacy was maintained with
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regards to lower urinary tract function although infusion of the low and high dose of 
Ro 60-0175 presented opposing effects on the bladder and urethra. At the high dose, 
Ro 60-0175 appeared to still be functional due to the fact that evoked increases in 
EUS-EMG activity were observed (suggesting activation of a specific mechanism had 
taken place) which would not be the case had desensitisation occurred. Indeed to 
fully confirm a lack of desensitisation in the present study, further experiments 
infusing just the largest dose of Ro 60-0175 would help further characterise and 
confirm the actions of this dose on EUS-EMG activity and the micturition reflex.
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4.4 Conclusion
From the present infusion study, it can be concluded that 5-HT2A receptors are 
involved in mediating excitatory actions on the external urethral sphincter and the 
micturition reflex, whereas 5-HT2C receptors are inhibitory on the micturition reflex. 
Additionally, neither of these two receptor subtypes are involved in reflex evoked 
urethral muscle regulation during micturition, nor are they involved in mediating the 
urethral smooth muscle contractions observed in chapter 3. Additional confirmation 
for the roles o f both the 5-HT2A and 5-HT2C receptors in mediating their respective 
bladder and urethral functions is provided from information obtained following 
measures of free plasma concentration of the compounds, of which selectivity of the 
receptor subtype was achieved following infusion of the compound at a specific target 
concentration. Moreover, evidence for a facilitatory role of 5-HT2A receptors in 
micturition rather than continence in the female rat is also demonstrated in this study.
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Experimental
group
n EUS-EMG Urethral Pressure 
(UP)
Mean A rterial Pressure 
(MAP)
H eart Rate 
(HR)
Baseline
FV
Test
nv
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A
mmHg
Baseline
bpm
Test
bpm
A
bpm
Saline 
(First dose infusion)
5 0.15 ± 0.08 0.20 ± 0.60 18 ± 0.1 18 ±0.3 -5 ± 2 97 ± 0.2 101 ± 1 5 ±0.5 356 ±5 359 ±2 3 ± 3
Saline 
(Second dose infusion)
5 0.15 ± 0.08 0.10 ±0.02 18 ± 0.1 17 ± 0.1 -17 ± 1 97 ± 0.2 90 ± 0.5 -7 ± 0.4 356 ±5 360 ± 4 4 ± 2
Saline 
(Third dose infusion)
5 0.15 ± 0.08 0.13 ±0.02 18 ±0.1 18 ±0.2 -7 ±3 97 ± 0.2 84 ± 1 -13 ± 1 356 ±5 355 ±4 2 ± 1
Saline + 4% CTE 
(First dose infusion)
5 0.27 ±0.02 0.39 ± 0.05 27 ±0.1 27 ± 0.2 -1 ± 1 97 ± 0.2 96 ± 1 -2± 1.0 348 ±3 350 ±2 2 ± 3
Saline + 4% CTE 
(Second dose infusion)
5 0.27 ± 0.02 0.29 ± 0.01 27 ± 0.1 27 ±0.1 -1 ± 1 97 ± 0.2 98 ± 0.3 1 ±0.3 348 ±3 355 ±3 7 ± 3
Saline + 4% CTE 
(Third dose infusion)
5 0.27 ± 0.02 0.24 ± 0.10 27 ± 0.1 27 ±0.1 -2 ± 0.5 97 ± 0.2 86 ± 0.5 -4 ±0.4 348 ±3 357 ± 2 9 ± 4
Table 4.4a Vehicle (Saline alone or Saline combined with 4% CTE) i.v. infusion experiments in urethane anaesthetized rats: baseline and test values 
and changes (A) in external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental
Group
n Volume Threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
ml
Test
ml
A
%
Saline 
(First dose 
infusion)
5 0.40 ± 0.03 rl 0.46 ± 0.04 17 ± 6 8 ± 1 rl 7 ± 1 -5 ± 4 0.18 ±0.03 rl 0.18 ±0.05 -9 ±13
r2 0.50 ± 0.06 38 ± 18 r2 9±  1 20 ± 14 r2 0.29 ± 0.06 85 ±52
Saline 
(Second dose 
infusion)
5 0.40 ±0.03 rl 0.50 ± 0.04 28 ± 3 8 ± 1 rl 8 ± 1 -1 ±8 0.18 ±0.03 rl 0.21 ±0.05 12 ±27
r2 0.45 ± 0.06 15 ± 6 r2 8 ± 1 4 ± 8 r2 0.20 ± 0.05 -20 ± 49
Saline 
(Third dose 
infusion)
5 0.40 ± 0.03 rl 0.46 ± 0.05 16 ± 7 8 ± 1 rl 7 ± 1 -16 ± 6 0.18 ±0.03 rl 0.11 ±0.03 -36 ± 11
r2 0.50 ± 0.06 28 ±12 r2 8 ± 1 -3 ± 10 r2 0.12 ±0.04 -37 ± 12
Saline + 4% CTE 
(First dose 
infusion)
5 0.49 ±0.11 rl 0.60 ±0.12 25 ± 12 11 ± 1 rl 11 ± 1 1 ±11 0.25 ± 0.09 rl 0.35 ± 0.08 64 ±23
r2 0.47 ±0.10 -5 ±7 r2 10±1 -1 ± 10 r2 0.22 ± 0.07 -10 ± 13
Saline + 4% CTE 
(Second dose 
infusion)
5 0.49 ±0.11 rl 0.62 ±0.18 22 ± 14 11 ± 1 rl 10 ± 1 -11 ± 8 0.25 ± 0.09 rl 0.3 ±0.14 15 ± 35
r2 0.52 ±0.10 10 ± 8 r2 11 ±2 -1 ± 9 r2 0.23 ±0.1 -6 ±17
Saline + 4% CTE 
(Third dose
5 0.49 ±0.11 rl 0.63 ±0.17 26 ± 16 11 ± 1 rl 10 ± 1 -11 ±3 0.25 ± 0.09 rl 0.23 ±0.14 -25 ± 14
infusion) r2 0.46 ± 0.08 -2 ± 9 r2 8 ± 1 -22 ± 4 r2 0.17 ±0.07 -33 ±11
Table 4.4b Vehicle (Saline alone or Saline combined with 4% CTE) i.v. experiments in urethane anaesthetized rats: baseline and test values and
changes (A) in volume threshold, pressure threshold and residual volume, rl and r2 represents reflex 1 and reflex 2.
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Experimental
group
n EUS-EMG Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
H eart Rate 
(HR)
Baseline
pV
Test
nv
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A
mmHg
Baseline
bpm
Test
bpm
A
bpm
Ro 60-0175 + Saline 
(27 pg kg'1 min'1)
6 0.49 ±0.07 0.64 ± 0.30 16 ± 0.1 18 ± 0.1 4 ± 1 97 ± 0.3 94 ± 0.6 -3 ±0.1 389 ±0.4 392 ±2 3 ± 2
Ro 60-0175 + Saline 
(90 pg kg'1 min'1)
6 0.49 ± 0.07 0.80 ±0.14 16 ±0.1 18 ±0.1 3 ± 1 97 ± 0.3 97 ± 0.4 0.4 ± 0.4 389 ± 0.4 410 ± 2 22 ±2
Ro 60-0175 + Saline 
(270 pg kg'1 min'1)
5 0.49 ±0.07 1.70 ± 0.12 144 ± 11 16 ±0.1 15 ±0.2 -28 ±2 97 ± 0.3 100 ±0.3 3 ± 1 389 ± 0.4 406 ± 1 13 ± 1
Ro 60-0175 
+ 4% CTE 
(27 pg kg'1 min'1)
5 0.22 ± 0.06 0.37 ± 0.06 23 ±0.1 25 ± 0.2 2 ±0.3 111 ±2 113 ± 0.1 0.2 ± 0.4 345 ±2 362 ±1 17 ± 2
Ro 60-0175 
+ 4% CTE 
(90 pg kg'1 min'1)
5 0.22 ± 0.06 0.90 ± 0.65 45 ±6 23 ±0.1 25 ± 0.09 5 ±0.7 111 ±2 122 ±0.2 9 ±0.5 345 ±2 387 ± 1 42 ±2
Ro 60-0175 
+ 4% CTE 
(270 pg kg'1 min'1)
5 0.22 ± 0.06 1.10± 0.10 1093 ± 141 23 ±0.1 23 ±0.1 -3 ± 1 111 ±2 132 ±0.3 19 ± 1 345 ±2 364 ± 4 19 ± 3
Table 4.5a Ro 60-0175 + Saline and Ro 60-0175 + 4% CTE i.v. infusion experiments in urethane anaesthetized rats: baseline and test values and changes 
(A) in external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental
Group
n Volume Threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
ml
Test
ml
A
%
Ro 60-0175 + 
Saline 
(27 ng kg'1 min’1)
6 0.38 ± 0.04 rl 0.61 ± 0.09 68+ 10 9+ 1 rl 11 + 1 21+8 0.19 + 0.03 rl 0.26 + 0.06 90 + 80
r2 0.65+ 0.04 74+14 r2 12 + 2 37 + 25 r2 0.32 + 0.06 81+29
Ro 60-0175 + 
Saline 
(90 tig kg'1 min'1)
6 0.38 ± 0.04 rl 0.42 ± 0.04 15 + 19 9+ 1 rl 12+1 35 + 23 0.19 + 0.03 rl 0.17 + 0.04 -5+17
r2 0.27 ± 0.03 -24+14 r2 12+1 31 ± 16 r2 0.14 + 0.03 -24+13
Ro 60-0175 + 
Saline 
(270 tig kg'1 min'1)
5 0.38 ± 0.04 rl 0.18 + 0.02 -51 + 11 9+ 1 rl 10 + 2 13 + 20 0.19 + 0.03 rl 0.11+0.02 -43 + 8
r2 0.20 ± 0.04 -45 ± 12 r2 8+ 1 -9+16 r2 0.12 + 0.03 -40 + 8
Ro 60-0175 + 4% 
CTE 
(27 tig kg1 min*')
5 0.47 ± 0.09 rl 0.69 + 0.12 54+18 9 + 0.5 rl 14 + 2 55 + 19 0.23 ± 0.07 rl 0.39 + 0.14 97 + 59
r2 0.75 + 0.16 59 + 8 r2 15 + 3 63 + 28 r2 0.45 + 0.14 105 + 27
Ro 60-0175 + 4% 
CTE 
(90 tig kg'1 min'1)
5 0.47 ± 0.09 rl 0.56 + 0.14 16+10 9 + 0.5 rl 12+1 33 + 15 0.23 ± 0.07 rl 0.27 + 0.12 10 + 20
r2 0.39 + 0.10 -18+11 r2 12 + 2 36+13 r2 0.19 + 0.07 -11+23
Ro 60-0175 + 4% 
CTE
(270 tig kg'1 min*1)
5 0.47 ± 0.09 rl 0.24 ± 0.04 -43 + 9 9 + 0.5 rl 14 + 2 46 + 22 0.23 ± 0.07 rl 0.12 + 0.03 -79 ± 50
r2 0.21+0.03 -50+10 r2 14 + 2 53 + 22 r2 0.14 + 0.03 -65 ± 57
Table 4.5b Ro 60-0175 + Saline and Ro 60-0175 + 4% CTE i.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A)
in volume threshold, pressure threshold and residual volume, rl and r2 represents reflex 1 and reflex 2.
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Experimental
group
n EUS-EMG Urethral Pressure 
(UP)
Mean A rterial Pressure 
(MAP)
H eart Rate 
(HR)
Baseline
nv
Test
nv
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A
mmHg
Baseline
bpm
Test
bpm
A
bpm
Ro; 27 ng kg'1 min1 
+ SB 242084 
(22.5;
3.5 pg kg'1 min'1)
5 0.40 ± 0.03 0.46 ±0.02 26 ± 0.3 28 ±0.1 7 ± 1 112 ±0.2 114 ±0.4 2 ±0.4 369 ±3 372 ±3 3 ± 3
Ro; 90 ug kg'1 min'1 
+ SB 242084 
(22.5;
3.5 ug kg'1 min'1)
5 0.40 ±0.03 0.34 ± 0.42 26 ± 0.3 28 ±0.1 7 ± 1 112 ±0.2 119 ±0.5 7 ±0.4 369 ±3 351 ±2 -18 ± 3
Ro; 270 pg kg'1 min'1 
+ SB 242084 
(22.5;
3.5 ug kg'1 min'1)
5 0.40 ± 0.03 0.87 ± 0.25 1381± 129 26 ± 0.3 27 ±0.1 3 ± 1 112 ±0.2 132 ±0.4 20 ± 0.3 369 ±3 373 ±2 4 ± 2
Ro; 27 pg kg'1 min'1 
+ SB 242084 
(67.5;
3.5 pg kg'1 min'1)
3 0.10 ±0.01 0.10 ±0.05 28 ± 0.2 29 ± 0.2 4 ± 1 99 ± 1 107 ±0.3 9 ± 1 387 ± 1 365 ± 1 -22 ± 1
Ro; 90 ^g kg'1 min'1 
+ SB 242084 
(67.5;
3.5 ug kg'1 min'1)
3 0.10 ±0.01 0.10 ±0.05 28 ± 0.2 29 ± 0.2 2 ± 1 99 ±1 111 ± 1 12 ± 1 387 ± 1 342 ±2 -44 ± 2
Ro; 270 pg kg'1 min'1 
+ SB 242084 
(67.5;
3-.5 PS kS'!min'i.
3 0.10 ±0.01 1.50 ±0.05 1259 ±88 28 ± 0.2 28 ±0.1 -1 ± 1 99 ± 1 118 ± 1 20 ± 1 387 ±1 340 ± 1 -46 ± 2
Table 4.6a Ro 60-0175 + SB 242084 (22.5 and 67.5 pg kg'1 min'1) i.v. infusion experiments in urethane anaesthetized rats: baseline and test values 
and changes (A) in external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental
Group
n Volume Threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
ml
Test
ml
A
%
Ro; 27 ug kg'1 min'1 
+ SB 242084 
(22.5; 3.5 ug kg'1 min'1)
5 0.43 ±0.11 rl 0.45 ± 0.07 54 ±45 9 ± 1 rl 12 ± 1 37 ±23 0.26 ± 0.09 rl 0.20 ± 0.04 18 ±54
r2 0.31 ±0.08 -29 ± 6 r2 10 ± 1 14 ± 12 r2 0.17 ±0.05 -29 ±12
Ro; 90 ug kg'1 min'1 
+ SB 242084 
(22.5; 3.5 ug kg'1 min'1)
5 0.43 ±0.11 rl 0.25 ± 0.06 -40 ±6 9 ±  1 rl 10 ± 1 21 ±11 0.26 ± 0.09 rl 0.11 ±0.03 -46 ± 14
r2 0.23 ± 0.05 -44 ±6 r2 11 ± 1 24 ±4 r2 0.10 ±0.02 -48 ± 13
Ro; 270 ug kg'1 min'1 
+ SB 242084 
(22.5; 3.5 ug kg'1 min'1)
5 0.43 ±0.11 rl 0.21 ±0.04 -46 ± 10 9 ±  1 rl 14 ± 1 57 ± 13 0.26 ± 0.09 rl 0.10 ±0.02 -49 ± 15
r2 0.20 ±0.04 -47 ± 10 r2 14 ± 1 65 ± 15 r2 0.14 ±0.04 -21 ±27
Ro; 27 ug kg'1 min'1 
+ SB 242084
3 0.31 ±0.06 rl 0.25 ± 0.03 -16 ± 5 9 ± 1 rl 7 ± 1 -19 ± 6 0.11 ±0.06 rl 0.05 ± 0.02 -36 ± 19
(67.5; 3.5 ug kg'1 min'1) r2 0.28 ± 0.05 -9 ±3 r2 7 ± 1 -18 ± 11 r2 0.04 ±0.01 -45 ± 23
Ro; 90 ug kg'1 min'1 
+ SB 242084
3 0.31 ±0.06 rl 0.18 ±0.06 -42 ±7 9 ± 1 rl 8 ± 2 16 ± 13 0.11 ±0.06 rl 0.04 ± 0.02 -62 ± 6
(67.5; 3.5 ug kg1 min ') r2 0.18 ±0.04 -40 ±5 r2 7 ± 2 -19± 15 r2 0.05 ± 0.02 -46 ± 19
Ro; 270 ug kg'1 min'1 
+ SB 242084
3 0.31 ±0.06 rl 0.14 ±0.04 -55 ±5 9 ±  1 rl 9 ± 3 -4 ±29 0.11 ±0.06 rl 0.03 ± 0.01 -61 ± 9
(67.5; 3.5 ug kg'1 min'1) r2 0.12 ±0.01 -60 ±3 r2 9 ± 1 7 ± 11 r2 0.03 ± 0.01 -65 ±8
Table 4.6b Ro 60-0175 + SB 242084 (22.5; 3.5 and 67.5; 3.5 ug kg'1 min'1) i.v. experiments in urethane anaesthetized rats: baseline and test values
and changes (A) in volume threshold, pressure threshold and residual volume, rl and r2 represents reflex 1 and reflex 2.
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Experimental group n EUS-EMG Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
nv
Test
gv
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A
mmHg
Baseline
bpm
Test
bpm
A
bpm
Ro; 27 pg kg'1 min'1 
+ MDL 100907 
(16.7; 0.83 pg kg'1 min'1)
5 0.30 ±0.01 0.51 ±0.04 25 ±0.1 26 ±0.1 1 ± 1 104 ±0.3 88 ±0.2 -16 ±0.4 372 ±1 362 ±1 -8 ±2
Ro; 90 pg kg'1 min'1 
+ MDL 100907 
(16.7; 0.83 pgkg'1 min'1)
5 0.30 ±0.01 0.35 ±0.01 25 ±0.1 27 ±0.1 6 ± 1 104 ±0.3 87 ± 0.4 -16± 1 372 ±1 359 ± 1 -3 ± 1
Ro; 270 pg kg'1 min'1 
+ MDL 100907 
(16.7; 0.83 ug kg'1 min'1)
5 0.30 ±0.01 0.40 ±0.02 25 ±0.1 25 ±0.1 -2 ± 0.4 104 ±0.3 87 ± 0.2 -17 ±0.3 372 ±1 344 ±3 -27 ±3
Table 4.7a Ro 60-0175 + MDL 100907 (16.7; 0.83 pg kg’1 min’1) i.v. infusion experiments in urethane anaesthetized rats: baseline and test values 
and changes (A) in external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
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Experimental
Group
n Volume Threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
ml
Test
ml
A
%
Ro; 27 tig kg'1 min'1 + 
MDL 100907 
(16.7; 0.83 iig kg'1 min*1)
5 0.44 ± 0.06 rl 0.48 ±0.10 10 ± 17 9 ±  1 rl 10 ± 1 16 ± 9 0.21 ±0.07 rl 0.19 ±0.08 -5 ±23
r2 0.63 ±0.11 51 ±29 r2 13 ± 2 48 ±25 r2 0.40 ±0.15 170± 136
Ro; 90 ^  kg’1 min'1 + 
MDL 100907 
(16.7; 0.83 |ig kg'1 min'1)
5 0.44 ± 0.06 rl 0.83 ± 0.07 84 ±35 9 ±  1 rl 17 ± 1 93 ±30 0.21 ±0.07 rl 0.63 ± 0.04 68 ± 10
r2 0.80 ± 0.08 97 ±28 r2 15 ± 1 70 ±20 r2 0.54 ± 0.06 62 ±13
Ro; 270 |ig kg'1 min'1 + 
MDL 100907 
(16.7; 0.83 }ig kg'1 min'1)
5 0.44 ±0.06 rl 0.77 ±0.12 83 ±29 9 ±  1 rl 13 ± 1 42 ±12 0.21± 0.07 rl 0.36 ±0.09 103 ± 42
r2 0.72 ±0.10 72 ±22 r2 13 ±2 42 ±14 r2 0.29± 0.08 53 ±37
Table 4.7b Ro 60-0175 + MDL 100907 (16.7; 0.83 ug kg'1 min*1) i.v. experiments in urethane anaesthetized rats: baseline and test values and 
changes (A) in volume threshold, pressure threshold and residual volume, rl and r2 represents reflex 1 and reflex 2.
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Experimental
group
n EUS-EMG Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
pv
Test
nv
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A
bpm
Baseline
bpm
Test
bpm
A
bpm
SB 242084 
(22.5; 3.5 jig kg'1 min'1)
5 0.10 ±0.02 0.10 ±0.05 28 ±1 27 ± 0.2 -4 ± 1 106 ± 1 102 ±0.2 -4 ± 1 353 ±2 357 ±2 4 ± 3
SB 242084 
(67.5; 3.5 ug kg'1 min'1)
5 0.10 ±0.02 0.13 ±0.05 28 ± 1 32 ±0.1 9 ± 1 106 ± 1 88 ± 0.5 -17 ± 1 353 ±2 326 ±2 -26 ±3
Table 4.8a SB 242084 (22.5; 3.5 and 67.5; 3.5 pg kg'1 min*1) i.v. infusion experiments in urethane anaesthetized rats: baseline and test values and 
changes (A) in external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
Experimental
Group
n Volume Threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
ml
Test
ml
A
%
SB 242084 
(22.5;
3.5 pg kg'1 min'1)
5 0.40 ± 0.07 rl 0.43 ± 0.08 6 ± 6 8 ± 1 rl 6 ± 1 -24 ± 11 0.17 ±0.1 rl 0.21 ±0.11 -1.2 ±34
r2 0.39 ± 0.08 -5.2 ± 6 r2 8 ± 2 -2 ± 19 r2 0.12 ±0.04 -27 ± 27
SB 242084 
(67.5;
3.5 pg kg'1 min'1)
5 0.40 ± 0.07 rl 0.43 ± 0.08 7 ± 13 8 ± 1 rl 7 ± 2 -12 ± 17 0.17 ±0.1 rl 0.13 ±0.06 -38 ± 23
r2 0.37 ±0.07 -7 ± 11
* - -..... . ■
r2 7 ± 1 -14 ± 15 r2 0.14 ±0.06 -29 ± 16
Table 4.8b SB 242084 (22.5; 3.5 and 67.5; 3.5 pg kg*1 min*1) i.v. experiments in urethane anaesthetized rats: baseline and test values and
changes (A) in volume threshold, pressure threshold and residual volume, rl and r2 represents reflex 1 and reflex 2.
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Experimental group n EUS-EMG Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
l»V
Test
PV
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A
mmHg
Baseline
bpm
Test
bpm
A
bpm
MDL 100907 
(1.67; 0.83 ug kg'1 min1)
5 0.48 ± 0.03 0.55 ± 0.04 26 ±0.1 27 ±0.1 4 ± 1 112 ± 1 100 ± 1 -11 ±0.2 346 ±2 357 ±2 11 ±3
MDL 100907 
(5.01; 0.83 pg kg'1 min1)
5 0.48 ± 0.03 0.35 ± 0.02 26 ±0.1 28 ±0.1 7 ± 1 112 ± 1 95 ±1 -16 ± 2 346 ±2 358 ±2 13 ± 3
MDL 100907 
(16.7; 0.83 pgkg'1 min1)
5 0.48 ± 0.03 0.57 ± 0.02 26 ±0.1 27 ±0.1 4 ± 1 112 ± 1 87 ± 1 -25 ± 0.4 346 ±2 389 ± 2 43 ±2
Table 4.9a MDL 100907 (1.67; 0.83, 5.01; 0.83 and 16.7; 0.83 ug kg'1 min*1) i.v. infusion experiments in urethane anaesthetized rats: baseline and 
test values and changes (A) in external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR)
241
Experimental
Group
n Volume Threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
ml
Test
ml
A
%
MDL 100907 
(1.67;
0.83 fig kg"1 min'1)
5 0.35 ± 0.05 rl 0.46 ± 0.07 38 ± 10 8 ± 1 rl 8 ± 1 13 ± 18 0.10 ±0.03 rl 0.13 ±0.05 31 ±25
r2 0.45 ± 0.07 30 ± 11 r2 8 ± 1 10 ± 19 r2 0.12 ±0.04 19 ±30
MDL 100907 
(5.01;
0.83 jig kg'1 min'1)
5 0.35 ± 0.05 rl 0.43 ±0.11 16 ± 15 8 ± 1 rl 9 ± 2 17 ± 19 0.10 ±0.03 rl 0.12 ±0.05 5 ±25
r2 0.44 ± 0.07 30 ± 12 r2 9 ± 1 l l ±  14 r2 0.10 ±0.05 43 ±78
MDL 100907 
(16.7;
0.83 fig kg'1 min'1)
5 0.35 ± 0.05 rl 0.44 ±0.11 18 ± 15 8 ± 1 rl 8 ± 1 4 ±22 0.10 ±0.03 rl 0.16 ±0.07 77 ±75
r2 0.41 ±0.08 12 ± 14 r2 7 ± 1 -5± 16 r2 0.10 ±0.02 -25 ± 11
Table 4.9b MDL 100907 (1.67; 0.83, 5.01; 0.83 and 16.7; 0.83 |ig kg'1 min'1) i.v. experiments in urethane anaesthetized rats: baseline and test values 
and changes (A) in volume threshold, pressure threshold and residual volume, rl and r2 represents reflex 1 and reflex 2.
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Chapter 5
Site of action of 5-HT2 receptor agonists
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W‘%
5.1 Introduction
As mentioned in the previous chapters, both 5 -HT2A and 5-HT2C receptors were observed 
to be involved in the control o f  micturition. However, the site o f  action o f  these two 
receptor subtypes was not established in the previous chapters. Several studies in the 
literature have demonstrated the involvement o f  central 5-HTi and 5-HT7 receptors in the 
control o f  micturition although there is not much in the literature with regards to central 
5 -HT2 receptors and their involvement in bladder and urethral function. A study by 
Espey et al (1992) provided a hint for the involvement o f  central 5 -HT2 receptors in 
micturition where they observed decreases in volume threshold following intrathecal 
administration o f  the 5 -HT1/2 receptor antagonist methysergide in awake cats. 
Additionally, there is no pharmacological evidence for the involvement o f  central 5 -HT2 
receptors in smooth and striated urethral responses, although their involvement can be 
postulated from binding and/or molecular studies where 5 -HT2 receptor mRNA was 
identified in the sacral parasympathetic nucleus and the O nufs nucleus o f several species 
(Helton et al., 1994). In addition to innervating the bladder, sacral parasympathetic 
nerves have been shown to be inhibitory on the urethra (de Groat et al., 1993; Ralevic & 
Bumstock, 1998) whereas motomeurones arising from the O nufs nucleus have been 
found to be either excitatory or inhibitory (see Fraser & Chancellor, 2003) on striated 
muscle activity.
It is clear from evidence in the literature that central 5-HT-pathways are involved in the 
control o f  micturition. The aim o f  the present study was therefore to investigate the site 
o f  action o f  the 5 -HT2 receptor agonist evoked responses observed on the bladder and
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urethra in the previous chapters (chapters 3 and 4). 5 -HT2 receptor agonists were 
administered either supraspinally (i.c.v.) or spinally (i.t.), and their effects on the bladder 
and urethra recorded. In some experiments, rats were pretreated with the peripherally 
acting non-selective 5 -HT2 receptor antagonist BW 501C67 (Mawson & Whittington, 
1970) in order to eliminate any peripheral actions o f  the 5 -HT2 receptor agonists on the 
bladder and/or the urethra.
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5.2 Results
Baseline values for all variables are shown in Tables 5.3-5.5.
5.2.1 Vehicle Control
Administration o f  5 -HT2 receptor agonist vehicle (0.9% wv'1 saline; i.v., i.c.v. and i.t.; n 
= 3-5) or 5 -HT2 receptor antagonist vehicle (100% DMSO; i.v; n = 3-5) evoked no 
significant changes in baseline EUS-EMG signal, urethral pressure and bladder distension 
caused by infusion o f  saline at a rate o f  0.1 ml min"1 (micturition reflex). Baseline MAP 
and HR were also unaffected.
5.2.2 Effect of BW 501C67 a peripheral acting 5-HT 
receptor antagonist
BW 501C67 (1 mg kg'1, i.v; n = 5) and saline had no significant effects on baseline EUS- 
EMG signal, urethral pressure, the micturition reflex, MAP and HR (Figure 5.1a & 5.2b).
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Figure 5.1a U r e t h a n e  a n a e s t h e t i s e d  f e m a l e  r a t s :  a  c o m p a r i s o n  o f  t h e  e f f e c t s  o f  B W  
5 0 1 C 6 7  a n d  v e h i c l e  ( s a l i n e )  o n  p e r c e n t a g e  c h a n g e s  ( A )  i n  e x t e r n a l  u r e t h r a l  s p h i n c t e r  
( E U S )  E M G  s i g n a l ,  u r e t h r a l  p r e s s u r e  ( U P )  a n d  m e a n  a r t e r i a l  b l o o d  p r e s s u r e  ( M A P ) .  
E a c h  p o i n t  r e p r e s e n t s  t h e  m e a n  v a l u e  a n d  v e r t i c a l  b a r s  s h o w  t h e  s . e . m e a n .  C h a n g e s  
c a u s e d  b y  B W  5 0 1 C 6 7  a n d  v e h i c l e  w e r e  c o m p a r e d  w i t h  D M S O  +  s a l i n e  c o n t r o l  u s i n g  
t w o - w a y  a n a l y s i s  o f  v a r i a n c e  f o l l o w e d  b y  t h e  l e a s t  s i g n i f i c a n t  d i f f e r e n c e  t e s t .
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Figure 5.1b Urethane anaesthetised female rats: a comparison o f  the effects o f  BW  
501C67 and vehicle (saline) on percentage changes (A) in volume threshold, pressure 
threshold and residual volume. Each bar represents mean value and vertical bars show 
the s.e.mean. Changes caused by BW 501C67 and saline were compared with DMSO 
+ saline control using Student’s unpaired t test. NS non-significant.
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5.2.3 Effect of BW 501C67 on agonist responses
5.23.1 BW  501C67 and WAY 161503 (5-HT2C)
BW 501C67 (100 jig kg'1, i.v; n = 5) failed to block the effects o f  WAY 161503 (300 fig 
kg'1, i.v) on baseline EUS-EMG signal (273 ± 32%) and urethral pressure (5 ± 1%;
Figure 5.2a). Onset o f  appearance o f  EUS-EMG firing following administration o f WAY 
161503 pre-treated with BW 501C67 was 82 ± 22s (c.f. 28 ±  11 WAY 161503 alone) and 
this evoked increase in EUS-EMG activity was observed to be ongoing up to 10 min, 
after which the bladder was emptied to test the micturition reflex and EUS-EMG firing 
stopped.
On the micturition reflex, pre-treatment o f  WAY 161503 with BW 501C67 had no effect 
on any o f  the variables measured (Figure 5.2b).
The pressor effect o f  W AY 161503 was significantly decreased following pre-treatment 
with BW 501C67 to 9 ±  1 mmHg (Figure 5.2a). HR was unaffected.
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Figure 5.2a Urethane anaesthetised female rats: a comparison of the effects of vehicle (DMSO 
+ saline) and pre-treatment of WAY 161503 with BW 501C67 on percentage changes (A) in 
external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood 
pressure (MAP). Each point represents the mean value and vertical bars show the s. e. mean. 
Changes caused by BW 501C67 and WAY 161503 were compared with DMSO + saline control 
using two-way analysis of variance followed by the least significant difference test. *,# P<0.05, 
** P<0.01, *** P0 .001 . (*), compared to DMSO + Saline, (#), compared to DMSO + WAY 
161503.
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Figure 5.2b Urethane anaesthetised female rats: a comparison o f  the effects o f  vehicle 
(DMSO + saline) and pre-treatment o f  W AY 161503 with BW  501C67 on percentage 
changes (A) in volume threshold, pressure threshold and residual volume. Each bar 
represents mean value and vertical bars show the s.e.mean. Changes caused by BW  501C67 
and W AY 161503 were compared with saline control using Student’s unpaired t test.
* P<0.05, ** P O .O l, NS non-significant.
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5.23.2 BW  501C67 and mCPP (5-HT2C)
BW 501C67 (100 fig kg'1, i.v; n = 5) also failed to block the effects o f  mCPP (300 pg 
kg'1) on baseline EUS-EMG signal (269 ± 44%) and urethral pressure (20 ± 2%; Figure 
5.3a). Onset o f  appearance o f  EUS-EMG firing following administration o f  mCPP pre­
treated with BW 501C67 was 16 ±  5s (c.f. 20 ±  5 mCPP alone). The increase in EUS- 
EMG activity was again observed to be ongoing up to 10 min after which the bladder was 
emptied to test the micturition reflex and EUS-EMG firing stopped.
In the presence o f  BW 501C67, mCPP still blocked the micturition reflex (as seen in 
chapter 3 for mCPP alone).
MAP and HR were again unaffected in these experiments.
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5.2.3.3 BW  501C67 and DOI
BW  501C67 (100 pg k g '1 and 1 mg kg '1, i.v; n = 4/5) failed to block the effects o f DOI 
(100 pg kg '1, i.v.) on baseline EUS-EMG signal (211 ± 29% and 133 ± 12%; Figure 
5.4a). Urethral pressure was unaffected (Figure 5.4a). Onset o f  appearance o f EUS- 
EMG firing following administration o f DOI pre-treated with both doses o f BW 501C67 
was 22 ± 4s and 58 ± 20s respectively (c.f. 17 ±  3s DOI alone). The onset o f  appearance 
o f  EUS-EMG firing following pre-treatment o f  DOI with the high dose o f  BW  501C67 
was found to be significantly increased when compared to DOI alone (see table 5.1 for 
summary o f  onset times o f  EUS-EMG activity). These evoked increases in EUS-EMG 
activity again were observed to be ongoing up to 10 m in until the bladder was emptied to 
test the micturition reflex and EUS-EMG firing stopped.
On the micturition reflex, BW 501C67 (100 pg kg '1) failed to block the excitatory effect 
o f  DOI on the reflex whereas the high dose (1 mg k g 1) significantly reversed the DOI 
evoked decrease in volume threshold to an increase (23 ± 7%; Figure 5.4b).
The pressor effect o f  DOI was attenuated following pre-treatment with BW 501C67. HR 
was unaffected.
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Figure 5.3a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and pre-treatment of mCPP with BW 501C67 on percentage changes ( A )  
in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial 
blood pressure (MAP). Each point represents the mean value and vertical bars show the 
s.e. mean. Changes caused by BW 501C67 and mCPP were compared with saline + saline 
control using two-way analysis of variance followed by the least significant difference test. 
* P<0.05, ** P<0.01.
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Figure 5.4a Urethane anaesthetised female rats: a comparison of the effects of vehicle 
(DMSO + saline) and pre-treatment of DOI with BW 501C67 on percentage changes 
( A )  in external urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean 
arterial blood pressure (MAP). Each point represents the mean value and vertical bars 
show the s. e. mean. Changes caused by BW 501C67 and DOI were compared with 
DMSO + saline control using two-way analysis of variance followed by the least 
significant difference test. (*), compared to DMSO + Saline, (#), compared to DMSO 
+ DOI.
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Figure 5.4b Urethane anaesthetised female rats: a comparison o f  the effects o f  vehicle 
(DMSO + saline) and pre-treatment o f DOI with BW 501C67 on percentage changes (A) in 
volume threshold, pressure threshold and residual volume. Each bar represents mean value 
and vertical bars show the s.e.mean. Changes caused by BW 501C67 and DOI were 
compared with saline control using Student’s unpaired t test. * P<0.05, **,## P<0.01, NS 
non-significant. (*), compared to DMSO + Saline, (#), compared to DMSO + DOI.
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5.2.4 5-HT2 receptor agonists i.c.v.
5.2.4.1 mCPP (5-HT2C)
mCPP i.c.v (300 ng kg'1; 5 j j.1, n = 3) had no significant effect on baseline EUS-EMG 
signal, urethral pressure, MAP and HR when compared to saline control (Figure 5.5a & 
5.5b).
On the micturition reflex, mCPP was inhibitory, with a significant increase observed on 
volume threshold (50 ±11%; Figure 5.5c).
5.2A.2 DOI (5-HT2A)
DOI i.c.v. (100 pg kg'1; 5 pi, n = 5) had no significant effect on baseline EUS-EMG 
signal and urethral pressure when compared to saline control (Figure 5.6a & 5.6b).
On the micturition reflex, DOI evoked a significant increase in pressure threshold o f 34 ± 
9% (Figure & 5.6c).
DOI significantly increased MAP by 13 ± 2 mmHg. HR was unaffected (Figure 5.6b).
257
A
30 _
B
os
£
bJD
a
10
6
o
« 5  O
P
W
1 min
AfterBefore30
40
A
4J
£
0
300 jig kg-1 mCPP i.c.v. 1 nun
Figure 5.5a Traces showing the effects of mCPP (300 pg kg'1, i.c.v.) on A baseline urethral pressure and EUS-EMG activity and B A in 
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Figure 5.5b Urethane anaesthetised female rats: a comparison of the effects of i.c.v. 
administration of vehicle (saline) and mCPP on percentage changes (A) in external 
urethral sphincter (EUS) EMG signal, urethral pressure (UP) and mean arterial blood 
pressure (MAP). Each point represents the mean value and vertical bars show the 
s. e. mean. Changes caused by mCPP were compared with saline control using two-way 
analysis of variance followed by the least significant difference test.
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Figure 5.5c Urethane anaesthetised female rats: a comparison o f the effects o f i.c.v. 
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pressure threshold and residual volume. Each bar represents mean value and vertical bars 
show the s.e.mean. Changes caused by mCPP were compared with saline control using 
Student’s unpaired t test. * P< 0.05, NS non-significant.
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Figure 5.6a Traces showing the effects of DOI (100 tig kg'1, i.c.v.) on A baseline urethral pressure and EUS-EMG activity and B A in 
bladder and urethral pressure and raw urethral striated muscle. * denotes onset o f saline infusion into the bladder.
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Figure 5.6b Urethane anaesthetised female rats: a comparison of the effects of i.c.v. 
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(MAP). Each point represents the mean value and vertical bars show the s.e.mean. 
Changes caused by DOI were compared with saline control using two-way analysis of 
variance followed by the least significant difference test. * P<0.05.
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Student’s unpaired t test. ** P< 0.05, NS non-significant.
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5.2.5 5-HT2 receptor agonists i.t.
5.2.5.1 DOI (5-HT2a)
DOI (100 ng kg'1; 10 nl, n = 3) significantly increased baseline EUS-EMG signal (24 ± 
5%; Figure 5.7a & 5.7b). Onset o f appearance o f EUS-EMG firing following 
administration o f DOI i.t. was 85 ± 68s (c.f. 17 ± 3s for i.v. DOI). Unlike the bolus i.v. 
data (see Chapter 3), the duration o f EUS-EMG firing was shorter, lasting for 
approximately 3 min.
On the micturition reflex, i.t. DOI had no significant effect on any o f the variables 
measured (Figure 5.7c).
DOI had no significant effect on either MAP or HR.
* Due to the positioning o f the animal, the miliar probe was not inserted into the urethral 
orifice and thus urethral pressure was not recorded for the intrathecal experiments.
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Figure 5.7a Traces showing the effects of DOI (100 pg kg'1, i.t.) on A baseline EUS-EMG activity and B A in bladder pressure and 
raw urethral striated muscle. * denotes onset of saline infusion into the bladder.
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Figure 5.7b U r e t h a n e  a n a e s t h e t i s e d  f e m a l e  r a t s :  a  c o m p a r i s o n  o f  t h e  e f f e c t s  o f  i . t .  
a d m i n i s t r a t i o n  o f  v e h i c l e  ( s a l i n e )  a n d  D O I  o n  p e r c e n t a g e  c h a n g e s  ( A )  i n  e x t e r n a l  u r e t h r a l  
s p h i n c t e r  ( E U S )  E M G  s i g n a l  a n d  m e a n  a r t e r i a l  b l o o d  p r e s s u r e  ( M A P ) .  E a c h  p o i n t  
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l e a s t  s i g n i f i c a n t  d i f f e r e n c e  t e s t .  * *  P < 0 . 0 1 .
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show the s.e.mean. Changes caused by DOI were compared with saline control using 
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Drug & treatment Receptor
selectivity
EUS EMG Urethral pressure Micturition Reflex Cardiovascular effects
Overall VolT Pressure T Residual
Vol
Blood
Pressure
Heart
Rate
BW 501C67 (i.v.) 5-HT2 antagonist 4— * 4— > 4— >
WAY 161503 
BW 501C67 
(i.v.)
5-HT2C no block, tended 
to potentiate
t 4—► «—► 4r~ * i 4— k
mCPP 
BW 501C67 
(i-v.)
5-HT2C no block, tended 
to potentiate
t r abolished x x x x x x x x x x x x t (variable) <r~*
DOI
BW 501C67 (100) 
BW 501C67(1000) 
(i.v.)
5-HT2A
I (not significant)
no effect 
inhibited T
4— > <— * blocked
blocked
mCPP (i.c.v.) 4 — > 4r-> inhibited t 4— > 4 -►
DOI (i.c.v.) 4 — > inhibited 4 -+ T t 4 -> T 4 -►
DOI (i.t.) f j  (lasted ~ 3 not measured no effect 4— * 4— > |  (variable)
min)
Table 5.1 Summary of 5 -HT2 receptor agonist and/or antagonist evoked responses (i.v., i.c.v. & i.t.) on EUS-EMG, urethral pressure, 
micturition reflex and cardiovascular effects
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Experimental Group n Onset time of EUS-EMG activity (s)
100 pg kg'1 BW ± 300 pg kg*1 
WAY 161503 i.v.
5 82 ±33
100 pg kg'1 BW + 300 pg kg '1 
mCPP i.v.
5 16 ± 5
100 pg kg'1 B W + 1 0 0  pg kg '1 
DOI i.v.
4 22 ± 4
1 mg kg'1 BW + 100 pg kg '1 
DOI i.v.
3 * 58 ± 20
B
Experimental Group n Onset time of EUS-EMG activity (s)
100 pg kg’1 DOI i.t. 3 85 ± 68
Table 5.2 Summary o f onset times o f appearance of EUS-EMG activity following A 
pre-treatment of WAY 161503, mCPP and DOI with BW 501C67 (i.v.); B intrathecal 
DOI. All values are expressed as means ± sem.
* Onset of appearance o f EUS-EMG activity following 1 mg kg '1 BW ± 100 pg kg"1 DOI 
i.v. was found to be significantly (P<0.05) increased when compared to DOI alone 
(chapter 3).
5.3 Discussion
To determine whether the site o f action o f the 5-HT2C receptor evoked responses on EUS- 
EMG activity, urethral pressure and the micturition reflex were mediated via a central or 
peripheral pathway, initial experiments in this study utilized the peripheral acting 5 -HT2 
receptor antagonist BW  501C67. BW 501C67, although a potent and selective 5 -HT2 
receptor antagonist, has been shown to be a poor blood-brain barrier penetrant (Mawson 
& Whittington, 1970), and is thus known to be a ‘peripheral acting’ 5 -HT2 receptor 
antagonist. A dose o f  100 pg kg’1 for BW  501C67 was chosen as it has been previously 
reported to be an effective dose at blocking peripheral responses to 5-HT without 
blocking serotonin-induced behavioural responses that are thought to be mediated 
centrally (M awson & W hittington, 1970). Therefore in the present study, data with BW  
501C67 indicates that the effect o f  mCPP, W AY 161503 and DOI on evoking EUS-EMG 
activity is due to a central action. Interestingly the low dose o f  BW 501C67 had a 
tendency to cause potentiation o f the mCPP evoked EUS-EMG activity in the first 
minute, while for W AY 161503 this tendency was delayed. The tendency to cause this 
potentiation was not observed for DOI. DOI was also tested against a very high dose o f  
BW 501C67, which also failed to block the evoked EUS-EMG activity, although there 
was a tendency to reduce the size o f the evoked EUS-EMG signal. However, this 
reduction in size o f the EUS-EMG signal was observed not to be significant when 
compared to DOI alone. The large dose o f BW 501C67 also failed to affect baseline 
variables and the micturition reflex when administered on its own. Further, the increase 
in urethral pressure caused by both mCPP and W AY 161503 was unaffected as was the 
inhibitory action o f mCPP and WAY 161503 on the micturition reflex by BW 501C67.
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This indicates that 5 -HT2C receptors located centrally cause inhibition o f the micturition 
reflex and is also consistent with the view  that 5 -HT2C receptors have not been found 
outside the central nervous system. There is little data on the affinity o f BW 501C67 for 
5-HT2 receptor subtypes; however Anderson et al.y (1992) did report that BW 501C67 
had a pK® o f 9.5 at 5 -HT2A and a pKo o f  8.5 at 5 -HT2C receptors, although nothing was 
reported on BW 501C67 affinity for the 5 -HT2B receptor. Thus it is not possible to 
conclude whether the failure o f  BW 501C67 to interfere with the evoked increase in 
urethral function is due to this effect being a central and/or peripheral mediated action.
I.c.v. administration o f  mCPP failed to cause increases in urethral pressure or EUS-EMG 
activity. Additionally, mCPP given i.c.v . failed to completely block the micturition reflex 
as it did i.v. suggesting additional sites o f  action for 5 -HT2C receptor in the control o f the 
micturition reflex. This could be at a sacral spinal level along with that site involved in 
evoking EUS-EMG activity. In this respect DOI given i.t. at the level o f the sacral spinal 
cord did evoke EUS-EMG activity but failed to affect the micturition reflex suggesting 
that 5 -HT2A receptors involved in the control o f micturition are at a supraspinal level. 
These data do not exclude 5 -HT2C receptors being involved in micturition at the 
supraspinal level and further implicate 5-HT2A receptors activating the external urethral 
sphincter activity at the level o f  the spinal cord. In this respect, 5 -HT2C receptors have 
been localised in the parasympathetic nucleus o f the sacral spinal cord (Bancillia et al., 
1999). The most obvious sites for the 5 -HT2A receptor involvement in EUS-EMG 
activation is at the sacral spinal cord where the O nuf s nucleus site is present and also 
where neurones innervating the external urethral sphincter which is composed o f skeletal
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muscle is found. The O nuf s nucleus also innervates the anal sphincter and has been 
found to contain a high density o f 5-HT2A and 5-ht5A receptors (D oly et al., 2004 a,b) as 
w ell as 5-HT2C receptors (Bancillia et al., 1999). As the bladder is required to be 80% 
full before this effect o f  5-HT2A receptor agonists can be observed, this would imply that 
a level o f afferent input from the bladder to these motomeurones is required and thus 
these receptors could be on the afferent terminals increasing the release o f the afferent 
transmitter. However the motomeurones in most cases have the 5-HT2A receptor located 
postsynaptically (D oly et al., 2004b) and this has been recently confirmed for O nuf s 
nucleus which also receives 5-HT innervation (Xu et al. 2007). Further, the present study 
does not indicate that the 5 -HT2A receptor plays a physiological role in the control o f the 
EUS nor does the present data indicate a physiological role for 5 -HT2C receptors in the 
micturition reflex. However, it is possible that these motomeurones in the O nuf s 
nucleus have to be slightly depolarised by a certain level o f afferent excitation before 
activation o f  5 -HT2A receptors can evoke action potentials. Additionally, motomeurones 
innervating the EUS did not exhibit 5-HT2A receptor labelling (Xu et al., 2007) and in 
female rats the density o f  5 -HT2A receptors was observed to be much lower than in males 
indicating that they are more involved in ejaculatory and erectile function (Xu et al., 
2007). It should be further considered that particular 5 -HT2A receptors involved in EUS- 
EMG activation could be located in another area or there may be, intriguingly, a cross 
over in pharmacology between 5-HT2A and 5-ht5A receptors. In this respect the 5-HT2A 
receptor antagonist ritanserin does have good affinity for this receptor, however little is 
know about the other ligands (see Thomas, 2006), although mianserin has a pKi o f 7.1 
(Dr David Thomas personal communication).
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The BW  501C67 studies indicate that the effects o f W AY 161503 i.v. on the micturition 
reflex have a peripheral component as the changes caused by W AY 161503 were not 
significantly different from control after BW 501C67 pretreatment, although the ability 
for mCPP to block the reflex was unaffected. For DOI, the ability to decrease volume 
threshold was blocked and reversed to an increase by BW 501C67, again indicating that 
the excitatory effect o f  DOI could be due to a peripheral action involving to a degree 
increased bladder smooth muscle tone through 5-HT2A receptor activation. However, 
i.c.v. DOI also caused a decrease in the pressure but not the volume threshold suggesting 
a central site o f  action. It is therefore possible that the DOI leaked out o f the brain to 
have a peripheral action, although peripherally DOI was observed to only affect volume 
threshold. These DOI actions on the micturition reflex are intriguing. Indeed it has been 
established that an inhibitory action on serotonergic neurones in the dorsal raphe nucleus 
is synonymous to excitatory actions on the micturition reflex (Testa et al., 2001). A 
study by Boothman et al (2003) found that systemic administration o f DOI inhibited 5- 
HT cell firing and these effects were observed to be reversed following pre-treatment 
with the 5-HT2a receptor antagonist MDL 100907, thus confirming the inhibition o f 5- 
HT cell firing by the 5-HT2a receptor subtype. It can therefore be hypothesized that DOI 
administered i.v. inhibits 5-HT cell firing in the dorsal raphe neurones which in turn 
decreases spinal 5-HT and removes the endogenous inhibitory mechanism responsible for 
inhibiting the micturition reflex and thus the excitatory effects observed on the 
micturition reflex. This would imply that there is a central component by which 5-HT2A 
receptors mediate their actions on the micturition reflex. However, from the present data,
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it is still difficult to conclude how much o f the effects o f  DOI on the micturition reflex 
are due to a peripheral and or central site o f action.
In the guinea-pig EUS excitation has been demonstrated to be due to activation o f 5-HT2C 
rather than 5-HT2A receptors (McMurray & Miner, 2005). However the function o f the 
external sphincter in this species is similar to that o f man but not the rat (see McMurray et 
al.y 2006), where it is part o f the “guarding reflex” i.e. EUS-EMG activity increases as 
the bladder fills to prevent incontinence whereas in the rat the external sphincter has 
pulsatile activity during micturition. This pulsatile activity is meant to aid voiding by 
acting as a pump. Therefore, as mentioned previously in the rat the external sphincter can 
be considered to aid micturition whereas in the guinea-pigs it can be considered to be part 
o f the mechanism where urine is retained i.e. inhibitory to micturition, which seems to be 
the general role o f 5-HT2c receptors in micturition.
The peripheral acting 5 -HT2 receptor antagonist BW 501C67 was observed to cause 
significant decreases in the pressor response o f both the 5 -HT2C and 5-HT2a receptor 
agonists WAY 161503 and DOI respectively. Additionally, administration o f DOI i.c.v. 
and not i.t. significantly increased blood pressure. Neither o f the compounds 
administered i.v. or i.c.v. were observed to have significant effects on heart rate. The 
present data would therefore suggest that the pressor responses observed following 
administration o f both the 5 -HT2C and 5-HT2A receptor agonists are due to either a central 
or peripheral mechanism. Moreover, only supraspinal and not spinal 5-HT2A receptors 
are involved in mediating the pressor response observed. Due to concerns on the
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selectivity o f  the compounds utilized in this study, W AY 161503 i.v. was probably 
activating 5 -HT2A in addition to 5 -HT2C receptors, and the pressor response observed was 
probably due to activation o f peripheral 5 -HT2A receptors. Indeed the pressor response o f  
WAY 161503 was blocked following pre-treatment with BW  501C67 thus confirming a 
peripheral mechanism. 5 -HT2A and not 5 -HT2C receptors have been found to be 
widespread in the cardiovascular system with a predominant location in the arterial 
smooth m uscle (Ullm er et al., 1995). With regards to a peripheral mechanism as 
mentioned previously, it is possible that this 5 -HT2A receptor mediated effect on blood 
pressure occurs due to vascular smooth m uscle contraction or central sympathoexcitation. 
5-HT2A receptors are also known to regulate vasopressin release which causes peripheral 
vasoconstriction thus resulting in a rise in blood pressure (Anderson et al., 1992;
Knowles & Ramage, 1999; Pergola et al., 1998). With regards to 5-HT2A receptors 
acting centrally to mediate their actions on blood pressure, results in the present study are 
in agreement with previous cat data (Andersson et al., 1995) where i.c.v. administration 
o f DOI caused significant increases in blood pressure, heart rate, cardiac and splanchnic 
sympathetic nerve activity and a decrease in femoral arterial conductance. It can be 
postulated that DOI administered i.c.v. mediated its actions by activating a central 
angiotensinergic pathway which causes vasopressin release (Saydoff et al., 1996) thus 
contracting vascular smooth muscle and causing an increase in blood pressure. 
Furthermore, as peripheral 5 -HT2 receptors were not blocked prior to administering DOI 
i.c.v., it may also be possible that the pressor response observed occurs via a peripheral 
mechanism.
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5.4 Conclusion
In conclusion, the results from the present study demonstrate that activation o f  5-HT2A 
receptors at the level o f  sacral spinal cord is responsible for excitation o f  the EUS, and 
further supports the view that the inhibitory action o f  5-HT2C receptors on micturition is 
centrally mediated. Additionally, data from the present study also provides evidence for 
the involvement o f  both central and peripheral 5-HT2A receptors in mediating blood 
pressure increases.
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Experimental
group
n EUS-EMG Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline
jiV
Test
jiV
A
%
Onset
s
Baseline
mmHg
Test
mmHg
A
%
Baseline
mmHg
Test
mmHg
A Baseline
bpm
Test
bpm
A
DMSO + Saline 5 0.26 ± 0.04 0.26 ± 0.02 - - 22 + 2 22 + 2 125 + 3 125 + 3 - 329+ 12 336 + 2 -
1 mg kg'1 BW + 
Saline
5 0.46 ±0.11 0.44 ± 0.02 23 ±2 23 ± 0.4 3 + 0.5 122 ±3 126 ± 1 5 ± 1 352 ± 10 344 ±3 -6 ± 1
100 |ug kg'1 BW + 
300 jig kg'1 WAY
5 0.36 ±0.12 1.65 ±0.23 273 ± 32 82 + 22 22 ± 1 23 ± 0.23 5+1 120 ±4 127 ± 1 9+1 371 ± 13 376 ±2 3 ± 1
100 jig kg'1 BW + 
300 jig kg'1 mCPP
5 0.74 + 0.31 3.60 ± 0.60 269 ± 44 16 + 5 19 ± 2 22 ± 1 20 + 2 114 ± 5 124 ±3 10 ± 2 340 ±13 317 ± 5 -10 ±4
100 jig kg'1 BW + 
100 Jig kg'1 DOI
4 0.35 ± 0.06 1.00 ±0.10 211+29 22 + 4 18 ±2 18 ±0.3 0.3 ± 0.4 108 ±4 112 ± 1 4 + 0.4 319 ± 23 303 ±8 -13 ± 4
1 mg kg'1 BW + 
100 jig kg'1 DOI
3 0.44 ± 0.08 1.00 ±0.10 133+12 58 + 20 24 ±2 26 ± 0.5 5+1 124 ±6 129 ± 1 5+1 361 ±9 364 ±3 2 ± 1
Table 5.3a Peripheral acting 5 -HT2 receptor antagonist BW 501C67 on agonist responses i.v. experiments in urethane anaesthetized rats: 
baseline and test values and changes (A) in external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate 
(HR)
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Experimental
Group
Volume threshold Pressure Threshold Residual Volume
Baseline
ml
Test
ml
A
%
Baseline
mmHg
Test
mmHg
A
%
Baseline
%
Test
%
A
%
DMSO + Saline 5 0.42 ± 0.06 0.42 ± 0.06 - 9 ± 1 9 ± 1 - 43 ±9 43 ±9 -
1 mg kg'1 BW + Saline 5 0.40 ± 0.06 0.45 ± 0.06 14 ± 10 8 ± 1 8 ± 1 1 ±4 45 ± 14 54 ±9 105 ± 79
100 gg kg'1 BW + 300 
gg kg"1 WAY
5 0.32 ± 0.07 0.39 ± 0.02 39 ±20 8 ±0.4 10 ± 2 21 ± 18 26 ±8 33 ±6 48 ±26
100 gg kg'1 BW + 300 
gg kg'1 mCPP
5
100 gg kg'1 BW + 100 
gg kg'1 DOI
4 0.27 ± 0.06 0.34 ± 0.06 -16 ± 12 11 ± 1 7 ± 1 -11 ± 17 32 ±6 26 ±7 46 ±39
1 mg kg'1 BW + 100 
gg kg'1 DOI
3 0.44 ±0.15 0.57 ± 0.22 23 ±7 9 ± 1 12 ± 2 44 ±43 64 ±6 76 ±6 21 ± 13
Table 5.3b Peripheral acting 5 -HT2 receptor antagonist BW 501C67 on agonist responses i.v. experiments in urethane anaesthetized rats: 
baseline and test values and changes (A) volume threshold, pressure threshold and residual volume
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(A)
Experimental
group
n EUS-EMG Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline Test A Onset Baseline Test A Baseline Test A Baseline Test A
pv pv % s mmHg mmHg % mmHg mmHg bpm bpm
Saline 5 0.32 ± 0.06 0.32 ± 0.02 - - 19 ± 2 19 ± 0.1 1 ±0.2 136 ±5 137 ±0.4 1 ±0.4 324 ±31 333 ±2 8 ± 2
300 |ig kg'1 mCPP 3 0.50 ±0.12 0.50 ±0.01 - - 24 ±4 24 ±4 10 ± 1 130 ± 2 134 ±1 5 ± 1 311 ±6 283 ±4 -28 ±4
100 pg kg'1 DOI 5 0.54 ±0.12 0.52 ±0.01 - - 21 ±2 21 ±2 6 ± 1 116 ± 2 129 ±2 13 ± 2 358 ± 14 363 ± 1 5 ± 1
(B)
Experimental
Group
Volume threshold Pressure Threshold Residual Volume
Baseline Test A Baseline Test A Baseline Test A
ml ml % mmHg mmHg % % % %
Saline 5 0.27 ±0.01 0.26 ± 0.05 -1 ±8 9 ± 1 8 ± 1 -4 ±6 58 ± 10 55 ± 11 -5 ±8
300 fig kg'1 mCPP 3 0.43 ± 0.04 0.64 ± 0.06 50 ± 11 8 ± 1 9 ± 1 14 ±23 50 ±21 59 ±26 8 ± 12
100 pg kg'1 DOI 5 0.33 ±0.05 0.39 ±0.07 14 ± 13 8 ± 1 11 ± 1 34 ±9 47 ±8 49 ±8 44 ±58
Table 5.4a & 5.4b 5 -HT2 receptor agonist i.c.v. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in (A)
external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR) and (B) volume threshold, pressure 
threshold and residual volume.
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(A)
Experimental
group
n EUS-EMG Urethral Pressure 
(UP)
Mean Arterial Pressure 
(MAP)
Heart Rate 
(HR)
Baseline Test A Onset Baseline Test A Baseline Test A Baseline Test A
pV pV % s mmHg mmHg % mmHg mmHg bpm bpm
Saline 3 0.30 ±0.01 0.38 ± 0.02 17 ±2 - - - - 108 ±2 109 ±0.3 1 ±0.3 337 ± 10 339 ± 1 2 ± 1
100 pg kg'1 DOI 3 0.34 ± 0.07 0.54 ±0.05 23 ±5 142 ± 106 - - - 103 ±9 129 ±3 25 ±3 342 ±21 319 ± 6 -23 ±6
(B)
Experimental
Group
Volume threshold Pressure Threshold Residual Volume
Baseline Test A Baseline Test A Baseline Test A
ml ml % mmHg mmHg % % % %
Saline 3 0.22 ±0.01 0.26 ± 0.05 -4 ± 13 12 ± 1 13 ±2 5 ± 11 37 ± 12 18 ± 5 -100 ± 4
100 pg kg'1 DOI 3 0.25 ±0.01 0.39 ±0.11 11 ±40 13 ± 1 18 ± 2 27 ±7 43 ±9 39 ± 14 -39 ± 40
Table 5.5a & 5.5b 5 -HT2 receptor agonist i.t. experiments in urethane anaesthetized rats: baseline and test values and changes (A) in (A)
external sphincter (EUS) EMG, urethral pressure (UP), mean blood pressure (MAP) and heart rate (HR) and (B) volume threshold, pressure 
threshold and residual volume.
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Chapter 6
General Discussion
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6 General Discussion
The present study investigated the role and sites o f action o f 5 -HT2 receptors in the 
control o f micturition in urethane anaesthetized female rats. From the literature, 5 -HT2 
receptor activation has been observed to inhibit micturition (Steers & de Groat, 1989, 
Guameri et al, 1996) with the receptor proposed to mediate its actions either spinally, 
supraspinally or at both levels. Additionally, it has been hypothesized that 5-HT2C 
receptors are involved in the supraspinal tonically active 5-HTiA autoreceptor pathway 
responsible for the excitatory actions o f the 5-HTiA receptor where activation o f 5-HTiA 
autoreceptors reduces spinal 5-HT, which in turn reduces activation o f the 5-HT2C 
receptors that are known to be inhibitory on the micturition reflex (de Groat, 2002).
Experiments in the present study demonstrate the involvement o f all three 5 -HT2 
receptors in the control o f  micturition in urethane anaesthetized female rats. By utilizing 
commercially available 5 -HT2 receptor agonists and antagonists, it was established that 
all three receptor subtypes played a different role in the control o f the lower urinary tract. 
The 5-HT2A receptor subtype was observed to be excitatory on both the micturition reflex 
and external urethral sphincter activity and the 5 -HT2B receptor was observed to be 
involved in urethral smooth muscle contraction. Additionally, the 5 -HT2C receptor was 
found to be inhibitory on the micturition reflex. Both 5 -HT2C and 5-HT2A receptors were 
observed to mediate their actions on the bladder and urethra via a central mechanism  
although a peripheral site o f action on the urethra cannot be ruled out.
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Attempting to deduce a mechanism by which the 5 -HT2A receptor mediated its actions on 
the external urethral sphincter was complicated further by the fact that recent molecular 
evidence has revealed labelling o f the 5-htsA and not 5-HT2A receptor on motomeurones 
directly innervating the external urethral sphincter (Xu et al., 2007). It is therefore 
possible that both these receptors are involved in causing the observed increases in EUS- 
EMG activity via a synergistic pathway or some form o f cross over in pharmacology 
takes place. Indeed both receptors are known to activate adenylyl cyclase (Gamovskaya 
et al., 1995; Berg et al., 1994; Francken et al., 1998,2001; Thomas et al., 2004) thus 
providing further evidence for a possible interaction between these two receptor subtypes. 
Additionally, the results in this study provide evidence for the existence o f species 
variation as the 5-HT2C receptor was observed to be the main 5 -HT2 receptor subtype 
mediating increases in EUS-EMG activity and inhibiting the micturition reflex in the 
guinea pig (McMurray & Miner, 2005), whereas in the rat the 5-HT2A receptor increased 
EUS-EMG activity and facilitated the micturition reflex. Moreover, in the dog, 
activation o f the 5-HT2C receptor was observed to increase urethral pressure (Conlon et 
al., 2005), whereas in the present study, the 5 -HT2B receptor was revealed as the receptor 
responsible for increasing urethral pressure in the rat.
It is o f interest from the present pharmacological experiments that the two urethral 
muscles function via independent receptors/mechanisms even though they have both been 
implicated as playing a role in continence in the rat (see Fraser & Chancellor, 2003). 
Interestingly, there has been a hint o f the involvement o f the external urethral sphincter in 
facilitating efficient voiding in the rat (Walters et al., 2006). Indeed whilst the 5-HT2A
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receptor has been established as the main 5 -HT2 receptor involved in mediating the 
increases observed in external urethral sphincter activity, the 5 -HT2B receptor has been 
implicated to be involved in urethral smooth muscle contraction. Although structurally 
linked, the origin o f activity o f both urethral muscles has been observed to be different. 
The excitatory pathway responsible for urethral smooth muscle contraction originates in 
sympathetic preganglionic neurones with efferent input to the urethral smooth muscle 
mediated via the hypogastric nerves. On the other hand, the excitatory pathway 
responsible for external urethral sphincter activity originates from the O nuf s nucleus 
with efferent input to the external urethral sphincter mediated via the pudendal nerves. 
Moreover, tracer studies have revealed a different supraspinal circuitry controlling both 
urethral muscles. Pseudorabies virus injected into the urethral smooth muscle infected 
the pontine micturition centre which is known to be responsible for micturition whereas 
injecting the virus into the external urethral sphincter primarily infected the pontine 
storage center which directly projects to the O nuf s nucleus and plays a role in storage 
(see Fraser & Chancellor, 2003). However, to a lesser extent the pontine micturition 
center was also infected following injections into the external urethral sphincter thus 
suggesting a crossover may exist between the functions o f  the urethral striated muscle in 
both continence and micturition. Collectively with support from the literature findings 
described above, pharmacological evidence from the present study in the rat favours the 
role o f the 5-HT2A receptor in aiding micturition rather than continence, whereas 5-HT2B 
and 5 -HT2C receptors are shown to be involved in continence. In theory, for effective 
continence to occur, an increase in external urethral sphincter activity should be 
synonymous to inhibition o f  the bladder as w ell as urethral smooth muscle contraction. It
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has been proposed that for this to occur, afferent signals travel from the contracting 
external urethral sphincter (characterized by the increased EUS-EMG activity) via the 
pudendal nerves to the sacral spinal cord inhibit parasympathetic bladder motomeurones 
directly through spinal intemeurones, as w ell as increasing sympathetic influence upon 
the bladder and urethral smooth muscle (see Park et al., 1997). However, this does not 
appear to be the case in the rat from the present data, as an increase in EUS-EMG activity 
following activation o f  the 5-HT2A receptor was characterized by excitatory actions on 
the bladder with no effects observed on the urethral smooth muscle thus providing 
evidence for a favourable action o f the 5-HT2A receptor in micturition. It would thus 
appear that afferent input from the external urethral sphincter to the sacral spinal cord 
activates parasympathetic bladder motomeurones as w ell as inhibiting the sympathetic 
influence to the bladder and urethral smooth muscle, with excitatory actions observed on 
the micturition reflex.
The inhibitory and excitatory actions o f the 5 -HT2 receptor ligands on the micturition 
reflex in the present study is intriguing as it provides further evidence for the involvement 
o f this receptor fam ily on bladder function. Previous rat studies have revealed that 
activation o f the 5-HT2C receptor has an inhibitory action on micturition and somewhat 
surprising, antagonists to this receptor are without effect (Steers & de Groat, 1989; 
Guameri et al., 1996; Testa et al., 2001). Moreover the present study also provides 
evidence for the excitatory actions o f the 5-HT2A receptor in bladder function in the rat.
It has also been demonstrated that the effects observed on bladder function are mediated 
via central 5 -HT2 receptors as the peripheral acting 5 -HT2 receptor BW 501C67 failed to
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attenuate/block the actions o f either the 5-HT2C or 5-HT2A receptor agonists.
Additionally, efficacy on the micturition reflex was observed following central 
administration o f  either 5-HT2C or 5-HT2A receptor agonists. However, from the present 
study there is no evidence for a physiological role o f these receptors in micturition as 
slow infusions o f the antagonists SB 242084 and MDL 100907 failed to reveal efficacy 
on the micturition reflex (see chapter 4). The lack o f a physiological involvement o f 5- 
HT2C receptors in micturition is interesting as evidence from the present study disagrees 
with the supraspinal tonically active 5-HTia autoreceptor (negative feedback) pathway 
proposed by de Groat (2002) thought to involve the 5 -HT2C receptor.
In the present study, a problematic aspect o f studying the function o f 5 -HT2 receptor 
subtypes in vivo was the seem ingly poor selectivity o f the agonists used to study these 
receptors. Indeed from previous studies the so called 5 -HT2C receptor agonists WAY 
161503, Ro 60-0175 and mCPP have displayed behavioural characteristics typical o f the 
5 -HT2C and not 5-HT2a/2b receptor including hypoactivity, penile grooming and 
hypophagia (M illan et al., 1997; Martin et al., 1998; Kennett et al., 2000) with these 
effects reversed by selective 5 -HT2C receptor antagonists. The fact that the EUS-EMG 
increases observed in chapter 3 following bolus dosing o f these agonists is blocked by 
both 5 -HT2C and 5-HT2A receptor antagonists implied activation o f both receptor 
subtypes, thus making interpretation o f the data more difficult. Additionally the lack o f 
blockade o f the 5-HT2C receptor evoked increase in urethral pressure laid further claim to 
a lack o f selectivity o f  these ligands as this response was concluded to be 5 -HT2B receptor 
mediated. Furthermore, the commercially available agonists used to study the effects o f
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both the 5-HT2A and 5 -HT2B receptors, DOI and BW 723C86 were reported as possessing 
very low  selectivity for their respective receptor subtype and should thus be referred to as 
5-HT2a/2c “preferring” rather than “selective” receptor agonists. Surprisingly, the 
selective 5 -HT2C receptor antagonist RS 102221 was observed to have inconsistent 
actions on 5-HT2C receptor agonist evoked responses on the bladder and urethra thus 
adding more doubt as to the selectivity o f these compounds in vivo. To overcome this 
problem, experiments in chapter 4 were designed to utilize a dosing regimen which 
involved infusion o f  the compound at a specific rate and dosage targeting the specific 
receptor subtype, with measures o f free plasma concentration o f the compound further 
confirming selectivity for the receptor subtype. By carrying out these controlled set o f 
experiments, conclusions regarding the role played by the 5 -HT2 receptor family in the 
control o f micturition could thus be made.
Although cardiovascular regulation was not the major focus o f this thesis, the 5 -HT2 
receptor was observed to be involved in cardiovascular regulation with the involvement 
o f both central and peripheral receptors. Central and peripheral activation o f 5-HT2A 
receptors increased blood pressure and this was proposed to occur following the release 
o f vasopressin which is known to cause vasoconstriction. Moreover, data from the 
present study was consistent with the view  that tonic activation o f 5 -HT2B receptors 
decreased blood pressure (see Ramage, 2001) with a mechanism thought to involve the 
release o f nitric oxide which causes vascular relaxation. Finally, 5 -HT2C receptors were 
found not to be involved in cardiovascular regulation.
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The experimental design and animal model used in these studies enabled further 
characterization o f the involvement o f 5-HT receptor subtypes in the control o f  
micturition with a focus on the 5 -HT2 receptor family. The cystometry m odel used in the 
present study is a straightforward model o f bladder and urethral functionality that enables 
acquisition o f appropriate and relevant information regarding the effects o f the 
compounds which can thereafter be translated into understanding autonomic innervation 
o f the lower urinary tract. The female rat was chosen as the species o f choice for the 
present study due to its ready availability within the academic and industrial laboratory. 
Additionally, the female rat has been extensively used to investigate the physiology and 
pathophysiology o f the bladder and how this relates to the control o f  micturition. 
Furthermore, even though distinct differences exist between the two species, several 
similarities regarding voiding such as patterns o f flow  and peak bladder pressure (Walters 
et al., 2006) exist, thus making the rat a suitable species to study lower urinary tract 
function.
The cystometric parameters measured on the micturition reflex in the present study 
included volume threshold, pressure threshold and residual volume. Justification for 
measuring these three parameters was to investigate the role played by 5 -HT2 receptors 
on voiding function. Data from the present study demonstrated that 5 -HT2C receptors 
affected the sensory limb o f  the micturition reflex pathway due to the increases observed 
on volum e and pressure threshold, as w ell as maintaining bladder compliance. 
Additionally, it is also possible that this receptor subtype had an effect on the somatic 
efferent pathway due to the increase in residual volume which would suggest urethral
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interference. On the other hand, the facilitatory actions o f  the 5-HT2A receptors 
characterised by decreased volume threshold and altered pressure threshold (primarily an 
increase in pressure threshold) indicated a change had occurred in the bladder’s ability to 
expand in order to accommodate urine (bladder compliance).
Future work in continuing with these studies would be to use the same compounds and 
translate them to a conscious rodent cystometry model which would be useful in enabling 
deductions be made on whether the actions mediated by the 5 -HT2 receptors in the 
anaesthetized animal are similar in the fully conscious state when the animal is 
undertaking everyday activities. Supraspinal and spinal electrophysiological recordings 
in combination with the pharmacological tools utilized in this study would also enable 
conclusions to be drawn as to whether the 5 -HT2 receptors are involved in processing 
afferent information from the bladder/urethra or efferent outflow to the bladder/urethra, 
or both. O f interest would be to investigate whether 5-ht5A receptors are physiologically 
involved in mediating the effects observed on EUS-EMG activity as molecular evidence 
demonstrates labelling o f  5-ht5A receptors on motomeurones directly innervating the 
external urethral sphincter (Xu et al., 2007).
From a clinical perspective, there is currently no evidence for the direct use o f  
compounds acting at the 5 -HT2 receptor in the treatment o f lower urinary tract 
dysfunctions. However, the present data may prove to be an important benchmark for the 
use o f  5 -HT2 receptors as potential therapeutic targets. Activation o f the 5-HT2A receptor 
subtype lead to a pronounced increase in external urethral sphincter activity and this was
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indicative o f contraction o f  the striated sphincter m uscles. As previously described, there 
is a dense accumulation o f  5 -HT2 receptors in the O nuf s nucleus in the rat (Thor et al., 
1993) which is responsible for the actions o f the external urethral sphincter. Further, it 
has been found that activation o f these receptors with a 5 -HT2 receptor agonist results in 
an increase in the guarding reflex that prevents urine leakage. On the other hand, the 
inhibitory actions o f the 5 -HT2C receptor subtype on the micturition reflex could be 
deemed as a model for the improvement in bladder capacity (demonstrated by the 
increase in volume threshold). Ideally, it would have been useful to apply the 5-HT2C/2A 
receptor agonists to a model o f  bladder irritation thus mimicking some o f the overactive 
bladder symptoms. Therefore this current preclinical study, demonstrating the excitatory 
actions o f 5 -HT2A receptors on the external urethral sphincter and the inhibitory actions 
o f the 5-HT2C receptors on the micturition reflex provides similar evidence to those 
observed following the use o f  the dual selective serotonin/noradrenaline reuptake 
inhibitor (SNRI) duloxetine which has been widely investigated for its use in the 
treatment o f women with stress urinary incontinence (see Jost & Marsalek, 2004). 
Similar to the data from the current study, duloxetine has been observed to cause a 
pronounced increase in urethral sphincter activity during the storage phase o f the 
micturition cycle (Thor & Katofiasc, 1995). Additionally, duloxetine was also observed 
to increase bladder capacity and striated sphincter activity in an anaesthetized acetic acid 
cat model thus emphasizing the value o f its use in the treatment o f  overactive bladder 
symptoms.
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In conclusion, the present study provides a promising strategy for the possibility of 5 -HT2 
receptors as potential targets for the treatment of disorders of the lower urinary tract 
including stress urinary incontinence and overactive bladder syndrome. Although it is 
not possible to directly translate the pharmacological data from the present rat study to 
humans due to the differences in bladder and urethral structures, there is evidence 
provided for the potential to manipulate this 5-HT receptor family which has been shown 
to facilitate or suppress micturition, in the current study. There is therefore a great 
capacity for growth in this field and the current study boosts this concept by further 
elucidating the role of 5-HT receptors in the control of micturition with great insight into 
their potential as therapeutic targets for lower urinary tract dysfunctions.
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5-HT2c receptor agonist Ro 60-175 and its role in the control of micturition in anaesthetized 
female rats
(Presented at the Society for Neuroscience meeting; October 2006)
Y.Mbaki, J.C. Gardiner1, G. McMurray1 & A.G. Ramage, Dept, of Pharmacology, UCL, London, 
discovery Biology, Pfizer Global R & D, Sandwich
5-HT2a and 5-HT2c receptors have been implicated in activation of the external urethral sphincter 
(EUS) and inhibition of the micturition reflex (MR) respectively in rats (Mbaki et al 2005, PA2 
online Vol3Issue4abst065P), while in guinea-pigs 5-HT2C receptors activate the EUS and inhibit 
the MR (McMurray and Miner 2005, The FASEB Journal 19, A536). This study further 
investigates the role of these receptors in micturition in the rat.
EUS EMG activity, bladder and urethral pressure (UP) were recorded in urethane anaesthetised 
female Sprague-Dawley rats (250-300g). Drug effects were evaluated on volume (VT) and 
pressure (PT) threshold during MRs evoked by saline infusion (0.1 ml min'1) into the bladder and 
on EUS EMG activity and UP at 80% of the bladder volume required to evoke a control MR. Ro 
60-0175 (5-HT2C agonist) was given i.v. as a bolus (300 fig kg'1; Cmax ~ 50nM free plasma 
concentration) or 30 min infusion (27, 90 and 270 pg kg'1 min'1 targeting 10, 30, and 100 nM free 
plasma concentration). MDL 100907, ketanserin (5-HT2A antagonists) and SB 242084 (5-HT2C 
antagonist) were given i.v. (30 pg kg'1 bolus) prior to i.v. bolus Ro 60-0175. Blood samples were 
taken for analysis of plasma concentration of Ro 60-0175. All values are means ± S.E.M (n=5/6).
Ro 60-0175 (i.v. bolus) significantly increased EUS EMG activity, UP, VT, and PT in 
comparison to vehicle controls (22 ± 3 v 1 ± 1 V; 2 ± 0.2 v 0.1 ± 0.1 mmHg; 0.4 ± 0.1 v 0.2 ± 
0.02 ml; 5.7 ± 1.6 v 0.5 ± 0.9 mmHg respectively). MDL 100907 and ketanserin blocked EUS 
EMG activity but not UP, VT or PT effects of Ro 60-0175. SB 242084 blocked die EUS EMG 
and PT but not the UP effects of Ro 60-0175 and reversed the increase in VT to a decrease. Ro 
60-0175 (27 and 90 pg kg'1 min'1) had no effect on EUS EMG activity or UP compared with 
saline control rats, whilst 270 pg kg*1 min*1 significantly increased EUS EMG activity (11 ± 1 v 
0.2 ±0.1 V). Ro 60-0175 (27 pg kg"1 min"1) significantly increased VT and PT whilst 90 and 270 
pg kg'1 min*1 significantly decreased VT.
These data suggest that whilst 5-HT2C receptor activation inhibits the MR, both 5-HT2A and 5- 
HT2C receptors are excitatory to the EUS. Neither receptor appears to be involved in the UP 
increase in rats. However, in guinea-pigs and dogs 5-HT2C receptor activation does increase UP, 
which is more predictive for humans (Conlon et al. 2005 Soc. for Neurosci. Abstr 48.14). Ro 60- 
0175 appears to activate 5-HT2A as well as 5-HT2C receptors at higher concentrations.
Supported by a BBSRC collaborative studentship
Mbaki et al. (2005). PA2onlineVol3 Issue4 abst 065P
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THE EFFECT OF 5-HT2C RECEPTOR AGONIST Ro 60-0175 IN THE CONTROL OF 
THE URETHRA AND MICTURITION IN ANAESTHETISED FEMALE RATS 
(Presented at the Physiological Society meeting; July 2006)
Y.Mbaki, J. Gardiner1, G. McMurray1 & A.G. Ramage, Dept, of Pharmacology, UCL, Hampstead 
Campus, London, NW3 2PF, discovery Biology, Pfizer Global R & D, Sandwich, CT13 9NJ.
In rats, stimulation of 5-HT2c receptors caused inhibition of the micturition reflex, while 
stimulation of 5-HT2A receptors caused activation of the external urethral sphincter (EUS);
(Mbaki et al 2005). However, in guinea-pigs using the selective 5-HT2C receptor agonist Ro 60- 
0175, it was shown that stimulation of 5-HT2C receptors caused activation of the EUS (McMurray 
& Miner. 2005). The present experiments were carried out to further investigate the effects of Ro 
60-0175 on EUS-EMG activity, urethral pressure and the micturition reflex in the rat.
Experiments were performed on spontaneously breathing female Sprague-Dawley rats (250- 
300g) anaesthetized with isofluorane (5% in 100% oxygen) and maintained with urethane (1.2 g 
kg'1, i.v.). Simultaneous recordings of EUS-EMG activity, urethral and bladder pressures, and 
carotid arterial blood pressure were made. Micturition reflexes were evoked by saline infusion 
(0.1 ml min'1) into the bladder. All substances were given as i.v. bolus doses. Changes were 
compared with vehicle controls for baseline EUS-EMG activity and urethral pressure by two-way 
ANOVA and the micturition reflex by unpaired Student’s f-test. All values are expressed as 
means ± S.E.M. P < 0.05 was considered to be significant.
Ro 60-0715 (300 pg kg'1, n=5) caused a significant increase in baseline EUS-EMG activity and 
urethral pressure (22 ± 3 v 1 ± 1 V & 2 ± 0.2 v 0.1 ± 0.1 mmHg). The selective 5-HT2C receptor 
antagonist SB 242084 (30 pg kg*1, n=5) blocked the effects of Ro 60-0175 on EUS-EMG activity 
but failed to block the increase in urethral pressure. The 5-HT2A receptor antagonists MDL 
100907 and ketanserin (30 pg kg'1, n=5) also blocked the effects of Ro 60-0175 on EUS-EMG 
activity but failed to block the increase in urethral pressure. Ro 60-0175 significantly increased 
bladder threshold pressure (5.7 ± 1.6 v 0.5 ± 0.9 mmHg), residual volume (0.2 ± 0.04 v 0.01 ± 
0.01ml) and volume threshold (0.4 ± 0.1 v 0.2 ± 0.02 ml). SB 242084 significantly decreased the 
effects of Ro 60-0175 on bladder threshold pressure and volume threshold. MDL 100907 and 
ketanserin failed to block the effects of Ro 60-0175 on bladder threshold pressure, residual 
volume and volume threshold.
These data indicate that activation of either 5-HT2A or 5-HT2C receptors can cause excitation of 
the EUS in the rat. The data above also confirms an inhibitory role of 5 HT2C receptors in the 
control of micturition. However, the receptor subtype by which 5 HT2 receptor agonists cause an 
increase in urethral pressure in the rat (Mbaki et al. 2005) remains to be determined. Interestingly 
in guinea-pigs and dogs it has been shown that 5-HT2C receptor activation increases UP, which is 
more predictive for humans (Conlon et al. 2005).
Y.M. is supported by a BBSRC PhD collaborative award with Pfizer.
Mbaki et al. (2005). PA2onlineVol3Issue4abst065P.
McMurray & Miner (2005). The FASEB Journal 19, A536.
Conlon et al. 2005 Soc. for Neurosci. Online abst. 48.14
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THE ROLE OF 5-HT2 RECEPTORS SUBTYPES IN THE CONTROL OF THE 
URETHRA AND MICTURITION IN ANAESTHETISED FEMALE RATS 
(Presented at the British Pharmacological Society meeting; December 2005)
Y.Mbaki, S. Westbrook1 & A.G. Ramage, Department of Pharmacology, University College 
London, Hampstead Campus, London, NW3 2PF, discovery Biology, Pfizer Global Research 
and Development, Kent, CT13 9NJ.
5-HT receptors are implicated in the control of the bladder, however little is known of their role 
in control of the urethra. Nevertheless, 5-HT2 receptor activation, by mCPP was reported to 
increase cavernous nerve activity (Steers & De Groat, 1989). The present experiments were 
carried out to investigate the effect of the 5-HT2 receptor agonists, mCPP, Ro 60-0175, DOI (see 
Knight et al. 2004) and WAY 161503 (Cryan et al. 2000) on urethral pressure and sphincter 
(EUS) EMG activity and the micturition reflex.
Simultaneous recordings of EUS-EMG activity, urethral and bladder pressure, BP and HR were 
obtained from urethane-anaesthetised (1.2 g kg'1) spontaneously breathing female Sprague- 
Dawley rats (200-300g). Micturition reflexes were evoked by saline infusion (0.1 ml min'1) into 
the bladder. All test substances were given i.v. Changes in EUS-EMG activity, urethral and 
bladder pressure, BP and HR were compared with those in vehicle controls using two-way 
ANOVA and the least significant difference test. Changes in the micturition reflex were 
compared with vehicle controls using unpaired Student’s Mest. All values are expressed as the 
mean ± s.e.mean. P < 0.05 was considered to be significant.
WAY 161503, Ro 60-0175, mCPP, (300 pg kg'1, n=5) and DOI (100 pg kg'1, n=5) each caused a 
significant increase in baseline EUS-EMG activity (179± 9%, 150±13%, 166±17%, & 198±15%). 
Only WAY 161503, Ro 60-0175 and mCPP significantly increased urethral pressure (10±2%, 
13±2% & 24±2%). The selective 5-HT2A receptor antagonist (Knight et al. 2004) ketanserin (30 
pg kg'1, n=5), blocked the effects of either WAY 161503 or DOI on EUS-EMG but not the ability 
of WAY 161503 to increase urethral pressure. The selective 5-HT2A receptor antagonist, MDL 
100907 (30 pg kg'1, n=3), also antagonised this effect of DOI. mCPP blocked the micturition 
reflex, whereas WAY 161503 and Ro 60-0175 significantly increased bladder threshold pressure 
(25±11% & 90±33%) and volume threshold (55±13% & 71 ±15%) and DOI decreased only 
volume threshold (-35±7%). Ketanserin potentiated the effects of WAY 161503 on the volume 
but not pressure threshold and blocked the effect of DOI on volume threshold. MDL 100907 also 
blocked the effect of DOI on volume threshold.
These data indicates that activation of 5-HT2A receptors evokes excitation of the external urethral 
sphincter, whereas it would seem that 5-HT2C receptor activation causes constriction of urethral 
smooth muscle and inhibits the micturition reflex.
Y. M. is in receipt of BBSRC PhD collaborative award with Pfizer.
Cyran, JF & Lucki, I (2000) J Pharmacol Exp Ther; 295, 1120-1126.
Steers, WD & De Groat, WC, (1989) Am J Physiol; 257, R1441-R1449.
Knight, AR et al., (2004). Naunyn Schmiedeb Arch Pharmacol; 370, 114-123.
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Role of §-HT2c receptors in the control of micturition in anaesthetized female rats 
(Presented at the International Union of Physiological Sciences meeting; April 2005)
Yvonne Mbaki1, Simon Westbrook2, Andrew G Ramage1: 'Dept, of Pharmacology, University 
College London, Hampstead Campus, London NW3 2PF, 2Discovery Biology, Pfizer Global 
Research and Development, Kent, CT13 9NJ U.K.
Rats (25Og) were anaesthetised with urethane (1.2g kg'1 i.v.); bladder and urethral pressures, 
sphincter (EUS)-EMG, BP and HR were recorded. The 5-HT2c agonists WAY 161503 or mCPP 
(300 pg kg'1; n = 5, i.v.) caused a significant increase in baseline EUS-EMG activity of 202 ± 15 
% & 124 ± 22%. WAY 161503 had no effect on urethral pressure, whereas mCPP significantly 
increased the urethral pressure by 26 ± 6 %. WAY 161503 significantly increased the residual 
volume (62 ± 23 %), while mCPP completely blocked the distension evoked micturition reflex. 
Both WAY 161503 and mCPP (300 pg kg*1, n = 3, 5 pi) given intracerebroventricularly (i.c.v.) 
and intrathecally (i.t.) had no effect on baseline variables, however on the reflex both drugs 
caused an increase in volume threshold and residual volume. In the presence of the peripheral 5- 
HT2 antagonist BW501C67 (100 pg kg*1, n = 6, i.v.) the effects of mCPP (i.v.) on EUS-EMG and 
urethral pressure tended to be potentiated (+569 ± 311% & +11 ± 11%). These data suggest that 
5-HT2C receptors in the brain and sacral spinal cord play an inhibitory role in the control of 
micturition while the ability of these agonists to increase baseline EUS-EMG is due to a 
peripheral site of action, probably not related to activation of 5-HT2 receptors. Supported by a 
BBSRC collaborative studentship
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Appendix (Chapter 7)
Determination of the relative expression 
levels of 5-HT2 receptors in the rat brain, 
bladder and urethra
355
* The work in this chapter was carried out courtesy o f Caroline Tolley (Discovery 
Biology, Pfizer, UK) who was investigating the sensitivity o f the Roche TaqMan qRT- 
PCR kit.
7.1 Introduction
Pharmacological characterization o f 5 -HT2 receptor subtypes revealed a role o f 5-HT2 
receptors in the lower urinary tract (see chapters 3 & 4). It was concluded that 5-HT2A 
receptors were excitatory on the external urethral sphincter and the micturition reflex and 
5 -HT2C receptors were inhibitory on the micturition reflex. Additionally, it was 
concluded that activation o f 5-HT2B receptors caused contraction o f the urethral smooth 
muscle.
5 -HT2 receptors have been well characterised at the molecular level with both central and 
peripheral distribution o f the receptor. Studies have revealed 5-HT2A receptor 
distribution in the CNS specifically in the cortical areas o f the brain (Pazos et al., 1985, 
1987; Lopez-Gimenez et al., 1997). Additionally, polymerase chain reaction (PCR) and 
southern hybridization analysis studies revealed 5-HT2A receptor mRNA in the spinal 
cord o f  the rat, cat, monkey and human tissue (Helton et al., 1994). 5-HT2B receptors 
were found to be mainly located in peripheral tissues including the adult gut and 
cardiovascular system (Loric et al., 1992). Some studies also provided evidence for a 
central distribution o f 5-HT2B receptors including cerebellum, cortex, hippocampus, 
amygdala and the spinal cord (Choi & Maroteaux, 1996; Helton et al., 1994). With 
regards to the 5-HT2C receptor subtype, distribution o f the receptor has mainly been
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observed in the central nervous system (both in the brain and spinal cord), with low to 
absent expression o f the receptor in peripheral tissues (Helton et al., 1994).
To my knowledge, there is no evidence in the literature examining the gene expression of 
the different 5 -HT2 receptor subtypes in the lower urinary tract. RT-PCR was therefore 
employed to identify the gene expression o f all three 5 -HT2 receptor subtypes in the 
bladder, urethra and brain o f female Sprague Dawley rats. This was done using the 
Roche TaqMan qRT-PCR kit. Performing this expression study therefore provided 
molecular evidence and support for the pharmacological observations made in the 
previous chapters regarding the involvement o f 5 -HT2 receptors in the control o f the 
lower urinary tract.
Below is a brief description o f the PCR technique utilized in this study.
7.1.1 Polymerase Chain Reaction
PCR may be defined as a biochemical and molecular biology technique that enables the 
replication o f DNA without the use o f a living organism. PCR uses a naturally occurring 
nuclease enzyme, polymerase, to catalyze the regeneration o f DNA, with a chain reaction 
that eventually exponentially amplifies the target DNA (Elrich, 1989). PCR is mainly 
used in gene technology for a broad variety o f experiments and analyses, such as 
hereditary disease detection, cloning o f genomic sequences, detecting viral pathogens as 
well as genetic fingerprinting (see Garcia & Ma, 2005).
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The three steps that are repeated over and over again to exponentially amplify the target 
DNA include denaturation, annealing and extension. The process of denaturation 
requires heating o f the template DNA mixture to a specific temperature (e.g. 90-95°C), 
thus allowing the DNA double strand to denature and separate into two separate strands. 
This is followed by the annealing process which involves cooling the template DNA 
mixture (50-60°C) to allow the primers (a pair o f synthesized short DNA segments 
consisting o f sense and antisense) to anneal to the right portion o f the separated template 
and enable the DNA polymerase to begin copying the template, thus building new 
complimentary DNA (cDNA). The temperature is thereafter raised (~72°C) and the third 
and final step, extension, takes place where the DNA polymerase links the loose 
deoxynucleotides to the primer and to each o f the separated DNA strands in the 
appropriate sequence. The whole process o f PCR requires repetition o f the above three 
steps 30-40 times.
The most commonly used DNA polymerase for the PCR system is the Taq DNA 
polymerase. The enzyme is a naturally occuring enzyme that is derived from Thermus 
aquaticus and is known to be both thermostable and heat resistant. Taq DNA polymerase 
has a 5 3 '  nuclease activity but lacks a 3 '- 5 ' proofreading exonuclease activity. These 
properties o f Taq DNA polymerase enable the amplification reaction to run through heat 
resistant cycles with no interruptions. Additionally, the use o f the enzyme significantly 
improves specificity and sensitivity o f the reaction, as well as increasing the yield and 
length o f the products (see Garcia & Ma, 2005).
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7.1.2 Reverse T ranscrip tase PC R  (RT-PCR)
RT-PCR is the method o f choice for detection o f mRNA (see Bustin, 2000), as it is the 
most sensitive and reliable technique when compared to Northern blot analysis and 
RNase protection assay. In RT-PCR, RNA and not DNA is used as the template, and the 
reverse transcriptase enzyme is needed to transcribe RNA to cDNA before the initiation 
o f PCR (see Garcia & Ma, 2005). RT-PCR can be used to quantify mRNA levels from 
very small samples, and due to its sensitivity may be used to quantify RNA from a single 
cell. Quantitating RT-PCR enables a comparison o f the amount o f a given mRNA in two 
different samples to be made (see Luftalla & Uze, 2006). For each sample, the amount of 
the specific mRNA is given relative to the amount o f reference mRNA that is constant in 
the two samples.
Real-time PCR enables data collection throughout the PCR process rather than at the end 
o f the process. Reactions in real-time PCR are therefore characterised by the point in 
time during cycling where amplification o f a target is first detected (threshold), rather 
than the amount o f target accumulated after a fixed number o f cycles. Introduction o f 
fluorogenic probes that use the 5 ' nuclease activity o f Taq DNA polymerase has greatly 
improved real-time systems for PCR. These fluorogenic probes enable the detection of 
only specific amplification products by emmiting a fluorescence signal. In the initial 
cycles o f PCR, there is little change in the fluorescence signal and this is thus defined as 
the baseline. When an accumulated target is detected, an increase in flourescence is 
observed in the cycle.
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mRNA is quantitated either as relative or absolute. Relative quantitation analyses 
compare changes in gene expression in a given sample relative to another reference 
sample. In addition to the reference sample, a calibrator is required to create a series of 
dilutions. These series o f dilutions can be used to contstruct a standard curve where a 
correlation plot is generated by subjecting the dilutions to amplification and real-time 
fluorescence detection, then plotting the known starting quantities against the measured 
threshold cycle (Ct) values.
It is important to note that the calibrator can be any nucleic acid as long as both the 
concentration and the length o f the amplicon is known (see Bustin, 2000).
Absolute quantitation on the other hand allows the precise determination o f copy number 
per cell, total RNA concentration, or unit mass o f tissue. An absolute standard curve for 
each individual amplicon is required in order to ensure accurate reverse transcription and 
PCR amplification profiles.
7.1.3 How the detection system works in RT-PCR
The flourogenic probe enables the detection o f a specific PCR product as it accumulates 
during PCR. The procedure o f how this detection sytsem works is described below (see 
Figure 7.1 for diagram).
■ An oligonucleotide probe is constructed containing a reporter (R) fluorescent dye 
on the 5 ' end a quencher (Q) dye on the 3 ' end. When intact, the proximity of the 
quencher dye greatly reduces the fluorescence emmitted by the reporter dye.
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■ If  the target sequence is present, the probe anneals downstream from one o f the 
primer sites and is cleaved by the 5 ' nuclease activity o f Taq DNA polymerase as 
the primer is extended.
■ Cleavage o f the probe involves, separating the reporter dye from the quencher 
dye, thus increasing the reporter dye signal, and removing the probe from the 
target strand thus allowing primer extension to continue to the end o f the template 
strand. The presence o f the probe therefore does not inhibit the overall PCR 
processs.
■ Within each cycle, additional reporter dyes are cleaved from their respective 
probes, thus resulting in an increase in fluorescence intensity that is proportional 
to the amount o f amplicon produced.
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Figure 7.1 Schematic representation showing how the detection system works in RT- 
PCR as described above. Q represents the quencher dye on the 3 ' end and R represents 
the flourescent reporter dye on the 5 ' end.
(Adapted from http://docs.appliedbiosystems.com/pebiodocs/04371089.pdf)
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7.2 Methods
Bladder and urethral tissues (both smooth and striated regions o f the urethra) were 
obtained from female Sprague-Dawley rats (n = 3). The isolated tissues were stored in 
RNAlater (the recommended solution for “in-tissue” RNA preservation) at a temperature 
o f 4°C, until time for mRNA expression analysis. A Roche TaqMan qRT-PCR kit was 
used for mRNA detection. The kit consisted o f sets o f 90 pre-validated probes in a 
library format that was stored in the freezer ready for use. Roche’s free web-based assay 
design centre was used to design primers specific for the 5HT2 receptors (5-HT2A, 5-HT2B 
and 5-HT2c) in order to attain assay specificity. The online design centre also suggested 
which probe to use for each o f the 5HT2 receptors investigated.
The isolated rat tissues o f the bladder and urethra, as well as rat brain were used to extract 
RNA, manufacture cDNA and consequently determine expression levels o f the 5HT2 
receptors in each tissue isolated. From carrying out serial dilutions, varying 
concentrations o f rat brain were used to construct a standard curve. The standard curve 
was used to calculate relative expression o f the 5 -HT2 receptor subtypes in the brain, 
bladder and urethra.
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7.3 Results
7.3.1 5-H T2A receptor expression
Graph showing the relative expression levels o f 5 -HT2A receptor mRNA in the rat 
urethra, bladder and brain tissue is shown in Figure 7.2a. 5-HT2A receptor mRNA was 
observed to be low to absent in the rat urethra. However, 5-HT2A receptor mRNA was 
observed to be abundantly expressed in the rat bladder relative to the rat brain and rat 
urethra (Table 7.2b).
7.3.2 5-H T2B receptor expression
Graph showing the relative expression levels o f 5-HT2B receptor mRNA in the rat 
urethra, bladder and brain tissue is shown in Figure 7.3a. The relative expression o f 5- 
HT2B receptor mRNA was observed to be highest in the rat urethra relative to both the rat 
bladder and rat brain (Table 7.3b).
7.3.3 5-H T2C receptor expression
Graph showing the relative expression levels o f 5-HT2C receptor mRNA in the rat 
urethra, bladder and brain tissue is shown in Figure 6.4a. 5-HT2C receptor mRNA was 
observed to be absent in the rat urethra and bladder but was observed to be abundantly 
expressed in the rat brain (Table 7.4b).
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Figure 7.2 (a) Histograms showing relative 5HT2A receptor expression in the rat
urethra, bladder and brain, (b) Table summarising mRNA concentration o f  5-HT2A
receptor expression in the rat urethra, bladder and brain.
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Figure 7.3 (a) Histograms showing relative 5HT2B receptor expression in the rat
urethra, bladder and brain, (b) Table summarising mRNA concentration of 5-HT2B
receptor expression in the rat urethra, bladder and brain.
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Figure 7.4 (a) Histograms showing relative 5HT2c receptor expression in the rat
urethra, bladder and brain, (b) Table summarising mRNA concentration o f 5-HT2c
receptor expression in the rat urethra, bladder and brain.
367
7.4 Discussion
In the present data, 5-HT2A receptor mRNA was observed to be low to absent in the rat 
urethra, but highly expressed in the rat bladder relative to the rat brain. These 
observations therefore help in further defining an excitatory role for 5 -HT2A receptors in 
micturition. Pharmacological evidence for an excitatory role o f the receptor is provided 
in the previous chapters where the 5 -HT2A receptor agonist DOI was observed to be 
excitatory on the external urethral sphincter and the micturition reflex, with significant 
blockade observed following pre-treatment with the selective 5-HT2A receptor antagonists 
ketanserin and MDL 100907. Further, infusion o f the high dose o f Ro 60-0175 (which 
was selective for the 5-HT2A receptor) was observed to be excitatory both on the external 
urethral sphincter and the micturition reflex, with blockade o f these effects by MDL 
100907. Claims in the literature for an excitatory role o f 5 -HT2A receptors on bladder 
function comes from an in vitro study carried out by Kim et al (2002) using isolated rat 
bladder muscle strips. The group found that the 5-HT2A receptor antagonist ketanserin 
abolished the serotonin-induced contraction o f the detrusor muscle, thus suggesting the 
involvement o f 5-HT2A receptors in mediating these excitatory effects. A lack of 
evidence o f 5-HT2A receptor mRNA expression in the rat urethra concurs with the in vivo 
results obtained in chapter 3. The data showed no significant increases on urethral 
pressure following administration o f DOI.
5 -HT2B receptor mRNA expression was mainly observed in the rat urethra relative to the 
bladder and brain. This should however be approached with caution as there was no 
distinction made regarding receptor expression between the two urethral muscles i.e.
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smooth or striated muscle. However, there is evidence in the literature demonstrating 
peripheral distribution o f the 5-HT2B receptor in stomach, intestine and pulmonary 
smooth muscle (Foguet et al., 1992; Kursar et al., 1994; Baxter et al., 1994). Therefore, 
if  5-HT2B receptor mRNA expression primarily occurred in the urethral smooth muscle, 
this would ascertain the involvement o f 5-HT2b receptors in urethral smooth muscle 
contraction as observed in chapter 3. The results from this study also concur with other 
studies in the literature where low to absent expression o f 5-HT2B receptor mRNA 
occurred in the rat brain (Kursar et al., 1994; Schmuck et al., 1994) which would explain 
the lack o f evoked responses by 5-HT2B receptor agonist and antagonist BW 723C86 and 
RS 127445 respectively on the micturition reflex as it is known to be mediated via a 
central mechanism. It should also be noted that there was a technical limitation regarding 
the expression o f the 5-HT2B receptor mRNA as the rat brain tissue used to construct the 
standard curve in this study, showed very low expression o f the 5-HT2B receptor mRNA, 
hence deeming the results less reliable. It would therefore have been more appropriate to 
construct the standard curve using a more highly expressing 5-HT2B receptor tissue such 
as stomach fundus smooth muscle.
5-HT2C receptor mRNA expression was expressed abundantly in the rat brain relative to 
the bladder and urethra. These results concur with other studies in the literature where 5- 
HT2C receptors have been identified in many parts o f the rat, human and monkey brain 
(Abramowski et al., 1995; Lopez-Gimenez et al., 2001) with low to absent expression in 
the peripheral tissues. Several studies in the literature have deduced that the mechanism 
for micturition is mediated centrally (see Ramage, 2006) and therefore a correlation may
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exist between the abundant expression of the 5-HT2C receptor mRNA in the brain and its 
function in micturition.
The molecular evidence provided in this study, correlates well with the pharmacological 
results observed in the previous chapters with regards to the role o f the three 5 -HT2 
receptor subtypes in micturition. Although the results present insights into 5 -HT2 
receptor mRNA expression in the lower urinary tract, linking mRNA receptor expression 
to receptor function should be approached with great caution. This is due to the fact that 
RNA processing events such as RNA editing may occur, thus altering the encoded 
receptor protein which may in turn alter the protein structure and physiological function 
o f the receptor (Niswender et al., 1998). This is especially the case with the 5-HT2C 
receptor which undergoes RNA editing thus resulting in generation o f multiple receptor 
isoforms with altered phospholipase C signal transduction (Niswender et al., 1998).
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7.5 Conclusion
In conclusion, from this study, molecular evidence was provided regarding expression of 
5 -HT2 receptor subtypes in the lower urinary tract o f the rat, with 5-HT2A receptor mRNA 
expression observed in the bladder, 5-HT2B receptor mRNA expression in the urethra and 
5 -HT2C receptor mRNA expression observed in the brain. Findings from this study 
support the evidence provided in the previous chapters where insights into the role o f the 
three 5 -HT2 receptor subtypes in the lower urinary tract were provided and confirmed 
following pharmacological characterisation o f the receptors and their role in the lower 
urinary tract.
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